ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 37 0 DECEMBER 1993 * NUMBER 12 Robert C. Moellering, Jr., Barbara E. Murray, Editor (1997) Editor in Chief (1995) University of Texas Health Science New England Deaconess Hospital Thomas D. Gootz, Editor (1995) Center Boston, Mass. Pfizer Inc. Houston, Tex. Michael Barza, Editor (1995) Groton, Conn. Herbert A. Kirst, Editor (1996) New England Medical Center Frederick G. Hayden, Editor Lilly Research Laboratories Hospitals (1995) Indianapolis, Ind. Boston, Mass. University of Virginia Health Editor (1994) George L. Drusano, Editor (1998) Sciences Center Chinstine C. Sanders, University ofMaryland School of Charlottesville, Va. Creighton University School of Medicine Medicine Baltimore, Md. Omaha, Neb. EDITORIAL BOARD Robert D. Abbott (1993) George M. Eliopoulos (1994) Gary R. Matzke (1995) Charles Shipman, Jr. (1994) Vincent T. Andriole (1993) John N. Galgiani (1993) Douglas Mayers (1994) David M. Shlaes (1994) Peter C. Appelbaum (1994) N. H. Georgopapadakou (1994) Antone A. Medeiros (1993) Thomas R. Shryock (1995) Gordon L. Archer (1995) Dale N. Gerding (1994) Michael Miller (1993) Robert W. Sidwell (1993) Devron Averett (1993) Allan Godfrey (1993) Henry W. Murray (1993) Fritz Sorgel (1995) Masanori Baba (1995) Sherwood L. Gorbach (1995) John D. Nelson (1995) Philip J. Spagnuolo (1994) Frank Balis (1994) Stephen B. Greenberg (1995) Harold C. Neu (1995) P. Frederick Sparling (1993) Franklin A. Neva (1995) David P. Speert (1994) Arthur L. Barry (1995) Scott M. Hammer (1995) Lee Spruance John G. Bartlett (1993) Margaret R. Hammerschlag (1995) Wright Nichols (1995) Spotswood Arnold S. Bayer (1994) Robert E. W. Hancock (1995) Charles H. Nightingale (1993) (1995) A. Pachla (1993) Harold Standiford (1994) Michel G. Bergeron (1995) W. Lee Hand (1995) Lawrence David A. Stevens (1995) Richard F. Bergstrom (1994) H. Hunter Handsfield (1995) Joseph S. Pagano (1993) (1994) Charles W. Stratton (1994) Karen K. Biron (1993) Leonid B. Heifets (1993) Thomas R. Parr, Jr. Stephen E. Straus (1993) Jurg Blaser (1994) David C. Hooper (1993) James E. Pennington (1995) Alan M. Sugar (1995) Gerald P. Bodey (1995) Michael R. Jacobs (1993) T. J. Perun (1995) Richard B. Sykes (1994) Karen Bush (1994) George A. Jacoby (1995) Brent Petty (1995) Francis C. Szoka, Jr. (1995) Claude Carbon (1995) Susan E. Jensen (1994) Philip A. Pizzo (1994) Francis P. Tally (1993) Suzanne Chamberland (1995) James H. Jorgensen (1993) Ronald Polk (1993) Diane E. Taylor (1993) Henry F. Chambers (1994) A. W. Karchmer (1994) Catherine P. Reese (1995) Fred C. Tenover (1994) Sarah H. Cheeseman (1995) Donald Kaye (1994) Richard C. Reichman (1995) Clyde Thornsberry (1995) Anthony Chow (1994) Robert E. Kessler (1993) Douglas D. Richman (1993) Alexander Tomasz (1994) Donald M. Coen (1993) George S. Kobayashi (1994) Allan Ronald (1993) Roger D. Toothaker (1994) Patrice Courvalin (1994) Donald J. Krogstad (1995) John P. Rosazza (1995) Thomas Walsh (1995) William A. Craig (1993) Philip Todd Lavin (1995) John Rotschafer (1995) Bernard Weisblum (1994) William L. Current (1993) Marc LeBel (1994) Robert H. Rubin (1993) Peter F. Weller (1995) Michael H. Cynamon (1995) Stephen A. Lerner (1995) Merle Sande (1994) Richard J. Whitley (1993) William E. Dismukes (1993) Stuart B. Levy (1995) W. Eugene Sanders, Jr. (1993) Richard Wise (1995) Gary V. Doern (1993) David R. Luke (1993) W. Michael Scheld (1995) James Woodworth (1993) Michael N. Dudley (1995) Gerald L. Mandell (1995) Raymond F. Schinazi (1995) Lowell S. Young (1994) David Durack (1994) J. Joseph Marr (1995) Robert T. Schooley (1993) Geoffrey J. Yuen (1995) Theodore Eickhoff (1994) Henry Masur (1993) Richard S. Schwalbe (1994) Barbara H. Iglewski, Chairman, Publications Board Linda M. Illig, Director, Joumals Kathleen M. Whalen, Production Editor Antimicrobial Agents and Chemotherapy, an interdisciplinary publication of the American Society for Microbiology (ASM), 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial, antiviral, antiparasitic, and anticancer agents and chemotherapy. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Journals Division. AntimicrobialAgents and Chemotherapy is published monthly, one volume per year. The nonmember print subscription prices are $250 (U.S.) (Canadians add 7% GST) and $294 (other countries) per year; single copies are $40 (Canadians add 7% GST). The member print subscription prices are $49 (U.S.) (Canadians add 7% GST) and $84 (other countries; single copies are $10 (Canadians add 7% GST). For prices of CD-ROM versions, contact the Subscriptions Unit, ASM. Correspondence relating to scriptions, defective copies, missing issues, and availability of back issues should be directed to the Subscriptions Unit, ASM; correspondence relating to reprint orders should be directed to the Reprint Order Unit, ASM; and correspondence relating to disposition of submitted manuscripts, proofs, and general editorial matters should be directed to the Journals Division, American Society for Microbiology, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Phone: (202) 737-3600. Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed. Second-class postage paid at Washington, DC 20005, and at additional mailing offices. POSTMASTER: Send address changes toAntimicrobial Agents and Chemotherapy, ASM, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Made in the U.S.A. Printed on acid-free paper. ISSN 0066-4804 Copyright © 1993, American Society for Microbiology. CODEN: AMACCQ All Rights Reserved. the copyright owner's consent that copies of the article may be The code at the top of the first page of an article in this journal indicates stated for use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the made personal MA 01970, for copying beyond that permitted by Sections per-copy fee through the Copyright Clearance Center, Inc., 27 Congress St., Salem, for 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, advertising or promotional purposes, for creating new collective works, or for resale. Author Index

Alcouloumre, Marcia S., 2628 Fallani, Stefania, 2693 Kondoh, Masumi, 2662 Reid, Carol D., 2606 Allen, Stanley D., 2716 Fich, Karen, 2550 Rice, Louis B., 2760 Aoki, Yuhko, 2656, 2662 Finegold, S. M., 2638 Lam, Patrick Y.-S., 2606 Rigon, Antonio, 2693 Arisawa, Mikio, 2656, 2662 Frachet, B., 2674 Larrick, James W., 2534 Roland, Gregory E., 2563 Ateshkadi, Arasb, 2650 Fraimow, Henry S., 2736 Lee, K., 2638 Rollwagen, Florence M., 2688 Franzini, P., 2545 Leggett, J., 2678 Rolston, Kenneth V., 2584 Bacheler, Lee T., 2606 French, Pamela, 2736 Le Gros, V., 2674 Rosenbaum, Beverly, 2584 Balzarini, Jan, 2540 Fukasawa, Masatomo, 2743 Lemmich, Else, 2550 Rosenberg, Ivan, 2540 Baqar, Shahida, 2688 Fukatsu, Hiroshi, 2756 Leser, Ulrike, 2612 Barmada, S., 2678 Levy, Stuart B., 2699 Sanada, Minoru, 2756 Beauchamp, Denis, 2727 Galgiani, John N., 2517 Lins, Ulysses, 2722 Sanders, Christine C., 2578 Becker, S. A. W. E., 2638 Garber, Sena, 2606 Lombardi, F., 2545 Sansano, Sebastiano, 2622 Bell, Constance A., 2668 Garcia, M. M., 2638 Louchahi, K., 2674 Sawada, Masashi, 2684 Benchimol, Marlene, 2722 Gaspar, Erzsebet, 2593 Scarnati, Helen, 2606 Bentorcha, Fairouze, 2593 Ghannoum, Mahmoud A., Maass, Gerhard, 2612 Schindler, Jay J., 2716 Bergeron, Michel G., 2727 2628 Manavathu, Elias K., 2645 Selan, L., 2618 Bergeron, Yves, 2727 Ghezzi, Pietro, 2527 Marshall, Steven A., 2747 Selsted, Michael E., 2628 Berlutti, F., 2618 Gilbert, D., 2678 Marshall, Steven H., 2760 Shafer, William M.j, 2710 Blais, Johanne, 2571 Gongalves, Noemia Mason, Edward O., Jr., 2522 Shimada, Hisao, 2656 Blom, Jens, 2550 Rodrigues, 2722 Matsuda, Kouji, 2756 Shimomoura, Yuko, 2534 Bodeau, Amy L., 2710 Goody, Roger, 2612 Maurin, M., 2633 Sironi, Marina, 2527 Borin, Marie T., 2650 Grewal, Jaswinder, 2645 McMurry, Laura M., 2699 Soussy, Claude J., 2588 Bradford, Patricia A., 2578 Guerry, Philippe, 2599 McNamara, Patrick J., 2706 Stair, Thomas O., 2754 Brion, N., 2674 McQueen, Teresa J., 2584 Stecca, Clara, 2693 Hand, Debra L., 2557 Mehta, Reeta T., 2584 Stoeckel, Klaus, 2706 Cantoni, Lavinia, 2527 Hand, W. Lee, 2557 Meservey, Mark A., 2563 Sumita, Yoshihiro, 2743 Carelli, Maria, 2527 Hansen, Lori M., 2699 Milocchi, Fabio, 2693 Summanen, P., 2638 Carey, Patrick M., 2650 Hara, Kohei, 2762 Mitsutake, Kotaro, 2762 Sutton, Lorraine, 2760 Carias, Lenore L., 2760 Hashizume, Terutaka, 2756 Miyasaki, Kenneth T., 2710 Tagliabue, G., 2545 Cesana, M., 2545 Hesse, Werner H., 2622 Miyazaki, Haruko M., 2762 Tanaka, Nobuo, 2756 Chamberland, Suzanne, 2571 Hirata, Michimasa, 2534 Miyazaki, Yoshitsugu, 2762 Tardif, Carole, 2571 Chen, Ming, 2550 Hirata, Takahiro, 2656 Morikawa, Keiko, 2684 Tardif, Manon, 2727 Christensen, S0ren Br0gger, Hirsh, Dwight C., 2699 Morikawa, Shigeru, 2684 Tarrand, Jeffrey J., 2584 2550 Holy, Antonin, 2540 Mueller, Barbara, 2612 Taylor, Diane E., 2645 Cohen, Michael A., 2563 Hoogkamer, Johannes F. W., Thaller, M. C., 2618 Colturani, F., 2545 2622 Nadelmann, Lynda, 2550 Theander, Thor G., 2550 Comodi-Ballanti, M. R., 2618 Hooper, David C., 2588 Naiman, Noreen A., 2668 Thormar, Halldor, 2540 Corbett, Anita H., 2599 Hoosen, Anwar A., 2733 Nakada, Naoki, 2656 Tidwell, Richard R., 2668 Cory, Michael, 2668 Horaud, Thea, 2593 Nakagawa, Susumu, 2756 Tod, M., 2674 Craig, William A., 2650 Howell, John M., 2754 Nakamura, Yumiko, 2662 Tomono, Kazunori, 2762 Huband, Michael D., 2563 Nakayama, Noboru, 2662 Trieu-Cuot, Patridk, 2593 Dal Pizzol, Virginia, 2693 Hughes, George S., 2650 Nervetti, G., 2545 Dazer, Maureen E., 2563 Ng, Eva Y., 2588 Van Den Ende, Jan, 2733 de Aquino Almeida, Joao Ibrahim, Ashraf S., 2628 Nicastro, G., 2545 van der Meer, Jos W. M., Carlos, 2722 Imbimbo, B. P., 2545 Novelli, Andrea, 2693 2527 Debyser, Zeger, 2540 Immendoerfer, Ulrike, 2612 Venuti, Elaine, 2736 de Cespedes, Gilda, 2593 Okamoto, Osamu, 2756 Viola, Renato, 2693 De Clercq, Erik, 2540 Jackson, M. Keven, 2716 Oliary, J., 2674 Visconti, M., 2545 de Lalla, Fausto, 2693 Jacoby, George A., 2760 Oseko, Fumimaro, 2684 Vogels, Maria T. E., 2527 Delbos, Frangoise, 2593 Jindrich, Jindrich, 2540 Osheroff, Neil, 2599 Desmyter, Jan, 2540 Johnson, Curtis A., 2650 Otto, Michael J., 2606 Warren, Reed P., 2716 de Souza, Wanderley, 2722 Jones, Ronald N., 2747 Watanabe, Junko, 2656 Dhindsa, Harinder S., 2754 Pacheco, Nancy D., 2688 Wexler, H. M., 2638 Domagala, John M., 2563 Kaku, Mitsuo, 2762 Passariello, C., 2618 Winslow, Dean L., 2606 Ducharme, Murray P., 2706.. Kamiyama, Tsutomu, 2656 Pellizzer, Giampietro, 2693 Wolfson, John S., 2588 Dunne, W. Michael, Jr., 2522 Kaplan, Sheldon L., 2522 Periti, Piero, 2693 Wright, Susan C., 2534 Dworkin, R., 2678 Kaufhold, Achim, 2740 Petitjean, O., 2674 Yoder, Steven L., 2563 Dykstra, Christine C., 2668 Keyhani, Afsaneh, 2584 Pfaff, Eberhard, 2612 Yoshida, Masao, 2534 Kharazmi, Arsalan, 2550 Pflieger, Philippe, 2599 Yoshihara, Fumie, 2662 Edwards, Barbara A., 2754 Kharsany, Ayesha B. M., Pohl, Jan, 2710 Edwards, David J., 2706 2733 Potgieter, Elsa, 2740 Zheng, Hui, 2534 Edwards, John E., Jr., 2628 Koenig, Bernhard, 2612 Privitera, G., 2545 Zhong, Jian, 2534 Koga, Hironobu, 2762 Zimmerli, Werner, 2622 Fairley, Terri A., 2668 Kohlhepp, S., 2678 Raoult, D., 2633 Zimmerman, Stephen W., Faleschini, E., 2545 Kohno, Shigeru, 2762 Rayner, Marlene M., 2606 2650 ACKNOWLEDGMENT

The following persons served as invited special reviewers for the journal during 1993, and their help is greatly appreciated.

L. B. Adams William Davis Fred Henderson R. B. Merrifield Y. Rikihisa Kenneth E. Aldridge Fernando de la Cruz M. J. Henry Wayne Meyers Michael Rinaldi N. E. Allen A. Deldar Erik Hewlett Louis H. Miller G. D. Roberts Raza Aly V. Deretic Martin Hirsch Marvin J. Miller Keith Rodvold David Amacher Louis Diamond Joachim Volker Holtje Hiroaki Mitsuya Julian I. Rood S. G. B. Amyes William Drew Jay Hoofnagle Harry L. T. Mobley Henry Rosen Koen Andries David A. Dubnau Thomas Hooton Keiko Morikawa T. Rosen Michael Apicella Richard Duma Thea Horaud J. Glenn Morris, Jr. Martin Rosenbert George Aronoff Gary Dunny Sally Hubert Gene Morse Philip Rosenthal Eurico Arruda Frank Dutko Joel Huff J. W. Murphy Paul Roy M. Arthur Paul H. Edelstein Walter Hughes Kzumi Nakashima Daniel Sahm Cyrus J. Bacchi John E. Edwards, Jr. Joseph R. Iaconis Yuziro Namba Robert Salata Johan S. Bakken J. M. Ehret C. B. Inderlied Thalia Nicas Louis D. Saravolatz R. H. Baltz Anton F. Ehrhardt William Jacobs Hiroshi Nikaido S. T. Schlossman Jan Balzarini Ingvar Eliasson J. L. Johnson David Nix Dennis Schmatz John Barrett Emilio Emini R. C. Johnson C. E. Nord Frederick R. J. Schmidt R. J. Baumann Janet Englund Victoria Johnson J. Staffan Normark Jerome Schwartz J. M. Becker Alejo Erice Warren D. Johnson M. N. Novilla Karen J. Shaw Robert Belshe James Evermann R. N. Jones Frank C. Odds Gerald Shockman John Bennett Bruce Farber Thomas C. Jones Richard Odom G. D. Sides Michael Bennish P. B. Fernandes Colin Jordan Donald Smee Kaiser John W. Ogle Herbert Benson Giora Feuerstein Allen B. James G. Olson Arnold L. Smith Richard Berger Scott Filler Edward Kaplan James W. Smith Sheldon Kaplan Andrew Onderdonk Brigitte Berger-Bachi Roberta Fontana Michael J. Otto Jean-Pierre Sommadossi Ed Bernard S. G. Franzblau G. E. Kenney Stephen Spector Marie Frere Douglas S. Kernodle Tim Palzkill Robert Betts Jean L. W. Parks Brian G. Spratt J. Biehle Robert A. Fromtling Louis Kirchhoff Allen C. Steere Phillip Furman Saul Kit Sally Parsons John Bilello Rudi Pauwels Joyce Sutcliffe John C. Boothroyd P. R. J. Gangadharam S. J. Klebanoff Jerome Klein Richard D. Pearson K. Takayama John Boyce R. H. Gelber Kenneth S. Thomson Itzhak Brook John Gerin Michael Kleinberg Jean-Claude Pechere Mark S. Klempner J. R. Perfect John Threlfall K. N. Brown Clarence Gibbs Tisdale Michael R. W. Brown B. Gicquel Tamsin Knox C. Perronne Margaret Daniel Butler Hagain Ginsburg Joseph Kovacs Edward Pesanti Edmund Tramont Frank M. Calia Arthur Girard R. B. Kundsin Lance Peterson Kenneth Tumecki Wayne Campbell R. P. Gladue S. Kuwahara William Petri Elaine I. Tuomanen Stephen A. Chartrand Richard V. Goering M. T. Labro Michael A. Pfaller J. R. Turner Ming Chen Simeon Goldblum Brandon Larder Larry K. Pickering David Tyrrell V. J. Chen Mark Goldman Karl L. M. Lavrijsen Michael Polis B. Ullman Ambrose L. Cheung Don Goldmann John M. Leedom Richard Pollard M. Vaara Ian Chopra E. Goldstein Francois LeGoffic D. A. Preston Jos van der Meer Sunwen Chou W. Manford Gooch Paul Lietman Richard Proctor Ralph van Furth T.-C. Chou Michael Gottlieb Philip D. Lister Steven J. Projan Mark Wainberg Ming Chu Hsu Eduardo Gotuzzo Hans Liu Paul Quie David H. Walker Joanna Clancy J. R. Graybill Benjamin Luft John P. Quinn R. J. Wallace, Jr. Robert A. Clark Max Grogl Paul T. Magee J. A. Radding Edward Walsh Thomas G. Cleary Richard Guerrant Dennis Maki A. Rahman Peter Walzer Donald Clewell S. Gundmundsson Michael H. Malamy Robert M. Rakita C. C. Wang Myron Cohen Laurent C. Gutmann G. G. Marconi R. N. Rao Richard Weiss S. T. Cole Richard Hafner Thomas J. Marrie G. J. Ras Eric Westin Edward Connor Ruth M. Hall Anthony Maxwell Nolin Rastogi Hannah M. Wexler J. W. Costerton W. H. Hall John McBride Jonathan I. Ravdin Richard Reinhard Wirth F. T. Counter Sandra Handwerger Robert McCabe Thomas Rea Brian Wispelway Jorge Crosa D. J. Hardy J. W. McFarland Michael Rein E. Wolinsky Clyde Crumpacker Alan Hay James McSharry Jack Remington Gary Wormser Eric Cundliffe M. P. Hayes John Mellors J. A. Retsema D. M. Yajko C. J. Czuprynski Kevin Hazen Rolf Menzel John H. Rex Oto Zak Richard Davey J. V. Heck Jay Merluzzi Louis B. Rice Michael Zasloff a U AMIERICAN SOCIETY FOR MICROBIOLOGY AND NATIONAL CENTER FOR INFECTIOUS DISEASES 1994 POSTDOCTORAL RESEARCH ASSOCIATES PROGRAM

Up to ten associate positions will be awarded by the American Society for Microbiology for full-time research on infectious diseases which cause significant public health problems. Associates will perform research in residence at the National Center for Infectious Diseases (NCID) which is headquartered at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. In addition to Atlanta, NCID operates laboratories in Ft. Collins, CO, Anchorage, AK, and San Juan, Puerto Rico. Eligible fields of study include: Bacterial and Mycotic Diseases, Viral and Rickettsial Infections, Nosocomial Infections, HIV/AIDS, Vector-borne Infectious Diseases, Sexually Transmitted Diseases, and Parasitic Diseases. The program is intended for individuals who have held a doctorate degree (Ph.D., Sc.D., or M.D.) since, but not earlier than, May 1, 1991. Exceptions may be made for those with more experience. The programn is open to both U.S. and foreign citizens. Qualified applicants will receive consideration without regard to race, creed, color, age, sex, or national origin. Diversity among associates is encouraged. The program provides an annual stipend ranging from $28,000 to $33,000 and up to $2,000 for professional development. The application deadline is February 1, 1994. The Postdoctoral Research Program is administered by the American Society for Microbiology. All inquiries regarding this program should be addressed to: Coordinator, Postdoctoral Research Program, American Society for Microbiology, 1325 Massachusetts Avenue, N.W., Washington, D.C. 20005; (202) 942-9299.

ASM ODO/NOID| AMERICAN SIETY CENTERS POR DISEASE CONTROL/NATIONAL CENTER FOR INFEc11OLIS DIS.ESES FOR MICROBIOLOGY AND PREVENION

- IU- 0U . AUTHOR INDEX VOLUME 37

Abdalla, Salah, 138 Azad, Raana F., 1945 Bennett, Sam, 825 Bonnet, M., 1015 Abe, Shigeru, 2228 Bennett, W. M., 347 Bordon, Florence, 1247 Acharya, Gopal, 2418 Babich, John, 2144 Benson, Constance A., 1444 Borin, Marie, 1137 Adam, D., 1620 Babst, Anna F., 1552 Benson, John M., 1343 Borin, Marie T., 2650 Adkinson, N. Franklin, Jr., Bacheler, Lee T., 2606 Bentorcha, Fairouze, 2593 Borner, Klaus, 1835 1463 Back, Arthur F., 1552 Berger, L. C., 1713 Borroto-Esoda, Katyna, 1720 Agacfidan, Ali, 1746 Bader, John P., 754 Bergeron, Michel G., 2727 Borsch, Carina M., 128 Aggarwal, Sunil K., 818 Baginski, Rainer, 750 Bergeron, Yves, 2727 Bosso, John A., 1414 Agrawal, Krishna C., 818 Bajaksouzian, Saralee, 1799 Berggren, Terriel, 2033 Bostian, Keith A., 377 Aguado, J. M., 2490 Bakken, Johan S., 1171 Berkowitz, Barry A., 393 Bouchard, Celine, 1373 Aguirre, Tania, 580 Balfour, Henry H., Jr., 357, Berlutti, F., 2618 Boucher, Charles, 1390 AIDS Clinical Trials Group 835 Bernan, Valerie, 1624 Boucher, Charles A. B., 1525, Virology Committee Ballet, Jean-Jacques, 889 Bernard, E., 921 2231 Resistance Working Group, Ballow, Charles H., 1065, Bernard, Edward M., 398, Boudinot, F. Douglas, 1343 1095 1073 2323 Boudjema, Karim, 1873 Ajiki, Yoko, 1749 Baltaian, Manik, 1614 Bertasso, A., 559 Boulerice, Francois, 1305 Akahane, Kazumi, 1764 Balzarini, J., 332 Berti, Marisa, 741 Bourget, Philippe, 54 Akalin, H. E., 1637 Balzarini, Jan, 2540 Bertrand, Kevin P., 1624 Bourneix, C., 1432 Akalin, H. Erdal, 1831 Bamberger, David M., 203 Bethell, Richard C., 1473 Bouvet, Olivier, 464 Akao, Mitsutaro, 1313 Bando, Kaori, 957 Bethune, Linda, 746 Bouza, Emilio, 1200 Akashi, Akira, 287, 1826 Baqar, Shahida, 2688 Betriu, Carmen, 1717 Bova, Carol A., 178 Akova, M., 1637 Baquero, F., 1982 Beumer, Henriette, 885 Bowden, Raleigh A., 1360 Akova, Murat, 1831 Baquero, Fernando, 2059, Beveridge, Terry J., 715 Bowdon, Bonnie J., 1004 Aksnes, Arne, 2024 2427 Beyer, Jorg, 1367 Boyce, Steven T., 1890 Alam, N. H., 1572 Baquero, Maria-Rosario, 2059 Bhatt, Arun D., 183 Boyd, Malcolm R., 642 Alcouloumre, Marcia S., 2628 Barbadora, Karen, 1238 Bhattacharya, M. K., 1197 Boyd, Michael R., 754, 1037 Alder, Jeffrey, 864, 1329 Barbhaiya, R. H., 1180 Bhattacharya, Prabhat Kumar, Bradford, Patricia A., 251, Aldridge, Kenneth E., 1986 Barbour, Alan G., 1115, 1704 2459 1989, 2578 Aliu, Yusuf O., 1050 Bargiggia, Stefano, 2212 Bhattacharya, S. K., 1197 Bradley, Suzanne F., 2003 Allard, J. P., 2239 Barker, Patrick J., 84 Bienen, E. Jay, 1082 Brake, W. B., 1713 Allegra, Carmen J., 1227 Barko, Nir, 2483 Bierman, Robert H., 778 Brandicourt, Olivier, 970 Allen, S. D., 1696 Barluzzi, Roberta, 2422 Bilello, John A., 115 Brasseur, Philippe, 889 Allen, Stanley D., 2716 Barmada, S., 2678 Billard, Lynne, 825 Bray, Patrick G., 1318 Allouch, P., 737 Barone, Joseph A., 778 Billhardt, Uta-Maria, 1659 Brazeau, Gayle A., 246 Alos, Ignacio, 2059 Barrios, Alcira Angelo, 859 Binczewski, Brian, 1238 Breslin, Barbara J., 2407 Alpert, Nathaniel M., 1270, Barrow, William W., 652 Bindra, Rani R., 1360 Bressolle, Francoise, 464 2144 Barry, A. L., 893 Birmingham, Mary C., 1065, Bril-Bazuin, C., 2318 Alteri, Enrica, 2087 Barry, Arthur L., 14 1073 Brion, N., 737, 2674 Althaus, Irene W., 1127 Barry, Beatrix, 1599 Biron, Karen K., 19 Broccali, Gianpietro, 2212 Amicosante, Gianfranco, 1324 Bartizal, Ken F., 39 Bischofberger, Norbert, 2247 Brockmeyer, N. H., 1010 Amirault, Pascal, 1790 Bartlett, John A., 2449 Bistoni, Francesco, 2422 Broder, Samuel, 810 Amsterdam, Daniel, 896 Bartlett, Marilyn S., 39, 1543, Bj0rneklett, Arvid, 2443 Brogard, J. M., 1488 Anaissie, Elias J., 51 2166 Black, Paul L., 71 Brook, I., 1882 Anderson, Kevin P., 1945 Bartos, Linda, 512 Black, Roberta J., 1095 Brook, Itzhak, 997, 1452, 1531 Andremont, A., 1432 Barza, Michael, 931 Blahy, Olga M., 1576 Brookshire, Kenneth W., 213 Andrews, Charla, 178 Barzen, Georg, 1367 Blais, Johanne, 1701, 2571 Brouwer, J. T., 595 Aoki, Hiroyuki, 2173 Basco, Leonardo K., 924 Blanchet, Francoise, 1790 Brown, Barbara A., 1850 Aoki, Yuhko, 2656, 2662 Bastone, Elisa B., 914 Blasi, Elisabetta, 2422 Brown, Prince, 613 Appelbaum, P. C., 1649 Batra, Kumar K., 1025 Blatter, Marianne, 1971 Brown, Richard B., 1 Arai, Sumio, 287, 1826 Bauchet, J., 633 Blazquez, J., 1982 Brown, Sheldon T., 398, 2323 Arakawa, Yoshichika, 984 Bauer, Friedrich Eckhard, Blazquez, Jesus, 2059 Bruch, Suzanne, 2449 Arduino, Jean-Marie, 1095 2153 Blom, Jens, 2550 Bruggeman, Cathrien A., 218 Argenson, Jean Noel, 1214 Bauer, Gerhard, 115 Blum, Hubert E., 1539 Brumfitt, W., 1558 Arika, Tadashi, 363, 785 Bayer, Arnold S., 546, 2030 Bodeau, Amy L., 2710 Bruneton, Jean, 859 Arisawa, Mikio, 2656, 2662 Bazmi, Hengameh Z., 875 Bodey, Gerald P., 51, 2504 Brunnemann, Sherry R., 93 Arison, Byron, 1737 Beam, Thomas R., Jr., 896 Bodey, G. P., 729 Bruno, Antonella, 1492 Aristoff, Paul A., 1127 Beauchamp, Denis, 2727 Bodmer, Thomas, 2054 Bryskier, Andre, 1560 Arlet, Guillaume, 2020 Beaudouin, Robert, 1264 Body, Barbara A., 39 Bubp, Jeff, 1137 Armstrong, Donald, 398, 2323 Beck, Francis, 1873 Bogaki, Mayumi, 839 Buckheit, Robert W., Jr., 754 Aronovitz, Gerson H., 159 Becker, S. A. W. E., 2638 Bohm, Rudolf, 1370 Burger, David M., 1426 Artaza, M. A., 1587 Beckett, Laurel A., 1095 Boivin, Guy, 357 Burstein, Esther, 2483 Arthur, Michel, 78, 1563 Beijnen, Jos H., 1426 Bolan, Gail A., 1670 Busch, Janice, 775 Arts, Eric J., 1305 Bell, Constance A., 2668 Bold, Guido, 2087 Bush, Karen, 851, 1989 Ashdown, Leslie R., 905 Beller, Jean-Paul, 1873 Bollen, A., 142 Busso, Mariano, 1127 Ashtekar, Dilip R., 183 Bellido, J. L. Mufioz, 911 Bombardelli, Ezio, 1492 Butler, T., 1572 Ashton, Sarah H., 393 Benchimol, Marlene, 2722 Bond, Lynne, 474 Butler, Thomas, 2418 Ateshkadi, Arasb, 2650 Bender, Rudolf, 1659 Bongaerts, G. P. A., 2017 Buu-Hoi, A., 2159 Atzori, Chiara, 1492 Bengtsson, Stellan, 2200 Bonnay, M., 1432 Byrnes, Vera W., 947, 1576 Averett, Devron R., 441 Bennett, Diane, 613 Bonnem, Eric, 512 Awan, Aftab R., 2478 Bennett, L. Lee, Jr., 1004 Bonner, Daniel P., 213, 1289 Cacalano, Grace, 667 Aymard, M., 2239 Bennett, Peter M., 153 Bonnesen, Shari Powers, 1614 Cahill-Feehan, Carol, 1693 i ii AUTHOR INDEX ANTIMICROB. AGENTS CHEMOTHER.

Cal, Stanley X., 1869 Citron, Diane M., 1150 Curvale, Georges, 1214 Downs, Mary Beth, 71 Caliendo, Angela M., 1480 Clanton, David J., 754 Cynamon, M. H., 2344 Drancourt, Michel, 1214 Callahan, Ronald J., 1270 Clark, Nancye C., 2311 Dreyer, Geoffrey B., 71 Callaway, James E., 1614 Clarkson, Allen B., Jr., 1082 Daffe, Mamadou, 1536 Driver, Vickie B., 1945 Calvat, Sylvie, 281 Clavier, Francoise, 970 Dal Bo, Lorenzo, 2212 Drusano, George L., 115, 483 Cambau, Emmanuelle, 1247 Clecner, Bya, 1373 Dale, Glenn E., 1400 Drusano, G. L., 2496 Cameron, Janet, 1390 Cleeland, Roy, 2144 Dal Pizzol, Virginia, 2693 DuBois, J., 574 Cameron, Janet M., 2231 Clement, Jacob, 864, 1329 Dalton, Harry, 2193 Dubois, Jacques, 1373 Cameron, Miriam L., 2449 Clemons, Karl V., 1177, 2224 Damiani, Aldo, 106 Ducharme, Murray P., 2706 Cammack, Nick, 1390, 2231 Clewell, Don B., 134, 2474 Dan, M., 293 Duchateau, V., 1860 Cammarata, Catherine, 1986 Coates, Jonathan A. V., 1473 Dandekar, Kishor A., 1160 Dudley, Michael N., 1723, Campbell, D. A., 1180 Cochereau-Massin, I., 633 D'Aquila, Richard T., 1095, 1756 Campbell, Lee Ann, 8 Coen, Donald M., 19 1480 Dueweke, Thomas J., 1127 Canfield, Craig, 1417 Coene, Marie-Claire, 2101 Davidson, Ross J., 1154 Dullenkopf, Klaus, 1367 Cannon, Deborah L., 875 Coffey, Tracey J., 1938 Davies, Julian, 2379 Dumas, J. C., 1232 Cantin, Line, 1993 Cohen, Louise G., 2187 Davis, Michelle, 19 Duncanson, F. P., 1580 Canton, Rafael, 2059 Cohen, Michael A., 2563 Day, C. A., 2506 Dunn, David L., 357 Cantoni, Lavinia, 2527 Cohen, Myron S., 950 Day, D. F., 2506 Dunne, W. Michael, Jr., 2522 Carbon, Claude, 1790, 2466 Cohen, Yves, 692 Dayer, P., 2132 Dupeyron, Jean-Pierre, 501 Carelli, Maria, 2527 Colaizzi, John L., 778 Dazer, Maureen E., 2563 Dupont, Marie-Ange, 1536 Carey, Patrick M., 2650 Cole, Stewart T., 414 de Anta, Teresa Jimenez, 138 Duport, Catherine, 962 Carias, Lenore L., 610, 1061, Coleman, Ruth A., 2027 de Aquino Almeida, Joao Durack, David T., 903 2760 Colina, F., 2490 Carlos, 2722 Durant, J., 921 Carret, G., 1685 Coll, Ramon, 868 de Beco, Virginie, 281 Dutko, Frank J., 297 Cars, Otto, 2200 Collatz, Ekkehard, 1247 Debyser, Zeger, 2540 Dutta, P., 1197 Carsenti-Etesse, H., 921 Collins, Linda, 2009 de Cespedes, Gilda, 2593 Duval, Jean, 78, 789, 1896, Carter, Stephen G., 144 Collins, Linda A., 598, 1364 Decker, William D., 754 2119, 2466 Cartwright, Frank D., 1726 Colturani, F., 2545 De Clercq, E., 332 Dworkin, R., 2678 Casadevall, Arturo, 1383 Comodi-Ballanti, M. R., 2618 de Clercq, Erik, 218, 2540 Dykstra, C. C., 1713 Casetta, A., 2159 Condra, Jon H., 947, 1576 de Graaff, J., 1184 Dykstra, Christine C., 2668 Cassileth, Peter A., 474 Conejo, Carmen, 187 de Jonge, Boudewijn L. M., Dylewski, Joseph, 1373 Cataldo-Caputzal, Lucille, Conly, J. M., 574 342 Earnhardt, K. I., 2261 1556 Connelly, Michele C., 2247 de la Coussaye, Echols, Roger, 1670, 2193 Cavalieri, Stephen J., 1171 Connor, Edward, 532 Jean-Emmanuel, 464 Edelstein, Martha A. C., 908 Cave, Andre, 859 Connor, James, 532 de Lalla, Fausto, 2693 Edelstein, Paul H., 908 Cekleniak, Natalie, 1624 Conway, Anthony J., 2033 Delbos, Frangoise, 2593 Edlund, Charlotta, 1665 Cercenado, E., 1604 Cook, James A., 393 del C. Ceinos, Maria, 1728 Edmonds, Kay, 1799 Cercenado, Emilia, 1200 Cooke, N. J., 804 Delehanty, John, 975 Edmund, Michael, 1238 Cesana, M., 2545 Cooksey, Robert C., 1348, Dellamonica, P., 921 Edwards, Barbara A., 2754 Cesana, Marina, 2298 2311 Delouis, Christine, 54 Edwards, David J., 2706 Chachaty, E., 1432 Cookson, Barry, 681 Del Valle, O., 1587 Edwards, Fitzroy F., 398, Chamberland, Suzanne, 1701, Cooley, Timothy P., 1480 Demain, Arnold L., 84 2323 1993, 2571 Cools, Willy, 2101 DeMuria, Deborah, 2187 Edwards, John E., Jr., 546, Chambers, Henry F., 1144 Cooper, Brian W., 234 Denaro, Maurizio, 741 2628 Chan, Chor-Bun, 2007 Cooper, Chester R., Jr., 2407 Denny, William, 403, 991 Egan, William, 1420 Chan, C. Y., 1001 Cooreman, M. P., 1506 De Rosa, Franco, 1679 Ehrett, Stuart, 1630 Chan, Marion Man-Ying, 1909 Corbett, Anita H., 2599 Derouin, Francis, 2371 Eledjam, Jean-Jacques, 464 Chandrasekar, P. H., 1927 Corey, Lawrence, 975 De Sarro, A., 1497 Eling, Wynand M. C., 276 Chapelsky, Martha, 775 Correa-Coronas, Rafael, 474 De Sarro, G. B., 1497 Eliopoulos, C. T., 366 Chaplain, C., 737 Correia, John A., 1270, 2144 Desmyter, Jan, 2540 Eliopoulos, George M., 507, Chastre, Jean, 281 Cory, Michael, 2668 De Souza, Wanderley, 580, 598, 1364, 2009 Chavalitshewinkoon, Porntip, Cosgrove, Yvonne T., 8 2722 Eliopoulos, G. M., 366, 1604 403 Costa, Yannick, 1896 DeStefano, M. S., 2344 Elliott, T. B., 1882 Cheeseman, Sarah H., 178 Costa-Perira, Rabi, 183 Dever, Lisa L., 1115, 1704 Ellner, Jerrold J., 1799, 1807 Chen, Ming, 2550 Costerton, J. W., 2000 DeVore, Kimberly M., 1480 Elsea, Sarah H., 2179 Cheng, A. F. B., 1001 Coudron, Philip E., 1447 Dhindsa, Harinder S., 2754 El Solh, N., 2159 Cheng, Yung-chi, 1420 Courvalin, Patrice, 78, 1456, Diasio, Christoph R., 1771 Emge, Thomas J., 1909 Chichino, Guido, 1492 1563, 1896, 2093, 2119 Diaz, M. Dolores, 1200 Emini, Emilio A., 947, 1576 Chimata, Minoru, 229 Cowsert, Lex M., 171 Dieck, Harold A., 1082 Emori, Masako, 722 Chimirri, A., 1497 Cox, H., 1924 Digranes, Asbj0rn, 2024 Engel, Lee S., 1856 Chin, Nai-Xun, 566 Cozens, Robert, 2087 Dijkstra, Jan, 2293 Enoxacin Prophylaxis Study Chio, Li-Chun, 1914 Craig, William A., 2650 Dionne, Gervais, 130 Group, 474 Chiodini, Rodrick J., 1645 Crane, Deborah D., 357 DiPiro, Joseph T., 1343, 1463 Entenza, J., 921 Chopra, Ian, 153 Crawford, Jack T., 1348 Doherty, Catherine, 123 Entenza, Jose, 1971 Chow, Andrew T., 1468 Cretton, Erika M., 1816 Doherty, Patrick, 1737 Erice, Alejo, 357, 835 Chow, Joseph W., 134, 1187, Crooke, Rosanne M., 1945 Domagala, John M., 2563 Erickson, John, 810 2474 Cruceyra, Antonio, 1717 Dombret, Marie-Christine, 281 Eron, Joseph J., 1480 Chow, Yung-Kang, 1480 Crumpacker, Clyde S., 1095 Donabedian, Susan, 134 Espinel-Ingroff, Ana, 39 Christensen, S0ren Br0gger, Cui, X., 2496 Donabedian, Susan M., 2474 Esteve, Montserrat, 868 2550 Cunningham, Francesca E., Donowitz, G. R., 2261 Etter, L., 2432 Chu, Chung K., 875 1343 Donta, I., 308 Etter, Laura, 1061 Chuah, See Kean, 1711 Curfs, Jo H. A. J., 276 Doury, Jean-Claude, 924 Chuard, Christian, 625 Currens, Michael J., 1037 Downey, Kathleen M., 1127 Fabre, David, 464 VOL. 37, 1993 AUTHOR INDEX iii

Fadat, G., 1955 Fuchs, Peter C., 14 Gilbert, D. N., 347 Hakusui, Hideo, 2173 Faessler, Alex, 2087 Fujii, K., 67 Gilja, Odd Helge, 2024 Halinen, Sirkka, 592 Fagon, Jean-Yves, 281 Fujisawa, Chiho, 2173 Gillespie, S. H., 2493 Hall, Geraldine, 39 Fairley, Terri A., 2668 Fujita, Y., 1043 Gilliland, Susan S., 436, 1377 Hall, J. E., 1713 Faleschini, E., 2545 Fukasawa, Masatomo, 2743 Gillum, J. Gregory, 2193 Hall, Joseph, 592 Falkenstein-Paul, Hildegard, Fukatsu, Hiroshi, 2756 Gilman, Thomas M., 93 Hall, L. M. C., 1637 696 Fukuoka, Takashi, 322 Gilmore, James D., 1452 Hall, M. C., 662 Fallani, Stefania, 2693 Fukuoka, Yoshikazu, 384 Giroux, M., 1232 Halstensen, Alfred, 2024 Fantin, Bruno, 2466 Fukutomi, Yasuo, 2265 Glauser, Michel P., 207, 1971 Halushka, Perry V., 393 Farinotti, Robert, 281 Fulton, David R., 1655 Gleaves, Curt A., 1360 Hamer, Davidson H., 931 Farmer, Susan W., 453 Fung-Tomc, Joan, 213, 1289 Goering, R. V., 2432 Hamilton, H., 1620 Farzadegan, H., 360 Furfine, Eric S., 2285 Goetz, Matthew B., 1334 Hamilton, Robert G., 1463 Farzadegan, Homayoon, 429 Furman, Phillip A., 1720, 2285 Goh, Khye Seng, 652, 1560 Hamilton-Miller, J. M. T., Fass, Robert J., 2080, 2348 Furudera, Takenori, 1826 Gohara, Yukiko, 287, 1826 1558 Faurisson, F., 633 Furuya, Nobuhiko, 675 Gold, H. S., 1604 Hamzeh, Fayez M., 602 Feibusch, Evan L., 106 Goldman, Hy, 1305 Hancock, Robert E. W., 453 Ferencz, Nicholas, 818 Gadgil, Shrikant D., 314 Goldman, Mark E., 947 Hand, Debra L., 2557 Fernandez, Herv6, 54 Gaffar, Maria C., 778 Goldstein, Beth P., 741 Hand, W. Lee, 2557 Ferraro, Mary Jane, 598, 1364 Galgiani, John N., 39, 2126, Goldstein, Ellie J. C., 1150 Hansen, Lori M., 2699 Ferraro, M. J., 366 2517 Goldstein, Neil H., 297 Hansen, Sharon L., 1334 Fey, P. D., 2432 Galimand, Marc, 1456, 1896, Gollapudi, Sastry V., 1711 Hanson, Linda H., 1177, 2224 Fich, Karen, 2550 2093, 2119 Golub, Lorne M., 592 Hanssen, Brenda R., 265 Fichtl, Richard E., 1504 Gallati, Harald, 2418 Gomez, Maria, 1717 Hara, Kohei, 2762 Field, Hugh J., 2478 Galtier, Marc, 464 Gomez, R., 2490 Hardie, J. M., 2493 Fields, Marc T., 203 Galvez, Antonio, 148 Gomez-Jimenez, J., 1587 Harding, G. K. M., 574 Fierer, Joshua, 2293 Gamage, Swarna, 403, 991 Gomez-Lus, Rafael, 138 Hare, Roberta S., 2074 Figgitt, David, 403, 991 Gambertoglio, John, 1137 Gonc,alves, Noemia Hare, R. S., 708 Filadoro, Francesco, 1958 Gangeness, David, 1171 Rodrigues, 2722 Hariprashad, June, 1504 Finegold, S. M., 2638 Gao, Qing, 130, 1390 Gong, Yi-Fei, 2247 Harrington, Joan A., 918 Finegold, Sydney M., 2509 Garber, Sena, 2606 Gooch, W. Manford, III, 159 Harrison, Barbara, 1444 Fischman, Alan J., 1270, 2144 Garcia, I., 2490 Gooding, Beth Briggs, 349 Harvey, Kevin, 2193 Fishman, Jay A., 1543 Garcia, Isabel, 187 Goody, Roger, 2612 Harvey, Tracey, 1711 Flaherty, John, 1137 Garcia, Jesus, 868 Goos, M., 1010 Hase, Toyoji, 363 Flandrois, J. P., 1685 Garcia, M. M., 2638 Gootz, Thomas D., 646, 2179 Hasegawa, Takaaki, 1781 Flexner, C., 360 Garcia-Rodriguez, J. A., 911 Gordillo, Manuel E., 1203 Hasegawa, Takashi, 2217 Flor, Soledad C., 1468 Gardner, Mark J., 314 Gorrens, Jos, 2101 Haselbeck, Bob, 1614 Fluckiger, Ursula, 1971 Gargallo-Viola, Domingo, 868 Gorzynski, Eugene A., 896 Hashimoto, Nobuo, 901 Foca, Alfredo, 393 Garneau, Valerie, 1701 Goss, Thomas F., 1073 Hashizume, Terutaka, 2756 Focht, Josef, 2298 Garon, Claude F., 46 Gotlib, Leah, 1576 Hattori, Hiroaki, 839 Foleno, Barbara D., 301 Gaspar, Erzsebet, 2593 Goto, Sachiko, 60 Hattox, Susan E., 178 Fong, Dunne, 1909 Gasser, I., 1587 Govan, John, 123 Hausler, Alex, 84 Foo, Hsin-Hsin, 2500 Gastafiares, Maria-Jose, 2427 Grady, Robert W., 1082 Havenith, Mick, 218 Foor, Forrest, 84 Gatti, Giorgio, 1137 Graham, Donald J., 1576 Hawkey, P. M., 804 Ford, Harry, Jr., 810 Gaudebout, Claude, 970 Grasso, S., 1497 Hayakawa, Isao, 2112 Ford, Jeanne, 2193 Gaudreau, Christiane, 1174 Green, Michael, 1238 Hayashi, Hideya, 810 Forrest, Alan, 1065, 1073, Geggel, Robert L., 1655 Grewal, Jaswinder, 2645 Hayashi, Ryogo, 100 2187 Gehanno, Pierre, 1599 Griffith, Jeffrey K., 1253 Hayden, Frederick G., 297 Fothergill, Annette W., 2307 Geisel, Janet, 393 Griggs, D. J., 662 Hayes, Michael M., 2500 Fouda, Hassan G., 314 Geleziunas, Romas, 1305 Grill, Susan, 1420 Hayman, Alan C., 246 Fournet, Alain, 859 Gelfusa, Vincenzo, 1190 Groothuis, Jessie R., 1655 Hayran, Murat, 1831 Fournier, Genevieve, 2020 George, Robert C., 681 Grosset, Jacques, 407, 692, Healy, Niamh, 1473 Foweraker, J. E., 804 George, William J., 818 1690 Heifets, Leonid, 111, 1380, Fox, Maureen C., 171 Georgii, Aletta, 2064 Gu, Ligang, 2265 2364 Foy, Jilanna, 1436 Georgopapadakou, N. H., Gu, Zhengxian, 130, 1390 Heijtink, R. A., 595 Frachet, B., 2674 559, 2045 Guay, David R. P., 436 Heikkila, Elina, 1297 Fraimow, Henry S., 2736 Gerard, Geoffrey C., 1334 Guay, Gordon G., 191 Heisig, Peter, 696 Francioli, Patrick, 1971 Gerbaud, Guy, 1456, 2093 Gueret, Dominique, 970 Heller, Allen H., 2193 Francioli, Patrick B., 207 Gerlach, E. H., 1696 Guerillot, F., 1685 Hemming, Val G., 1655 Franzblau, Scott G., 1997 Gerok, Wolfgang, 1539 Guerra, Isabel, 148 Hendrix, Craig W., 429 Franzini, P., 2545 Ghaleh, Bijan, 1777 Guerry, Philippe, 2599 Hengels, K. J., 1506 Freifeld, Alison, 495 Ghannoum, Mahmoud A., Guinea, Jesus, 868 Hengge, U. R., 1010 French, Pamela, 2736 546, 2628 Gulakowski, Robert J., 754 Henry, N. K., 554 Fresnadillo, M. J., 911 Ghezzi, Maria Cristina, 1958 Gulnik, Sergei, 810 Herndon, Betty L., 203 Frey, Carrie, 39 Ghezzi, Pietro, 2527 Gunther, Michael R., 950 Herrero, J. A., 2490 Frick, Lloyd W., 2285 Ghione, Mario, 1492 Gupta, Pramod, 864, 1329 Hesse, Werner H., 2622 Fridland, Arnold, 2247 Ghosh, Dilip Kumar, 2459 Gupta, Rachna, 882 Heudes, Didier, 1790 Friedland, Ian R., 1630 Giamarellou, Helen, 308 Gur, D., 1637 Hewitt, Ross G., 512 Froelich-Ammon, Stacie J., Gibert, Claude, 281 Gur, Deniz, 1831 Heykants, Jos, 2224 646 Gikas, Achilleas, 51 Gutmann, L., 1406 Hickey, Sheila, 1630 Fromtling, Robert A., 39 Gilbart, James, 32 Gutmann, Laurent, 1247, 1387 Hidaka, T., 67 Frost, R. Wayne, 2106 Gilbert, D., 2678 Hidaka, Takayoshi, 722 Fu, K. P., 301 Gilbert, Deborah, 1723 Haag, Jo Jean, 1670 Hikida, Muneo, 199 Fuchs, P. C., 893 Gilbert, Deborah H., 1756 Hackbarth, Corinne J., 1144 Hill, Bertha C., 2311 iv AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Hill, Craig L., 1707 Imada, Akira, 100 Kaatz, Glenn W., 128, 1086 Koehler, Joy M., 905 Hill, Edgar, 975 Imagawa, Yatsuka, 2486 Kabir, I., 1572 Koenig, Bernhard, 2612 Hill, James M., 1856 Imbimbo, B. P., 2545 Kadurugamuwa, Jagath L., Koeppe, Peter, 1835, 2153 Hille, Heidemarie, 2153 Imbimbo, Bruno P., 637, 2212 715 Koffel, Jean-Claude, 1873 Hilligoss, Donald M., 314 Imboden, Paul, 2054 Kageyama, Seiji, 810 Koga, Hironobu, 1877, 2762 Hintermann, Gilberto, 84 Imhoff, Tracy, 2030 Kaiser, Allen B., 702 Koga, Tetsufumi, 1749 Hiraga, Y., 1043 Immendoerfer, Ulrike, 2612 Kaku, Mitsuo, 2762 Koh, Julia G., 778 Hirakata, Yoichi, 675 Imtiaz, Uzma, 2438 Kakuta, Sachiko, 229 Kohlhepp, S., 2678 Hiramatsu, Keiichi, 1219, Inagaki, Yoshio, 2486 Kallenius, Gunilla, 1285 Kohlhepp, S. J., 347 2278 Inamatsu, T., 1043 Kalvakuntla, Laxman, 729 Kohnen, P. W., 347 Hirata, Michimasa, 2534 Inciardi, John F., 1025 Kam, Kai-Man, 2007 Kohno, Shigeru, 1877, 2762 Hirata, Takahiro, 2656 Ingman, Tuula, 592 Kamchonwongpaisan, Kojima, Tsuyoshi, 839 Hirsch, Martin S., 1480 Inomata, Norikazu, 199 Sumalee, 1108 Koks, Cornelis H. W., 1426 Hirsh, Dwight C., 2699 Inoue, Eiko, 1547 Kamide, Ryoichi, 2217 Kolek, Benjamin, 213, 1289 Hiscott, John, 130 Inukai, Masatoshi, 980 Kamiyama, Tsutomu, 2656 Kolenda, Herbert, 1518 Hiscox, Steven A., 1473 Ioannides-Demos, Lisa L., Kamwan, Chantana, 2407 Kondoh, Masumi, 2662 Hitchcock, C. A., 1962 914 Kaplan, Edward L., 159 Konttinen, Yrjo T., 592 Hitchcock, Michael J. M., Irvin, James D., 835 Kaplan, Joan C., 1480 Kopp, U., 224 1816 Isaacson, David M., 301 Kaplan, Sheldon L., 2401, Koranyi, Katalin I., 314 Hizi, Amnon, 1037 Ishida, Hiroko, 2112 2522 Kort, Jens J., 115 Hjeln, Ulrika, 1285 Ishida, Mariko, 2327 Kar, Kalipada, 2459 Korting, Hans C., 2064 H,o, Chi-Tang, 1909 Islam, A., 1572 Kar, Sujata, 2459 Kotani, Hitoshi, 2500 Ho, Dah Hsi, 2504 Isono, Fujio, 980 Karayiannakos, P., 308 Kotnik, V., 1786 Ho, May, 2418 Israel, Debra, 2139, 2193 Karlowsky, James A., 1154 Koup, Richard A., 178 Hoban, Daryl J., 1154 Ito, Hideaki, 839 Karp, Judith E., 1847 Kovacs, Joseph A., 1227, Hobden, Jeffery A., 1856 Itoh, Tomoo, 2327 Kato, Haru, 957 1674 Hocquemiller, Reynald, 859 Iwagaki, Akitaka, 164 Kato, Katsuyoshi, 1781 Krahenbuhl, James L., 2265 Hoepelman, Andy I. M., 885 Iwahi, Tomoyuki, 100, 769 Kato, Michiyuki, 1764 Krausgrill, P., 1506 Hoffman, Jacob M., 947 Iwasaki, Shigeo, 1313 Kato, Naoki, 957 Kreeger, John M., 1645 Hoffner, Sven E., 1285 Iwatani, Wakao, 785 Kato, Nobuo, 984, 1781 Krinke, Alison J., 2454 H0iby, E. Arne, 2024 Katsuta, Mitsuo, 322 Kristensen, Gun, 1665 Holder, Ian A., 1890 Jackson, M. Keven, 2716 Kauffman, Carol A., 2003 Kruse, James A., 1927 Holy, A., 332 Jackson, W. E., 1882 Kaufhold, Achim, 2740 Krusell, Allan R., 1132 Holy, Antonin, 2540 Jacoberger, Bernadette, 1873 Kaul, Sanjeev, 1160, 1816 Kubat, Tina, 1171 Honore, Nadine, 414 Jacobs, Michael R., 1799, Kawada, Harumi, 1749 Kuebelbeck, Virginia, 835 Hoogkamer, Johannes F. W., 1807 Kazanjian, Powel H., 2187 Kumar, Ashir, 159 2622 Jacobs, M. R., 1649 Keirns, James J., 178 Kuo, Cho-Chou, 8 Hoogkamp-Korstanje, Jacobs, William R., Jr., 1348 Kellam, Paul, 1525 Kurata, Tadashi, 2173 J. A. A., 2017 Jacobus, David P., 1417 Kenny, George E., 1726 Kuritzkes, Daniel R., 1095 Hook, Edward W., III, 1670 Jacobus, Nilda V., 2270 Kernodle, Douglas S., 702 Kurtzberg, Joanne, 144 Hooper, David C., 2588 Jacoby, George A., 2760 Kessler, Joseph A., 144 Kusne, Shimon, 1238 Hoosen, Anwar A., 2733 Jansen, Robert W., 441 Keusch, Gerald, 1056 Kuwahara-Arai, Kyoko, 1219 Hopkins, Sam, 1720 Janssen, David A., 2003 Keyhani, Afsaneh, 246, 2584 Kuwano, Koichi, 287, 1826 Horaud, Thea, 2593 Jantos, Christian, 846 Kharazmi, Arsalan, 2550 Kuypers, Frans, 1108 Hori, Satoshi, 2278 Japour, Anthony J., 1095 Khardori, Nancy, 729, 882 Horii, Toshinobu, 984 Jarvinen, Helina, 1158 Kharsany, Ayesha B. M., Labia, Roger, 939, 962 Horiuchi, Sankichi, 2486 Jarvis, Ken, 1329 2733 LaBombardi, Vincent J., 1556 Hoshino, Kazuki, 2112 Jarvis, Kenneth, 864 Kibbler, C. C., 2493 Lachance, Nathalie, 1174 Hostetler, John S., 2224 Jayanetra, P., 2000 Kidd, Lauren B., 1816 Lacroix, Jean-Michel, 2037 Houck, Herbert J., 613 Jeanfavre, Deborah Durham, Kiehn, Timothy E., 2323 Ladizensky, Esther, 2483 Hougen, Thomas, 1655 1693 Kierszenbaum, Felipe, 2235 Lafredo, Stephen C., 301 Howell, John M., 2754 Jefson, Martin R., 646 Killmar, John, 1417 Lagrange, Philippe H., 2020 Howells, R. E., 2337 Jehl, F., 1488 Kimura, Masashi, 801 Lahiri, M., 1197 Howells, Robert E., 1318 Jehl, Francois, 501 Kimura, Sadao, 2228 Lai, Cham-Fai, 2007 Huang, Hua-Bin, 566 Ji, Baohong, 407 King, Anna, 746 Lai, Jiunu, 1614 Huang, Jun-Li, 1370 Jin, Y. F., 662 Kinowski, Jean-Marie, 464 Laizure, S. Casey, 448 Huang, Wai Mun, 457 Jindrich, J., 332 Kinsman, Oonagh S., 1243 Lalande, Valerie, 407 Huart, Alain, 1777 Jindrich, Jindrich, 2540 Kinzig, M., 1860 Lam, Joseph S., 715 Huband, Michael D., 2563 John, Joseph F., 1334 Kishimoto, Toshio, 801 Lam, K., 2000 Hughes, George S., 2650 Johnson, C. C., 2069 Kishore, Alugupalli R., 240 Lam, Patrick Y.-S., 2606 Hughes, Stephen H., 1037 Johnson, Curtis A., 2650 Kiso, Yoshiaki, 810 Lambert, C., 1860 Hughes, Walter T., 1417 Johnson, David E., 483 Kitzis, Marie-Dominique, 1387 Lambert, Dennis M., 71 Huhn, Dieter, 1367 Johnson, Elma, 1264 Kleim, Jorg-Peter, 1659 Lambert, Thierry, 1456, 2093 Huls, Christine E., 1414 Johnson, E. M., 1962 Kiemens, S. P., 2344 Lamer, Christian, 281 Huovinen, Pentti, 1158, 1297 Johnson, James R., 2033 Kleter, G. E. M., 595 Lamothe, Francois, 1174 Husson, M., 1860 Johnson, Lance C., 441 Klietmann, Wolfgang, 2298 Lamp, Kenneth C., 605, 1931 Johnson, Victoria A., 1095 Klimkait, Thomas, 2087 Landman, David, 1904 Ibrahim, Ashraf S., 546, 2628 Jones, R. N., 1696 Klimm, K., 366 Lane, James, 532, 1095, 1127 Ichiyama, Satoshi, 984 Jones, Robert B., 1670 Kiopman, Gilles, 1799, 1807 Laneelle, Gilbert, 1536 Iijima, Masako, 322 Jones, Ronald N., 349, 2747 Klugman, Keith P., 1938 Lang, Marc, 2087 lizawa, Yuji, 100 Jones, S. K., 1713 Knapp, C. C., 1696 Lang, R., 2333 Ikeda, Yasushi, 384 Jorgensen, James H., 1115, Knapp, Joan S., 1552 Lange, Joep M. A., 1525 Ilksoy, Nurcan, 875 1704 Kobayashi, Teruaki, 2042 Lantero, Marta, 2427 VOL. 37, 1993 AUTHOR INDEX v

Larder, Brendan A., 1525 Lo, Kuen-Kong, 2007 Martin, Stephan, 1278 Miksits, Klaus, 1367 Larrick, James W., 2534 Lo, Shyh-Ching, 2500 Martinez, Anthony, 1674 Milatovic, D., 1620 Larsson, Alison J., 1377 Lockwood, Graham, 297 Martinez, J. L., 1982 Miller, Carole B., 1847 Last-Barney, Kathleen, 1693 LoCoco, John M., 301 Martinez-Bueno, M., 148 Miller, George H., 2074 Lastilla, Marco Gregorio, 1679 Lode, Hartmut, 1835 Martinez-Vazquez, J. M., Miller, G. H., 708 Lavoie, Suzanne R., 1447 Lombardi, F., 2545 1587 Miller, Jeffry, 2139 Lawlor, Michael T., 234 Loncle, V., 2159 Martino, Piero, 1190 Millet, V., 2239 Lawrence, A. Jean, 1869 Long, William J., 1576 Marutani, Kiyoshi, 2217 Milocchi, Fabio, 2693 Lawrence, Theresa, 896 Lonks, John R., 1742 Marx, Gerald R., 1655 Mimoto, Tsutomu, 810 Lawrence, William D., 512 Lopardo, Horacio A., 1728 Marzella, Louis, 120 Minamimura, Masashi, 1547 Lazard, Thierry, 692, 1690 Lopez-Berestein, Gabriel, 246 Mason, Edward O., Jr., 2401, Mirabelli, Christopher K., 171 Lazardi, Keyla, 580 Lorscheider, Fritz L., 825 2522 Mitra, U., 1197 Lazdins, Janis, 2087 Lortholary, Olivier, 1790 Massidda, Orietta, 1324 Mitsuhashi, Susumu, 793, Lazzaroni, Marco, 2212 Louchahi, K., 737, 2674 Masuda, Nobuhisa, 322 1547 LeBlanc, Barbara, 2504 Louis, F. J., 1955 Masukawa, Yoshikazu, 199 Mitsutake, Kotaro, 2762 Le Bras, J., 1955 Louis, J.-P., 1955 Matera, Giovanni, 393 Mitsuya, Hiroaki, 810 Le Bras, Jacques, 924, 970 Lowdin, Elisabeth, 2200 Materman, E., 1620 Mitten, Michael, 1329 Lebsack, M. E., 775 Lu, Zhihong, 1771 Mathez, Dominique, 2206 Mitten, Mike, 864 Leclercq, Roland, 78, 789, Lumbreras, C., 2490 Matsubara, Shuzo, 1826, 2217 Miyasaki, Kenneth T., 2710 1896, 2119, 2466 Lupia, Raul H., 818 Matsuda, Kouji, 2756 Miyazaki, Haruko M., 2762 Lee, Hsi-Ming, 592 Luthy, Ruedi, 1056 Matsumoto, Fumio, 2217 Miyazaki, Shuichi, 60 Lee, K., 2638 Matsumoto, Keizo, 164 Miyazaki, Yoshitsugu, 2762 Lee, Ving J., 851, 2270 Maass, Gerhard, 2612 Matsumoto, Masahiko, 2217 Miyoshi, Akio, 2217 Lee, Yun-Sang, 2007 Macalintal, Clarissa, 851 Mattie, H., 2318 Mobarakai, Neville K., 1904 Leemann, T., 2132 Maderazo, Eufronio G., 1132 Matumoto, Masahiko, 1826 Mobashery, Shahriar, 2438 Leggett, J., 2678 Maeda, Akio, 1313 Mauel, Jacques, 991 Mochizuki, Hidenori, 2412 Le Gros, V., 737, 2674 Maeland, Arild, 2443 Maurin, M., 1410, 2633 Moellering, R. C., Jr., 366, Lei, Shau-Ping, 1614 Magallanes, Marcus, 2293 Maxwell, Anthony, 126 1604 Leibowitch, Jacques, 2206 Magnuson, Terry, 1610 Mayers, Douglas L., 1095, Moellering, Robert C., Jr., Le Jeune, Ludo, 2101 Mahr, Gerhard, 1518 1127 507, 598, 1364, 2009 Lemeteil, Denis, 889 Majerus, P., 142 Mayhall, C. Glen, 1334 Moguilevsky, N., 142 Lemmich, Else, 2550 Majumder, Sarmila, 2235 Mazzolla, Rosanna, 2422 Moland, Ellen S., 260 Lentino, Joseph R., 339 Malanoski, Gregory J., 598, McClure, Harold M., 1816 Molina, Judith, 1353 Lepine, Guylaine, 2037 2009 McCracken, George H., Jr., Molinas, Catherine, 78 Lepocher, H., 1410 Maldonado, Rosa A., 1353 1630 Molitoris, Eric, 2509 Lerner, Stephen A., 2438 Maldonado, Rosa Amelia, 580 McEntee, M. F., 360 Moloo, Shamshudeen K., Lertora, Juan J. L., 818 Malessa, R., 1010 McGahren, Jim, 1624 1163 Leser, Ulrike, 2612 Maliszewski, Maureen L., 512 McGlynn, Marion, 1624 Moncada, Jeanne, 1746 Leske, Valeria L., 835 Mallet, D., 1410 McGrath, Betty J., 1723, 1931 Mondain, V., 921 Lettieri, John T., 2106 Mallie, Jean-Pierre, 1510 McGuirk, Paul R., 646, 2179 Monteil, H., 1488 Levin, James M., 1444 Mamber, Stephen W., 213 McKiel, Joan R., 1756 Monteil, Henri, 501 Levison, M. E., 2069 Mamman, Mohammed, 1050 Mc.Koy, Judith, 1264 Montgomerie, John Z., 1334 Levitsky, Sidney, 2106 Manavathu, Elias K., 2438, McLaughlin, Margaret M., Moody, Julia A., 2454 Levy, Stuart B., 825, 2699 2645 178 Moore, Carol, 1264 Lew, Daniel P., 625 Mancini, Carlo, 1958 McLean, Allan J., 914 Mor, Natan, 111, 1380, 2364 Lew, D. P., 2132 Mann, Paul A., 2074 McLinn, Samuel E., 159 Moreno, E., 2490 Lewin, Clement, 123 Mansat, V., 1232 McMahon, James B., 754, Morgan, U. M., 328 Lewis, Mark G., 71 Mant, Tim G. K., 637 1037 Morikawa, Keiko, 270, 2684 Li, Cong, 2030 Mao, Jinghe, 950 McMillan, Angela, 875 Morikawa, Shigeru, 270, 2684 Li, M. S. K., 1001 Maqueda, Mercedes, 148 McMurry, Laura M., 2699 Morisaki, Naoko, 1313 Li, Ronald C., 371, 523 Maraki, Sofia, 51 McNally, Eugene J., 1693 Morris, Anne B., 1 Li, Shu C., 914 Marceau-Day, M. L., 2506 McNamara, Patrick J., 2706 Morrison, Donald, 681 Liebman, Howard A., 1480 Marchan, Edgar, 580 McQueen, Teresa J., 2584 Morrison, Paul J., 637 Lietman, Paul S., 429, 602 Marchbanks, C. Randall, McWhinney, P. H. M., 2493 Morrison, Susan, 532 Lim, Seung T., 1264 1723, 1756 Mechlinski, Witold, 778 Morse, Gene D., 512 Lima, Viera, 1108 Marchesi, Francine, 2054 Medeiros, Antone A., 1742 Moskovitz, Bruce L., 778 Lindley, Ivan J. D., 276 Marco, Francesc, 138 Meenhorst, Pieter L., 1426 Mourton, Tracy, 1610 Lindquist, S., 224 Marcos, Angeles, 138 Mehl, Paul, 2470 Moynihan, Melinda, 2179 Lindstrom, Terry D., 265 Margolick, Joseph B., 429 Mehta, Reeta T., 2584 Mroczkowski, Tomasz F., Lindy, Otso, 592 Marichal, Patrick, 2101 Meichsner, Christoph, 1659 1670 Lins, Ulysses, 2722 Mariotte, Sophie, 939 Meissner, H. Cody, 1655 Mueller, Barbara, 2612 Liotta, Dennis C., 875, 1720, Markham, Richard B., 429 Mellors, John W., 875 Muffat-Joly, Martine, 1599 2206, 2285 Markowitz, Sheldon M., 1447 Menard, Robert, 78 Muller, Hans-Jochen, 1835 Lipke, Peter N., 1264 Marler, J. K., 1122 Menck, Sylvia, 1518 Mulligan, Maury E., 1334 Littlejohn, Tim G., 761 Marlin, Steven D., 1693 Menninger, John R., 2027 Mummaw, Nancy, 89 Liu, Tiepu, 1771 Marrakchi-Benjaafar, S., 633 Merluzzi, Vincent J., 1693 Munayyer, H., 708 Liu, Yu-Ying, 2144 Marshall, Bonnie, 825 Merz, William G., 1847, 2407 Munioz, Patricia, 1200 Livermore, David G., 1243 Marshall, Steven A., 2747 Meservey, Mark A., 2563 Mufioz, Victoria, 859 Livermore, D. M., 1637 Marshall, Steven H., 2760 Meshnick, Steven R., 1108 Murakami, Kimihiro, 2412 Livni, E., 1270, 2144 Martel, A. Y., 574 Meyer, A. P., 2318 Murakawa, Yohko, 810 Livornese, L. L., 2069 Martin, Andrea, 1278 Michel-Briand, Yvon, 962 Murphy, Noel B., 1163, 1167 Lizasoain, M., 2490 Martin, David H., 1670, 1986 Mierzwa, Ronald, 2074 Murray, Barbara E., 1203, Lloyd, Robert M., Jr., 875 Martin, J. Louise, 1720 Mikami, Yuzuru, 1313 1966 vi AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Murray, Gilles, 1373 Niu, Wei Wei, 667 Pangon, B., 737 Pocidalo, Jean-Jacques, 692, Murray, Henry W., 1504 Nix, David E., 371, 523, 775, Pankuch, G. A., 1649 1599, 1690 Murray, P. R., 1696 1065, 1073 Paradiso, Linda, 474 Pocidalo, J. J., 633 Muth, Peter, 1518 Nochy, Dominique, 1790 Pares, Marta, 868 Pohl, Jan, 2710 Muthiani, Anthony M., 1167 Nolte, Frederick B., 39 Paris, Maria, 1630 Poiesz, Bernard, 512 Myers, Dorothea E., 835 Nomizu, Motoyoshi, 810 Park, Matthew K., 120 Polk, Ronald, 2193 Myers, Roy A. M., 120 Noordergraaf, J. H., 317 Parker, Anita C., 1028, 2391 Polk, Ron E., 2139 Mylvaganam, Haima, 2024 Nord, Carl Erik, 1665 Parker, William B., 1004 Pollack, Jay R., 1171 Norden, C. W., 1580 Parniak, Michael A., 1390 Pollack, Matthew, 164 Naas, Thierry, 939, 962 Nordlander, E., 1977 Paschalides, Panagiotis, 495 Poncioni, Bernard, 2087 Nabeshima, Toshitaka, 1781 Nordmann, P., 1406 Pascual, Alvaro, 187 Ponglertnapagorn, Preecha, Nadai, Masayuki, 1781 Nordmann, Patrice, 939, 962 Pasculle, A. William, 1238 164 Nadelmann, Lynda, 2550 Noriega, A. R., 2490 Passariello, C., 2618 Poppe, Susan M., 1127 Naesens, L., 332 Norman, Allyn, 775 Patchen, M. L., 1882 Porro, Gabriele Bianchi, 2212 Nagamuta, Masahiro, 2217 Normark, S., 224 Patel, Jayesh A., 339 Portmann, R., 293, 2132 Nagano, Hiroyuki, 2217 Norwegian Yeast Study Patel, S., 2493 Potgieter, Elsa, 2740 Nagase, Mitsumasa, 229 Group, 2443 Patterson, Jan Evans, 134 Pottecher, Thierry, 501 Nagata, Kumiko, 769 Noskin, Gary A., 2470 Patterson, Thomas F., 2307 Pourtois, M., 142 Nagatake, Tsuyoshi, 164 Novelli, Andrea, 2693 Patton, Dorothy L., 8 Powell, Francoise, 1227 Powell, Marie, 1264 Nagrajan, K., 183 Oberg, Bo, 1370 Patton, Melissa, 2244 Nahata, Milap C., 314 Paulfeuerborn, Wolfgang, 1835 Pozzi, Luann M., 19 O'Brien, Julie A., 947 Pradier, C., 921 Naidu, A. Satyanarayan, 240 O'Callaghan, Richard J., 1856 Paulsen, Ian T., 761 Naidu, Smita S., 240 Pav, Joseph W., 178 Pramanik, A. J., 1264 Odds, Frank C., 39, 685 Prange, Hilmar W., 1518 Naiman, N. A., 1713 Odenholt-Tornqvist, Inga, Pavicic, M. J. A. M. P., 1184 Naiman, Noreen A., 2668 Payares, Gilberto, 580, 1353 Prichard, Lynn E., 540 2200 Prichard, Mark N., 540 Nakada, Naoki, 2656 Offensperger, Silke, 1539 Pearson, Bridget A., 1473 Nakae, Taiji, 2385 Pedemonte, Ronald, 754 Prince, Alice, 667 Offensperger, Wolf-Bernhard, Prince, Randall A., 1414 Nakagawa, Susumu, 2756 1539 Pefanis, Angelos, 308, 507 Nakamura, Mika, 839 Pelaez, Teresa, 1200 Privitera, G., 2545 Ogawa, Nobuya, 2042 Proenca, Rui, 667 Nakamura, Shinichi, 839 Oguma, T., 1043 Pellizzer, Giampietro, 2693 Nakamura, Yumiko, 2662 Peng, Tao, 2126 Progulske-Fox, Ann, 2037 Ohashi, Masayuki, 2412 Prosser, Barbara L., 2144 Nakano, Shigeyuki, 2042 Ohdo, Shigehiro, 2042 Penn, Charles R., 1473 Nakaya, Rintaro, 2486 Pennell, Andrew T., 1343 Pryka, Randy D., 2106 Ohmichi, M., 1043 Pudney, Mary, 2371 Nakayama, Noboru, 2662 Ohno, Akira, 675 Penni, Adrio, 1190 Namavar, F., 1184 Perea, Evelio J., 187 Puel, J., 1232 Ohshima, Yumi, 2173 Pulverer, Gerhard, 750 Narayan, O., 360 Ohshita, Yoshihiro, 2278 Peregrine, Andrew S., 1050, Narayanan, Ven L., 754 1163, 1167 Pussard, Eric, 970 Ohta, Michio, 984 Pye, G. W., 1962 Narita, Hirokazu, 384 Ohya, Satoshi, 322 Perfect, John R., 903, 2449 Narita, Teruo, 322 Oishi, Kazunori, 164 Periti, Piero, 2693 Quale, John M., 1904 Nash, Donald R., 1850 Oizumi, Kotaro, 287 Perri, Mary Beth, 134, 1187, Queener, Sherry F., 1543, Nasr, Mohamed, 2166 Okamoto, Osamu, 2756 2474 1914, 2166 Nateghpour, M., 2337 Okamura, Noboru, 2486 Perronne, Christian, 692, 1690 Quemard, Annaik, 1536 Nau, Roland, 1518 Okazaki, Osamu, 2173 Perry, Caroline R., 32 Quinn, John P., 1989 Ndifor, Anthony M., 1318 Okonogi, Kenji, 100 Perry, Greg, 637 Quinquis, Valerie, 54 Ndoutamia, Guelmbaye, 1163 Oleske, James, 532 Peter, Jean-Daniel, 501 Quint, W. G. V., 595 Nelson, Donald J., 2285 Oliary, J., 2674 Petersen, Peter J., 2270 Quintero, Julio C., 1576 Nelson, Jeffrey A., 1444 Ollert, Markus W., 2064 Petitjean, O., 737, 2674 Quintiliani, Richard, 234 Nelson, Kenrad E., 2407 Olsen, Kurt, 1630 Petteway, Stephen R., Jr., 71 Nerhood, Lynda, 429 Onuki, Youichi, 2327 Pettinger, Mary B., 1360 Radstrom, Peter, 761 Nervetti, G., 2545 Opravil, Milos, 1056 Petty, Brent G., 429 Raffi, Francois, 1777 Neu, Harold C., 566 Osada, Yasuaki, 2112 Pfaff, Eberhard, 2612 Ragual, Rhonda J., 1334 Neumann, Theresa, 2244 Osborne, A. J., 2069 Pfaller, M. A., 893 Rainey, Petrie M., 1842 Neumann, Theresa M., 1670 Oseko, Fumimaro, 270, 2684 Pfaller, Michael A., 14, 39 Ralph, Ray, 403, 991 Neyfakh, Alexander A., 128 Osheroff, Neil, 646, 2179, Pfefferkom, Elmer R., 2358 Ramiliarisoa, Olivao, 924 Ng, Eva Y., 2588 2599 Pflieger, Philippe, 2599 Rand, Kenneth H., 613 Ngoma, Michel, 901 Osmon, D. R., 554 Phan, Lienhanh, 2241 Rankin, Catherine D., 144 Ngu, Jacob L., 1318 Ossi, Michael J., 159 Philippon, Alain, 2020 Ransijn, Adriana, 991 Nguyen, Hieu, 729 Otabe, Yohko, 2217 Phillips, Ian, 746 Raoult, D., 491, 1410, 2633 Nguyen, Minh-Hong, 875 Otero, J. R., 2490 Phillips, Robert, 1373 Raoult, Didier, 1214, 1733 Nicastri, Emanuele, 1190 Otteni, Jean-Claude, 1873 Picazo, Juan J., 1717 Raponi, Giammarco, 1958 Nicastro, G., 2545 Otto, Michael J., 2606 Pichichero, Michael E., 159 Rasaily, R., 1197 Nicolas, Marie-Helene, 939 Ou, Ching-Nan, 2401 Piddock, L. J. V., 662 Rasmussen, Beth A., 851, Nicolas, M. H., 1406 Pilkiewicz, Frank G., 1869 1989 Nicolle, L. E., 574 Paccaly-Moulin, Anne, 407 Piperacillin-Tazobactam Skin Rastogi, Nalin, 652, 1560 Nightingale, Charles H., 234 Pacheco, Nancy D., 2688 and Skin Structure Study Rather, Philip N., 2074 Nightingale, Stephen D., 1869 Pachucki, Constance T., 339 Group, 1580 Rather, P. N., 708 Nikaido, Hiroshi, 322, 1393 Paessens, Arno, 1659 Piras, Marta M., 580 Rathod, Pradipsinh K., 1102 Niki, Yoshihito, 801 Pagano, Joseph S., 144 Piras, Romano, 580 Ravens, U., 1010 Nimmo, G., 1924 Pahissa, A., 1587 Piret, Jacqueline, 84 Ray, Stephen, 1270 Nishikawa, Sae, 2042 Painter, Barbara, 1756 Pitha, P., 360 Rayner, Marlene M., 2606 Nishikawa, T., 1043 Painter, George, 1720 Pitsakis, P. G., 2069 Reardon, John E., 918 Nishiki, Katsuyuki, 199 Painter, George R., 2285 Pitzurra, Lucia, 2422 Reboli, Annette C., 1334 Nishimoto, Mitsunobu, 287 Pal, Kollol, 1693 Pizzo, Philip A., 495 Reichart, Cindy, 2244 VOL. 37, 1993 AUTHOR INDEX vii

Reichelderfer, Patricia S., Rozenberg-Arska, Maja, 885 Schleif, William A., 947, 1576 Sluchak, Julia A., 1927 1095 Rubeglio, Etelvina A., 1728 Schloegel, M., 1488 Smaoui, Hatem, 1510 Reid, Carol D., 2606 Rubin, Robert H., 619, 1270, Schmidheini, Tobias, 2054 Smith, Anthony M., 1938 Reig, Roser, 138 2144 Schmidts, Hans-Ludwig, 846 Smith, C. Jeffrey, 1028, 2391 Reilly, J., 1180 Rubinstein, E., 2333 Schneider, Christine L., 1576 Smith, Colin, 1243 Renard, S., 1432 Ruble, Cheryl A., 1086 Schneider, Peter, 2087 Smith, James W., 2166 Rende-Fournier, Rosanna, Ruffing, Thomas L., 947 Schols, D., 332 Smith, Marilyn S., 144 2119 Ruhnke, Markus, 2153 Schrenzel, J., 2132 Smithuis, F. M., 1977 Resconi, Anna, 741 RV-43 Study Group, The, Schulman, Marvin, 1737 Snoeck, R., 332 Resnick, Lionel, 1127 1095 Schultz, Robert J., 754 Snydman, David R., 1655 Reuhl, Kenneth R., 419 Ryan, D. Michael, 1473 Schulze, Andrea, 750 So, Antero G., 1127 Reusser, Fritz, 1127 Rybak, Michael J., 605, 1931 Schuurman, Rob, 2231 Soejima, Rinzo, 801 Reynoldson, J. A., 328 Ryzlak, Maria T., 419 Scotti, Roberto, 741 Soike, Kenneth F., 1370 Rhodes, Audrey, 1576 Sedman, Allen J., 775 Soler, Paul, 281 Ribera, E., 1587 Saari, Herkko, 592 See, Darryl M., 1593 Sommadossi, Jean-Pierre, Ribner, Bruce S., 1334 Sacks, Steven, 637 Segal, Jack L., 93 1816 Rice, Louis B., 610, 1061, Safrin, Sharon, 975, 2241 Segatore, Bernardetta, 1324 Sonke, R. Lee, 532 2760 Sagiv, R., 293 Segreti, John, 1444 Sonoda, Fuminari, 164 Rice, Roselyn J., 1552 Saha, M. R., 1197 Seifert, Harald, 750 Soong, Seng-jaw, 1771 Rich, Josiah, 2187 Saissi, Gilbert, 464 Seifert, Michael, 2153 Sorgel, F., 1860 Richardson, Judith F., 1219 Saito, A., 1043 Seilheimer, Dan K., 1414 Sorgel, Fritz, 1518 Richman, Douglas D., 1207 Saito, H., 67, 1259 Selan, L., 2618 Sorsa, Timo, 592 Ricketts, Anthony P., 2358 Saito, Hajime, 722 Selsted, Michael E., 2628 Soussy, Claude J., 2588 Riess, Gunther, 1659 Saleh-Mghir, A., 633 Semmel, Marianne, 26 Spector, Thomas, 602, 918 Rigon, Antonio, 2693 Saletan, Stephen L., 1869 Seo, Susan M., 1086 Sperber, Steven J., 106 Rimland, David, 1334 Samonis, George, 51 Seta, Nathalie, 1790 Spicer, W. John, 914 Rinaldi, Michael G., 39, 1383, Samuels, D. Scott, 46 Setacci, Domenico, 1324 Spitzer, Eric D., 1383 1847, 2307 Sanada, Minoru, 2756 Setogawa, Tomoichi, 722 Spratt, Brian G., 1938 Ringwald, Pascal, 924 Sanchez, Ana, 1717 Shaddix, Sue C., 1004 Springer, Timothy A., 1278 Ripamonti, Franca, 741 Sanders, Christine C., 251, Shafer, William M., 2710 Srdanov, Gordana, 1707 Risse, Gisa, 1367 260, 1375, 2578 Shafran, S. D., 574 Srinivas, Ranga V., 2247 Rittel, Werner, 183 Sanders, Paula L., 448 Shaharabany, Miriam, 1037 Stair, Thomas O., 2754 Robbins, Brian L., 2247 Sanders, W. Eugene, Jr., 260 Shannon, William M., 1004 Stals, Frans S., 218 Robert, Alexandre, 1510 Sands, Michael, 1 Shapiro, Theresa A., 1193 Stanat, Sylvia C., 19 Robert, Marta, 868 Sandven, Per, 2443 Shasha, B., 2333 Standiford, Harold C., 483, Roberts, Glenn D., 39 Sangaletti, Ornella, 2212 Shaw, Karen J., 2074 1334 Roberts, William L., 1842 Sannerud, Kim J., 835 Shaw, K. J., 708 Stanislawski, Lena, 26 Robillard, Norman J., 1756 Sansano, Sebastiano, 2622 Shawar, Ribhi, 882 Stanislawski, Marc, 26 Rodriguez-Creixems, Marta, Santander, Celina, 1728 Shimada, Hideyo, 2042, 2327 Stark, Christina A., 1665 1200 Santora, Julie, 512 Shimada, Hisao, 2656 Staszewski, Schlomo, 1576 Rodvold, Keith A., 436, 2106 Saral, Rein, 1847 Shimada, J., 1043 Staunton, Donald E., 1278 Roesel, Johannes L., 2087 Sardana, Vinod V., 947, 1576 Shimada, K., 1043 Stecca, Clara, 2693 Rogers, Marc B., 2391 Saric, Muhamed, 1082 Shimizu, K., 1043 Steckelberg, J. M., 554 Rogge, Mark C., 1468 Sato, K., 67, 1259 Shimomoura, Yuko, 2534 Steele, Lorraine C., 1850 Roilides, Emmanuel, 495 Sato, Katsumasa, 722 Shimomura, Masahiko, 229 Steele, Paul, 1436 Roland, Gregory E., 2563 Sato, Kenichi, 2112 Shimoyama, Takashi, 769 Steib, Annick, 1873 Rollwagen, Florence M., 2688 Satoh, Hiroshi, 769 Shinnick, Thomas M., 1348 Steide, Jean-Alex, 1264 Rolston, Kenneth, 882 Satta, Giuseppe, 1324 Shipkowitz, N. L., 864 Stein, Andreas, 1214 Rolston, Kenneth V., 2584 Savani, Dora V., 903 Shipman, Charles, Jr., 540 Stein, Daniel S., 448 Rolston, Kenneth V. I., 2504 Sawada, Masashi, 2684 Shirasaka, Takuma, 810 Stein, Gary E., 89 Romand, St6phane, 2371 Scaglia, Massimo, 1492 Shlaes, David M., 610, 1061, Steingrube, Vincent A., 1850 Romero, Donna L., 1127 Scarnati, Helen, 2606 1238 Stephens, L. Clifton, 729 Ronco, Esthel, 962 Scavone, Joseph M., 2187 Shlaes, D. M., 2432 Stevens, David A., 1177, Rondel, Richard K., 2298 Schaberg, Dennis R., 2003 Shlaes, J. H., 2432 1334, 2224 Rose, Lucy M., 1004 Schachter, Julius, 1746 Shyu, W. C., 1180 Stevens, Robert C., 448 Rosen, Mark, 483 Schacker, Tim, 975 Siadak, Anthony, 164 St. John, Lisa, 2285 Rosenbaum, Beverly, 729, Schaeverbeke, Jean, 1510 Siegert, Wolfgang, 1367 Stoeckel, Klaus, 2706 882, 2584 Schaeverbeke, Madeleine, Sijbesma, Rint, 1707 Stotka, Jennifer, 2139 Rosenberg, Ivan, 2540 1510 Silve, Gaby, 1536 St-Pierre, Claude, 1373 Roser, Roberto, 868 Schafer-Korting, Monika, Silver, Lynn L., 377 Strauss, H. William, 1270, Rosner, Judah L., 2251 2064 Silverman, Edward G., 1869 2144 Rosner, Manfred, 1659 Schaffner, Carl P., 419 Simon, Sanford, 592 Strle, Franc, 1444 Roth, Elizabeth, 1576 Schalm, S. W., 595 Sinclair, Ian, 1270 Strosberg, A. Donny, 26 Roth, Richard S., 1543 Schedletzky, Holger, 696 Singh, Kavindra B., 1203 Stuber, Dietrich, 1400 Rothstein, David M., 191, Schell, Wiley A., 2449 Singlas, Eric, 1777 Sugar, Alan M., 39 1624 Schentag, Jerome J., 371, 523, Sirisanthana, Thira, 2407 Sugiyama, Takashi, 2042 Rotschafer, John C., 436, 1065, 1073 Sironi, Marina, 2527 Sullivan, John L., 178 1377, 2454 Schiefer, Hans Gerd, 846 Sjostedt, Svante, 1665 Sullivan, Maureen C., 234 Rotstein, Coleman, 896 Schinazi, Raymond F., 875, Skold, Ola, 761 Sullivan, Veronica, 19 Rouse, M. S., 554 1707, 2206 Skumik, Mikael, 1297 Sum, Phaik-Eng, 2270 Rouse, Philippa, 2231 Schindler, Jay J., 2716 Skurray, Ronald A., 761 Sumita, Yoshihiro, 2743 Rouveau, Martine, 2020 Schipper, Pauline, 1525, 2231 Slavin, Monica A., 1360 Summanen, P., 2638 Roy, Tapon, 178 Schlabach, Abner J., 1576 Slocombe, Brian, 32 Summers, Anne O., 825 viii AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Sun, He, 1132 Thauvin-Eliopoulos, Claudie, Vance-Bryan, Kyle, 436, 2454 Waskin, Hetty A., 2449 Sundstrom, Lars, 761, 1297 507 Vanden Bossche, Hugo, 2101 Wassmundt, Frederick W., Suomalainen, Kimmo, 592 Thayer, Walter R., 1645 van den Broek, P. J., 2318 754 Supp, Andrew P., 1890 Theander, Thor G., 2550 Van Den Ende, Jan, 2733 Watanabe, Junko, 2656 Supparatpinyo, Khuanchai, Then, Rudolf L., 1400 Van der Auwera, P., 1015, Watanabe, Kiwao, 164 2407 Thom, Edna, 2144 1860 Watanabe, Kunitomo, 957 Sutton, David, 642 Thomas, Richard C., 1127 Vanderkolk, Julie, 2364 Watanabe, Taiji, 2412 Sutton, Lorraine, 2760 Thompson, R. C. A., 328 van der Meer, Jos W. M., Waterbury, Julie A., 1576 Suzuki, Eiko, 1219 Thomson, Kenneth S., 1375 276, 2527 Watson, Durward A., 1869 Suzuki, Yasuyuki, 229 Thormar, Halldor, 2540 Van De Velde, Vera, 778 Watts, J. L., 1122 Svensson, Ulla, 240 Thornsberry, Clyde, 1122 van Leeuwen, Remko, 1525 Waysbort, A., 1232 Swan, S. K., 347 Ticehurst, Julia, 1473 Vantha, Wanta Sok, 1977 Wear, Douglas J., 2500 Swaney, Steven M., 1127 Tidwell, Richard R., 2668 van Winkelhoff, A. J., 1184 Webb, Douglas, 1270, 1383 Swanson, Keith A., 778 Tidwell, R. R., 1713 van Woensel, J. B. M., 1977 Webb, Vera, 2379 Swedberg, Gote, 761 Tijnagel, Jolanda, 1525 Vapiwala, Manisha, 419 Weickmann, Joachim, 1614 Swenson, Christine E., 1869 Tilles, Jeremiah G., 1593 Varela, Manuel F., 1253 Weidekamm, E., 293, 2132 Swenson, Jana M., 2311 Tilling, Janet, 1473 Vaudaux, Pierre, 625 Weidner, Wolfgang, 846 Ting, Windsor, 2106 Vazquez, Jose A., 2474 Weinstein, Melvin P., 106 Titus, Donna L., 1576 Venditti, Mario, 1190 Weinstein, Robert A., 1989 Taburet, Anne-Marie, 1777 Tiwari, M., 2418 Venitz, Jurgen, 2139 Weislow, Owen S., 754 Tagliabue, G., 2545 Tod, M., 737, 2674 Venuti, Elaine, 2736 Wennersten, C. B., 1604 Taira, Kazushige, 1877 Todo, Yozo, 384 Verboom, T., 1184 Wennersten, Christine, 2009 Takada, Kanji, 810 Tokuda, Yoshiko, 2228 Verdier, Francoise, 970 Wennersten, Christine B., Takahata, Masahiro, 384 Tolkoff-Rubin, Nina E., 619 Vergara, Yolanda, 138 598, 1364 Takashima, Ikuo, 901 Toltzis, Philip, 1610 Verhoef, Jan, 885 Were, Joab B. O., 1193 Takatsuki, Akira, 980 Tomasz, Alexander, 342 Verschure, M. H., 317 Westphal, J. F., 1488 Takayama, Satoshi, 1764 Tomazic, J., 1786 Videler, Joseph, 1480 Wexler, Hannah M., 2509 Takeda, Katsuo, 287 Tomioka, H., 67, 1259 Vieler, Elke, 846 Wexler, H. M., 2638 Tal, Ruth, 1037 Tomioka, Haruaki, 722 Vila, Jordi, 138 Weyer, Claudia, 1367 Talan, D. A., 1580 Tomonaga, Fumiya, 2042 Vilde, Jean-Louis, 692, 1690 Whiley, R. A., 2493 Talarico, Christine, 19 Tomono, Kazunori, 2762 Villareal, Kara, 39 Whitby, M., 1924 Talbot, George H., 474 Tong, William, 398 Vimy, Murray J., 825 White, E. Lucile, 754 Tallan, B. M., 554 Torres, Carmen, 2427 Vince, Robert, 1004 White, John, 1137 Tally, Francis P., 2270 Torres, H., 491 Vincent, S., 2432 White, Michael, 1436 Tamura, Toshihide, 769 Tournay, C., 142 Viola, Renato, 2693 Whitman, M. S., 2069 Tan, J. S., 1580 Towle, Michelle, 2193 Visbal, Gonzalo, 580 Wiedemann, B., 224 Tan, Tina Q., 2401 Toyosawa, Toshio, 60 Visconti, M., 2545 Wiener, Janis, 1989 Tanaka, Koji, 1945 Trautmann, Matthias, 2153 Vishvanathan, N., 183 Wilairat, Prapon, 403 Tanaka, Kouichi, 2217 Trias, Joaquim, 322 Visser, Maarten R., 885 Wilber, R. B., 1180 Tanaka, Makoto, 2173 Trieu-Cuot, Patrick, 2593 Voeller, Donna, 1227 Wilcox, Gary, 1614 Tanaka, Mayumi, 2112 Trifillis, A. L., 2496 Vogels, Maria T. E., 276, Williams, Denise S., 1447 Tanaka, Nobuo, 2756 Troke, P. F., 1962 2527 Williams, G., 1924 Tanaka, Yasunori, 957 Truffot-Pernot, Chantal, 407 Von Bandel, Marc, 1873 Willmott, Christopher J. R., Tanimura, M., 1043 Trujillano, I., 911 Vorachit, M., 2000 126 Taniyama, Yumi, 1547 Tselentis, Yannis, 51 Vrenzos, George, 51 Wilson, Jeanne E., 1720 Tankovic, Jacques, 789 Tseng, Cheng-Chuang, 1826 Wilson, W. R., 554 Tarasi, Agapito, 1190 Ts'o, Paul 0. P., 429 Wacharotayankun, Wingard, John R., 1847 Tardif, Carole, 2571 Tsuda, Toshihiko, 2412 Rochaporn, 984 Winkler, Irvin, 1659 Tardif, Manon, 2727 Tsuda, Yasuyuki, 2327 Wainberg, Mark A., 130, Winslow, Dean L., 2606 Tarpley, W. Gary, 1127 Tsui, S. Y. T., 1001 1305, 1390, 2231 Wireman, Joy, 825 Tarrand, Jeffrey J., 2584 Tsuji, Akiyoshi, 60 Walcott, Sarah M., 1473 Wise, Richard, 637 Tateda, Kazuhiro, 675 Tsuji, Miho, 2228 Waldvogel, Francis A., 625 Wise, W. Curtis, 393 Taylor, David, 1552 Tudela, Encarna, 868 Walker, Clay B., 2037 Wishnow, R. M., 1580 Taylor, Diane E., 457, 2645 Turgeon, Fernand, 1174 Walker, Karla J., 1377, 2454 Witt, Mallory D., 2030 Taylor, Lester C., 2285 Turik, Michael, 2193 Walker, Maja, 2087 Witzig, Richard S., 1997 Teggi, Antonella, 1679 Turner, Ronald B., 297 Walker, Sheila, 1558 Woestenborghs, Robert, 2224 Teitz, Yael, 2483 Tzeng, Jausheng, 1909 Wallace, Richard J., Jr., 1850 Wojcik, Stan, 991 Wolanski, Bohdan S., 1576 Teixeira, M., 1232 Uckun, Fatih M., 835 Walsh, Thomas J., 1334 Telenti, Amalio, 2054 Walter, Eike, 1539 Wolfgang, Jill A., 1576 Ueda, Yasushi, 2217 Wolfson, John S., 2588 Tenorio, Carmen, 2427 Ueno, Kazue, 957 Walzer, Peter D., 1436 Tenover, Fred C., 2311 Wang, Julie, 2139 Wong, Edward S., 1447 Unal, S., 1604 Woodcook, Jocelyn, 637 Tenovuo, Jorma, 1158 Unal, Serhat, 1831 Wang, Li, 1781 ter Kuile, F. O., 1977 Wang, Shaomeng, 1799, 1807 Woodford, Neil, 681 Urbina, Julio A., 580, 1353 Woods, Jacqueline M., 1473 ter Laak, E. A., 317 Ussery, Michael A., 71 Wang, Ying, 457 Terpenning, Margaret S., 2003 Ward, S. A., 2337 Woods-Cook, Kathie, 2087 Utsui, Yukio, 2278 Wraber, B., 1786 Testa, Raymond T., 2270 Uzun, Omrum, 1831 Ward, Stephen A., 1318 Thadepalli, Haragopal, 1711 Warden, Glenn D., 1890 Wright, Esther L., 652 Thadepalli, Harini D., 1711 Vaara, Martti, 354, 2255 Warnock, D. W., 1962 Wright, Susan C., 2534 Thal, Lee Ann, 134, 1187, Valdivia, Eva, 148 Warren, John R., 2470 Wrighton, Steven A., 265 2474 Valero-Guillen, Pedro, 1536 Warren, Reed P., 2716 Wudl, Fred, 1707 Thaller, M. C., 2618 Valette, M., 2239 Wasan, Kishor M., 246 Thanassi, David G., 1393 Vallee, E., 633 Washington, J. A., 1696 Xiao, Xinfa, 84 Thauvin-Eliopoulos, C., 1604 Vallois, J. M., 633 Washington, John A., II, 1375 Xicota, M. Angels, 868 VOL. 37, 1993 AUTHOR INDEX ix

Yamada, Hidehiko, 2412 Yao, Gang-qing, 1420 Young, Robert D., 1102 Zhanel, George G., 1154 Yamada, Hideo, 2327 Yasuda, Hiroshi, 322, 1749 Yuthavong, Yongyuth, 1108 Zhang, Ruiwen, 1771 Yamaguchi, Hideyo, 785, 2228 Yazawa, Katsukiyo, 1313 Zhang, Yansheng, 1850 Yamaguchi, Keizo, 60, 675 Yeaman, Michael R., 546 Zabinski, Richard A., 1377, Zheng, Hui, 2534 Yamaguchi, Totaro, 287 Yew, W. W., 1001 2454 Zhong, Jian, 2534 Yamaguchi, Yoshiyuki, 26 Yoder, Steven L., 2563 Zaccardi, Joe, 1624 Zhou, Xiang Yang, 1387 Yamamoto, Naoki, 2486 Yokoo, Mamoru, 363 Zakut, H., 293 Zhou, Zhu, 1816 Yamamoto, S., 1043 Yokota, Takeshi, 1749, 2217 Zannier, Arnold, 1214 Zienicke, Helga, 2064 Yamashiro, Yoshiko, 384 Yoneyama, Hiroshi, 2385 Zappala, M., 1497 Zieroth, Shelley R., 1154 Yamazaki, Masatoshi, 2228 Yoshida, Hiroaki, 839 Zarins, Lidija T., 2003 Zimmerli, Werner, 2622 Yamazaki, Toshiyuki, 100 Yoshida, Masao, 2534 Zausner, A., 2069 Zimmerman, Stephen W., Yancey, R. J., Jr., 1122 Yoshida, Takuji, 793 Zenilman, Jonathan M., 2244 2650 Yang, Ying-Zi, 1108 Yoshihara, Fumie, 2662 Zervos, Marcus J., 134, 1187, Zinner, Stephen H., 1756 Yang, Youjun, 851 Yoshiyama, Yuji, 2042 2474 Zon, Gerald, 171 Yano, Takafumi, 287 Young, Glenda, 1850 Zeytinoglu, Aysin, 218 Zscheck, Karen K., 1966 SUBJECT INDEX VOLUME 37

A77003 tant, 975 postantibiotic effect, 1001 human immunodeficiency virus type 1 ribonucleotide reductase inhibitor, 975 M. haemophilum preclinical evaluation, 115 herpes simplex virus resistance in vitro activities, 2323 toxicity pencyclovir, 2241 pharmacokinetics preclinical evaluation, 115 herpes simplex virus susceptibility attachment to collagen for local deliv- aac(6')-Ii strains from organ transplant recipi- ery in wounds, 1890 characterization, 1896 ents after acyclovir or ganciclovir patients with septic multiple-organ E. faecium prophylaxis, 357 failure during intermittent hemo- specificity for, 1896 herpes simplex virus type 1 filtration, 464 aac(3)-VIa comparative evaluation, 642 postantibiotic effect E. cloacae salmonellae M. fortuitum, 1001 biochemical analysis, 2074 in vitro activities, 106 synergy Abelson murine leukemia virus Aeromonas hydrophila ethambutol, 1285 thiosemicarbazones 1-lactamase M. malmoense, 1285 v-abl protein, suppression of, 2483 P-lactam resistance, contribution to, Aminoglycosides Abscesses 1324 6'-N-acetyltransferase ampicillin-sulbactam carbapenems, high specificity for, 1324 aac(6')-Ig gene, characterization of, comparative evaluation, 610 Aeromonas spp. 2093 cefoxitin in vitro susceptibilities combinations comparative evaluation, 610 tropical isolates from Queensland, inhibitors of glycosylation and fatty E. coli Australia, 905 acid and peptide biosynthesis, 652 ampicillin-sulbactam, comparative Afipia felis M. avium, 652 evaluation, 610 antibiotic susceptibilities F. oryzihabitans cefoxitin, comparative evaluation, 610 axenic medium and cells, 1410 in vitro activities against clinical iso- 2-Acetylpyridine 5-[(dimethylamino)thio- AG-2000 lates from patients with cancer, carbonyl]-thiocarbonohydrazone H. pylori 2504 cytomegalovirus urease activity, inhibition of, 769 P. aeruginosa resistance potent inhibition of replication, 602 Agar dilution ant(4')-IIa, nucleotide sequence analy- ganciclovir G. vaginalis sis and DNA hybridization stud- potentiation of antiviral effects, 602 susceptibilities to 25 antimicrobial ies, 708 3-N-Acetyltransferase agents, 2733 population pharmacokinetics E. cloacae Albendazole oncology patients, 1025 aac(3)-VIa gene, biochemical analysis hydatid disease resistance gene nomenclature of, 2074 treatment of, 1679 letter to the editor, 927 Acetyltransferases N-n-Alkyl-3,4-dihydroxybenzamide T. brucei brucei resistance phenotype P. aeruginosa T. brucei brucei in vivo system to select for blood- aac(6')-Ib, characterization of, 1456 in vitro and in vivo activities, 1082 stream-form transfectants, 1167 Acinetobacter baumannii Allopurinol riboside 8-Aminoquinolones aminoglycoside-modifying enzymes pharmacokinetics P. cannii production of, 138 probenecid, effects of, 1193 in vivo and in vitro studies, 2166 P-lactamase production, 138 Alpha-1-antitrypsin Amopyroquin chloramphenicol acetyltransferase doxycycline malaria production of, 138 protection from human neutrophil col- P. falciparum, 970 in vitro susceptibilities, 138 lagenase and gelatinase, 592 P. falciparum Acinetobacter haemolyticus Alpha interferon malaria treatment, 970 aac(6')-Ig gene pharmacokinetics Amorolfine 6'-N-acetyltransferase, 2093 transplacental passage, two assay Candida spp. Acinetobacter spp. techniques, 1232 temperature, effect on activity, 685 antimicrobial susceptibility, 750 Aluminum hydroxide Amoxicillin Actinobacillus actinomycetemcomitans levofloxacin B. burgdorferi HPQYNQR inhibition of absorption of, 2173 in vitro susceptibility, 1444 in vitro activity, 2710 AM-1155 combinations IIGGR Mycobacterium spp. clavulanic acid, 14 in vitro activity, 2710 in vitro activity, comparative evalua- H. influenzae, 1-lactamase producing Acyclic nucleoside phosphonates tion, 1259 and nonproducing, ampicillin re- bis(pivaloyloxymethyl) prodrugs Ames Salmonella TA102 assay sistant, 14 metabolism and in vitro antiretroviral quinolones comparative evaluation activities, 2247 bacterial mutagenicity, 213 chronic bronchitis, 2298 herpesviruses Amikacin rufloxacin, 2298 (S) and (R) enantiomers, 332 A. haemolyticus resistance otitis media (S) and (R) enantiomers aac(6')-Ig gene, characterization of, S. pneumoniae, penicillin resistant, herpesviruses, 332 2093 1599 retroviruses, 332 combinations pharmacokinetics retroviruses aztreonam, 308 local gastric and serum concentrations (S) and (R) enantiomers, 332 ceftazidime, 308 after different oral applications, visna virus endocarditis, 308 1506 inhibition of replication, 2540 imipenem, 1931 S. mutans Acyclovir P. aeruginosa, 308, 1931 in vitro susceptibility, 1158 combinations E. coli resistance synergy 348-U87, 975 bleomycin, increase of, 1982 H. pylon, 1184 herpes simplex virus, acyclovir resis- M. fortuitum metronidazole, 1184

x VOL. 37, 1993 SUBJECT INDEX xi

metronidazole, hydroxymetabolite of, E. faecium, 1904 high-capacity in vitro assessment, 441 1184 endocarditis, 507, 1447 Artemisinin ampD S. aureus, P-lactamase hyperproduc- iron-dependent free radical generation, C. freundii ing, 507 1108 sequences of wild-type and mutant sulbactam, 251, 507, 610, 1447 mechanism of action genes, comparison with those in susceptibility testing with a predictor iron dependence, 1108 E. coli, 224 panel, 251 AS-48 E. coli E. faecium resistance, 1904 antibodies, neutralizing sequences of wild-type and mutant endocarditis, 2069 immunocytological studies, 148 genes, comparison with those in H. influenzae Aspergillosis C. freundii, 224 distribution in patients with lower res- amphotericin B Amphotericin B piratory tract infections, effect on, aerosol, prophylaxis, 1367 aspergillosis, 2307 804 comparative evaluation invasive pulmonary, prophylactic in- H. parainfluenzae itraconazole-cyclodextrin versus am- halations, 1367 distribution in patients with lower res- photericin B in a rabbit model, C. albicans piratory tract infections, effect on, 2307 comparative evaluation, 729 804 pulmonary, invasive disseminated infection in normal and oxidant-scavenging activities amphotericin B, aerosol, for prophy- granulocytopenic mice, 729 neutrophil functions, effect on, 950 laxis, 1367 interleukin-6, reduction in release, Amsacrine Aspergillus fumigatus 1958 P. carinii aspergillosis tumor necrosis factor alpha, reduction activity in vitro and in a mouse model, itraconazole-cyclodextrin versus am- in release, 1958 1543 photericin B in a rabbit model, C. neoformans Anaerobic organisms comparative evaluation, 2307 in vitro susceptibility, 1383 Bay Y3118 D0870 recurrent meningitis, isolates from pa- in vitro activity, 2509 in vivo and in vitro activities, 2412 tients with, 1383 FK037 itraconazole Candida spp. in vitro activity, 957 efficacy in a rat model, 2762 temperature, effect on activity, 685 MDL 62,879, 746 Atovaquone comparative evaluation 9-Anilinoacridines combinations fluconazole, 2030 Leishmania spp. clarithromycin, 2371 itraconazole, 2307 in vitro activity, 991 minocycline, 2371 endocarditis structure-activity relationships, 991 pyrimethamine, 2371 C. parapsilosis, 2030 P. falciparum sulfadiazine, 2371 C. tropicalis, 2030 chloroquine resistant, 403 T. gondii immunological effects on splenocytes mode of action, 403 in vitro and in vivo activities, 2371 from immune-normal and immune- structure-activity relationship, 403 Avermectins compromised mice, 2716 Antibiotic carryover S. erythraea in vitro and in vivo studies, 2228 quinolones glycosylation, microbial conversion L. donovani antibiotic-removal beads, elimination by, 1737 T-cell-deficient mice, 1504 with, 1377 3'-Azido-2',3'-deoxythymidine leishmaniasis, visceral Antibodies synergy T-cell-deficient mice, 1504 AS-48 carbovir, 144 liposomal immunocytological studies, 148 human immunodeficiency virus type 1, immunological effects on splenocytes neutralizing 144 from immune-normal and im- simian immunodeficiency virus-in- 3'-Azido-3'-deoxythymidine mune-compromised mice, 2716 fected macrophages, 360 toxicity liposome composition P. aeruginosa flagella thymidine kinase activity, correlation role in distribution of drug in serum therapeutic effects in a murine model, with circadian variation in, 1771 lipoproteins, 246 164 time of administration, effect on, 1771 mono-methyl ester derivative Antifungal agents 3'-Azido-3'-deoxythymidine neurotoxicity, comparative evaluation, susceptibility testing human immunodeficiency virus type 1 419 broth macrodilution, 39 replication in human fetal brain mac- murine tumor necrosis factor yeasts, pathogenic, 39 rophages, effect on, 1305 augmentation of production, 2228 triazino[5,6-b]indoles 3'-Azido-3'-deoxythymidine monophos- neurotoxicity GR99060, 1243 phate mono-methyl ester derivative, compar- GR99062, 1243 exonucleolytic repair of AZT-terminated ative evaluation, 419 ant(4')-IIa DNA rats, comparative evaluation, 419 P. aeruginosa inhibition of, 918 P. marneffei nucleotide sequence analysis and 3'-Azidothymidine response of human immunodeficiency DNA hybridization studies, 708 simian immunodeficiency virus virus-infected patients, 2407 Antipneumocystis agents macrophages, comparative evaluation, temperature screening assay 360 role in distribution of drug in serum development and characterization, Azithromycin lipoproteins, 246 1674 B. burgdorferi Ampicillin Antiviral agents in vitro activity, comparative evalua- combinations combinations tion, 1704 ciprofloxacin, 1904 strategic design and three-dimensional Brucella spp. comparative evaluation, 610 analysis, 540 in vitro activity, comparative evalua- E. coli intra-abdominal abscess model, hepatitis B virus tion, 911 610 selectivity, high-capacity in vitro as- C. pneumoniae E. faecalis, j-lactamase producing, sessment, 441 in vitro activity, 1746 highly gentamicin resistant, 1447 selectivity C. trachomatis xii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

in vitro activity, 1746 rufloxacin B. fragilis combinations T-cell subsets and tumor necrosis fac- cloning and characterization of cepA pyrimethamine, 1993 tor production in infected mice, reveal new subgroup, 2391 T. gondii, 1993 effect on, 1711 Bacteroides spp. cross-resistance S. aureus, polymicrobial infection cefoxitin resistance, 1028 frequency distribution curves, scatter- mice, 1531 novel Ambler class A, 1028 grams, and regression analyses, temafloxacin C. coli 2080 evaluation of activity by an in vitro P-lactam susceptibilities, 1174 enteric bacterial pathogens pharmacodynamic system, 2454 carbapenem hydrolyzing in vitro activity, 1203 tet(Q) E. cloacae, biochemical properties, gram-negative organisms nucleotide and deduced amino acid 939 outer membrane permeability barrier, sequences, 2037 CP-70,429 354 Bacteroides gracilis stability to, 1547 in vitro activities Bay Y3118 E. cloacae frequency distribution curves, scatter- in vitro activity, 2509 biochemical properties, 939 grams, and regression analyses, Bacteroides spp. cloning of gene into E. coli, 939 2080 Bay Y3118 E. coli L. micdadei in vitro activity, 2509 clavulanate, 2059 inhibition of intracellular strains, 2261 ,-lactamase sulbactam, 2059 lymphocyte response cefoxitin resistance, 1028 tazobactam, 2059 in vivo activities, 1786 novel Ambler class A, 1028 E. faecalis M. avium cefoxitin resistance mobilization of gene, 1187 cross-resistance, 2364 J-lactamase, 1028 production by, 1966 M. avium complex Bacteroides thetaiotaomicron fecal activity rats treated with cyclosporine, 398 E. coli, polymicrobial infection healthy volunteers after cefixime treat- M. haemophilum mice, 1531 ment, 1432 in vitro activities, 2323 S. aureus, polymicrobial infection FK-037 M. kansasii mice, 1531 stability to, 566 susceptibility testing, 1997 Bay y 3118 H. alvei pharmacokinetics broth macrodilution assays ceftazidime resistant, 1375 pediatric patients, multiple oral doses in vitro activity and comparative eval- K pneumoniae of suspension, 314 uation, 2348 P-lactams, broad spectrum, resistance S. aureus Bay y3118 to, 984 uptake by human monocytes, 2318 gram-negative organisms ,-lactams, extended spectrum, resis- T. gondii anaerobic, 1649 tance to, 2020 protein synthesis, inhibition of, 1701 comparative susceptibilities, 1649 MGH-1, 2760 Aztreonam gram-positive organisms plasmid encoded, TEM derived, 2020 C. albicans anaerobic, 1649 plasmid mediated, AmpC type, trans- colonization of the human gastrointes- comparative susceptibilities, 1649 ferable, 984 tinal tract, effect on, 51 in vitro activities YOU-1, 2760 combinations gram-negative organisms, 2017 YOU-2, 2760 amikacin, 308 gram-positive organisms, 2017 MGH-1 endocarditis, 308 Benzimidazoles gene sequences for, 2760 P. aeruginosa, 308 Giardia spp. minireview endocarditis in vitro activity, 328 induction of, molecular basis for, 153 P. aeruginosa, 308 Bis-benzimidazoles N. farcinica P. aeruginosa P. carindi characterization, 1850 endocarditis, 308 pneumonia, treatment of, 1713 P. aeruginosa yeast colonization of the human gastro- Benzoxazinorifamycin carbapenem resistance, role in, 1387 intestinal tract, effect on, 51 M. avium complex extended spectrum, characterization radiometric method, determination by, of, 962 Bacteroides fragilis 67 OXA-11, extended-spectrum variant of Bay Y3118 Benzoxazinorifamycins OXA-10, 1637 in vitro activity, 2509 KRM-1648 P. cepacia, 249 M. avium, 722 chromosomal penicillinase, member of cepA Benzylpenicillin AmpC family, 667 cloning and characterization reveal a Pneumococcus spp. plasmid mediated new subgroup of P-lactamases, postantibiotic effect, 2200 P-lactams, broad spectrum, resistance 2391 Streptococcus spp. to, 984 ciprofloxacin postantibiotic effect, 2200 E. coli, 1989 T-cell subsets and tumor necrosis fac- ,B-Lactamase inhibitors K pneumoniae, 984, 1989 tor production in infected mice, combinations S. aureus effect on, 1711 P-lactams, 702 blaI and blaRI, regulation by, 1144 clindamycin S. aureus, borderline methicillin sus- cefazolin, inactivation and efficacy of, in vivo efficacy, correlation with in ceptible, 702 203 vitro susceptibility, 997 S. aureus, methicillin resistant, 702 cefmetazole, inactivation and efficacy mice, 997 13-Lactamases of, 203 E. coli, polymicrobial infection A. baumannii production by, 1966 mice, 1531 production by, 138 Streptococcus spp., group A beta-he- quinolones A. hydrophila molytic in vivo efficacy, correlation with in ,B-lactam resistance, contribution to, production of, role in infection man- vitro susceptibility, 997 1324 agement, 1452 mice, 997 carbapenems, high specificity for, 1324 susceptibility testing VOL. 37, 1993 SUBJECT INDEX xiii

predictor panel for evaluating meth- Bis-benzimidazoles in vitro activity, comparative evalua- ods, 2578 G. lamblia tion, 911 tazobactam correlation of antigiardial activity, Butenafine kinetic interactions, 851 DNA binding affinity, and giardial C. albicans TEM-1 topoisomerase II inhibition, 2668 mechanisms of action, 785 hydrogen bonding by serine 235 for structure-activity studies, 2668 percutaneous permeation, 363 cephalosporinase activity, 2438 Blastomyces dermatitidis T. mentagrophytes YOU-1 D0870 guinea pigs, 363 gene sequences for, 2760 murine blastomycosis, 1177 YOU-2 Blastomycosis Camptothecin gene sequences for, 2760 D0870 P. carinii P-Lactams murine, 1177 activity in vitro and in a mouse model, A. hydrophila resistance Bleomycin 1543 metallo-p-lactamase, cphA encoded, E. coli Campylobacter coli 1324 amikacin and streptomycin resistance, 3-lactamase-positive and -negative C. coli susceptibility 1982 strains j-lactamase-positive and -negative S. cerevisiae P-lactam susceptibilities, 1174 strains, 1174 cell wall anchorage of mannoproteins, Campylobacterjejuni combinations disruption of, 1264 cytokines 1-lactamase inhibitors, 702 Boric acid effect of oral recombinant interleukin S. aureus, borderline methicillin sus- Candida spp. on mucosal immunity in mice, ceptible, 702 temperature, effect on activity, 685 2688 S. aureus, methicillin resistant, 702 Borrelia burgdorferi DNA gyrase E. faecium resistance azithromycin gyrA, cloning and nucleotide se- synergistic combinations, resistance in vitro activity, comparative evalua- quence, 457 to, 1238 tion, 1704 gyrA minireviews clarithromycin cloning and nucleotide sequence, 457 penicillin-binding protein resistance, hamsters, 1329 quinolone resistance 2045 in vitro activity, comparative evalua- DNA gyrase mutations, characteriza- penicillin-binding protein resistance tion, 1704 tion of, 457 minireview, 2045 coumermycin Al Tet(O) synergy growth inhibition and induction of re- effect of mutational alteration of Asn- E. faecium resistance, 1238 laxation of supercoiled plasmids, 128, 2645 Biapenem 46 tetracycline resistance comparative evaluation erythromycin effect of mutational alteration of Asn- imipenem, 2009 in vitro activity, comparative evalua- 128, 2645 gram-negative bacteria, 2009 tion, 1704 Campylobacter spp. gram-positive bacteria, 2009 in vitro susceptibilities, 1444 azithromycin P. aeruginosa vancomycin in vitro activity, 1203 phenotypic resistance induced by sa- in vitro activity, 1115 Candida albicans licylate, 2743 Bronchitis amphotericin B Bilobalide chronic comparative evaluation, 729 P. carinji rufloxacin and amoxicillin, compara- disseminated infection in normal and in vitro and in vivo activities, 1492 tive evaluation, 2298 granulocytopenic mice, 729 Bilophila wadsworthia Broth macrodilution assay tumor necrosis factor alpha, reduction Bay Y3118 Bay y 3118 in release, 1958 in vitro activity, 2509 in vitro activity and comparative eval- aztreonam imipenem uation, 2348 colonization of the human gastrointes- morphological response, 2638 yeasts tinal tract, effect on, 51 penicillin-binding protein patterns, susceptibility testing, 39 butenafine 2638 Brucella melitensis mechanisms of action, 785 Bioavailability experimental murine brucellosis ceftazidime cefetamet pivoxil streptomycin alone and in combination colonization of the human gastrointes- syrup and tablet formulations to with ciprofloxacin, doxycycline, tinal tract, effect on, 51 healthy male volunteers, 2706 and rifampin, 2333 ceftriaxone (-)-cis-5-fluoro-1-[2-(hydroxymethyl)- Brucella spp. colonization of the human gastrointes- 1,3-oxathiolan-5-yl] cytosine azithromycin tinal effect 51 studies with rats, 2285 in vitro activity, comparative evalua- tract, on, clindamycin tion, 911 cilofungin healthy volunteers and AIDS patients, clarithromycin comparative evaluation, 729 1137 in vitro activity, comparative evalua- disseminated infection in normal and fluconazole tion, 911 granulocytopenic mice, 729 patients with AIDS, 2187 dirithromycin D0870 Biofilms in vitro activity, comparative evalua- in vitro activities, 2126 S. epidermidis tion, 911 in vivo and in vitro activities, 2412 diffusion of rifampin, 2522 doxycycline-rifampin fluconazole resistance diffusion of vancomycin, 2522 comparative evaluation, 1831 patients infected with human immuno- Bioscreen C ofloxacin-rifampin deficiency virus type 1, correla- benzylpenicillin comparative evaluation, 1831 tion to therapy and symptoms, postantibiotic effect, 2200 rifapentine 2449 Bis(pivaloyloxymethyl) prodrugs in vitro activity, comparative evalua- fluconazole susceptibility metabolism and in vitro antiretroviral tion, 911 emergence of resistance of Norwegian activities, 2247 roxithromycin strains, 2443 xiv SUBJECT INDEX ANTiMICROB. AGENTS CHEMOTHER.

imipenem-cilastatin salicylate, 2743 efficacy, 203 colonization of the human gastrointes- LJC 10,627 S. aureus tinal tract, effect on, 51 neurotoxicity in rats, low levels of, P-lactamase-mediated inactivation and itraconazole 199 efficacy, 203 placebo-controlled trial, 89 P. aeruginosa resistance Cefonicid myeloperoxidase, human recombinant cephalosporinase, role in, 1387 peritonitis, spontaneous bacterial candidicidal activity, 142 panipenem comparative evaluation, 1587 picolinic acid P. aeruginosa resistance induced by pharmacokinetics protective effect on mice, 2422 salicylate, 2743 protein binding in adult and neonatal Ro 09-1470 Carbenicillin sera, 1343 inhibition of P-450 lanosterol C-14 epimers protein binding demethylase, 2662 stereoselective renal tubular secretion adult and neonatal sera, 1343 ticarcillin-clavulanic acid in human volunteers, 2327 Cefoperazone colonization of the human gastrointes- Carbovir combinations tinal tract, effect on, 51 cellular metabolism E. coli, 1927 Candida glabrata effects on, 1004 K pneumoniae resistance, 1061 fluconazole resistance, 1962 metabolism, 1004 P. aeruginosa, 1927 Candida parapsilosis synergy sulbactam, 1061, 1927 amphotericin B, 2030 3'-azido-2',3'-deoxythymidine, 144 Cefotaxime endocarditis, 2030 human immunodeficiency virus type 1, B. burgdorfen fluconazole, 2030 144 in vitro susceptibility, 1444 Candida spp. Carboxyquinolones E. coli amorolfine Q-35 comparative evaluation, 846 temperature, effect on activity, 685 L. interrogans, 901 epididymitis, 846 amphotericin B Cecropin postantibiotic effect in pooled cerebro- temperature, effect on activity, 685 C terminus, modification of spinal fluid and Mueller-Hinton boric acid broad-spectrum antimicrobial activity, broth, 1154 temperature, effect on activity, 685 essential for, 1614 epididymitis flucytosine Cefaclor comparative evaluation, 846 temperature, effect on activity, 685 H. influenzae E. coli, 846 platelet microbicidal protein P-lactamase producing and nonproduc- H. influenzae fungicidal activity, 546 ing, ampicillin resistant, 14 P-lactamase producing and nonproduc- susceptibility testing Cefazolin ing, ampicillin resistant, 14 current status of the standardization abscesses pharmacokinetics process, minireview, 2517 P-lactamase-mediated inactivation and terbinafine efficacy, 203 cerebrospinal fluid of patients with temperature, effect on activity, 685 pharmacokinetics uninflamed meninges, passage terconazole protein binding in rats, 1781 into, 1518 temperature, effect on activity, 685 proconvulsant effects postantibiotic effect Candida tropicalis DBA/2 and Swiss mice, 1497 E. coli, in pooled cerebrospinal fluid amphotericin B, 2030 S. aureus and Mueller-Hinton broth, 1154 endocarditis, 2030 13-lactamase-mediated inactivation and S. pneumoniae breakpoint fluconazole, 2030 efficacy, 203 letter to the editor, 616 Candidiasis seizures Cefoxitin itraconazole DBA/2 and Swiss mice, 1497 abscesses, intra-abdominal placebo-controlled trial, 89 Cefepime comparative evaluation, 610 CAP18 in vitro activity Bacteroides resistance gram-negative organisms multicenter comparison, 1696 P-lactamase, 1028 in vitro activity, 2534 pharmacokinetics E. coli gram-positive organisms cystic fibrosis patients, 1414 comparative evaluation, 610 in vitro activity, 2534 Cefetamet pivoxil Cefozopran Capnocytophaga spp. bioavailability K pneumoniae antimicrobial susceptibilities syrup and tablet formulations to respiratory tract infection, 100 letter to the editor, 1206 healthy male volunteers, 2706 P. aeruginosa Capnocytophaga sputigena Cefixime urinary tract infection, 100 HPQYNQR 1-lactamase activity, fecal S. aureus in vitro activity, 2710 healthy volunteers after drug treat- IIGGR ment, 1432 thigh muscle infection, 100 in vitro activity, 2710 C. difficile shedding Cefpodoxime proxetil Carbapenems healthy volunteers after drug treat- ex vivo susceptibility P-lactamase hydrolysis ment, 1432 studies with patients receiving contin- E. cloacae, 939 gastrointestinal symptoms uous ambulatory peritoneal dialy- biapenem effect on in healthy volunteers after sis, 2650 P. aeruginosa resistance induced by drug treatment, 1432 pharmacokinetics salicylate, 2743 H. influenzae studies with patients receiving contin- BO-2727 1-lactamase producing and nonproduc- uous ambulatory peritoneal dialy- in vitro activity, 2756 ing, ampicillin resistant, 14 sis, 2650 F. oryzihabitans pharmacokinetics Cefprozil in vitro activities against clinical iso- biliary excretion in patients with pharmacokinetics lates from patients with cancer, T-tube drainage, 1488 tonsillar and adenoidal tissues, pene- 2504 Cefmetazole tration into, 1180 imipenem abscesses tonsillopharyngitis, streptococcal P. aeruginosa resistance induced by 1-lactamase-mediated inactivation and comparative evaluation, 1620 VOL. 37, 1993 SUBJECT INDEX xv

Ceftazidime typhoid fever antibiotic activity and host defense C. albicans 5 days, comparative evaluation, 1572 mechanisms, 2622 colonization of the human gastrointes- yeast colonization of the human gastro- pharmacodynamic activity in human tinal tract, effect on, 51 intestinal tract, effect on, 51 skin blister fluid, 2622 combinations Cefuroxime S. aureus amikacin, 308 H. influenzae endocarditis, 554 endocarditis, 308 ,-lactamase producing and nonproduc- methicillin susceptible, 554 P. aeruginosa, 308 ing, ampicillin resistant, 14 Cephems E. coli resistance in vitro activity S-1108 ,-lactamase, 1989 multicenter comparison, 1696 pharmacokinetics, 1043 endocarditis pharmacokinetics safety of and carnitine status of pa- P. aeruginosa, 308 protein binding in adult and neonatal tients, 1043 H. alvei resistance sera, 1343 CGI 17341 f3-lactamase producing, 1375 protein binding M. tuberculosis in vitro activity adult and neonatal sera, 1343 in vitro and in vivo activities, 183 multicenter comparison, 1696 S. mutans CGP 53437 K. pneumoniae resistance in vitro susceptibility, 1158 antiviral activity ,-lactamase, 1989 Cefuroxime axetil human immunodeficiency virus type 1 P. aeruginosa pharyngitis protease, 2087 endocarditis, 308 comparative evaluation, 159 Chagas' disease P. cepacia Streptococcus spp. ICI 195,739-terbinafine comparative evaluation, 123 comparative evaluation, 159 murine model, 1353 P. pseudomallei resistance group A, 159 ketoconazole-terbinafine biofilm cells, 2000 pharyngitis, 159 murine model, 1353 pharmacokinetics suspension Chancroid healthy volunteers, 1835 comparative evaluation, 159 agents for treatment of, currently recom- patients with septic multiple-organ group A streptococcal pharyngitis, 159 mended and newer failure during intermittent hemo- Cephalosporin 7a-hydroxylase H. ducreyi from the United States and filtration, 464 S. clavuligerus Thailand, 1552 serum bactericidal activities, 1835 cloning and expression in S. lividans, in vitro susceptibilities, 1552 side effects, 1835 84 Chlamydia pneumoniae yeast colonization of the human gastro- Cephalosporinases azithromycin intestinal tract, effect on, 51 P. aeruginosa in vitro activity, 1746 Ceftibuten carbapenem resistance, role in, 1387 OPC-17116 H. influenzae Cephalosporins in vitro and in vivo activities, 801 ,-lactamase producing and nonproduc- B. fragilis and E. coli infection sparfloxacin ing, ampicillin resistant, 14 mice, 1531 in vitro and in vivo activities, 801 Ceftizoxime B. fragilis and S. aureus infection tosufloxacin B. burgdorferi mice, 1531 in vitro and in vivo activities, 801 in vitro susceptibility, 1444 B. thetaiotaomicron and E. coli infection Chlamydia psittaci Ceftriaxone mice, 1531 OPC-17116 C. albicans B. thetaiotaomicron and S. aureus infec- in vitro and in vivo activities, 801 colonization of the human gastrointes- tion sparfloxacin tinal tract, effect on, 51 mice, 1531 in vitro and in vivo activities, 801 C. bumetii cefozopran tosufloxacin shell vial assay, 491 K pneumoniae, 100 in vitro and in vivo activities, 801 combinations P. aeruginosa, 100 Chlamydia spp. endocarditis, 1971 respiratory tract infections, 100 OPC-17116 netilmicin, 1971 S. aureus, 100 in vitro and in vivo activities, 801 concentrations in plasma during liver urinary tract infections, 100 sparfloxacin transplantation, 1873 cefpodoxime proxetil in vitro and in vivo activities, 801 gonorrhea, uncomplicated ex vivo susceptibility, 2650 tosufloxacin single-dose therapy, comparative eval- pharmacokinetics, 2650 in vitro and in vivo activities, 801 uation, 1670 E1077 Chlamydia trachomatis in vitro activity in vitro and in vivo activities, 60 azithromycin multicenter comparison, 1696 F. oryzihabitans in vitro activity, 1746 peritonitis, spontaneous bacterial in vitro activities against clinical iso- CI-960 comparative evaluation, 1587 lates from patients with cancer, salpingitis, 8 pharmacokinetics 2504 doxycycline cerebrospinal fluid of patients with FK037 comparative evaluation, 1373 uninflamed meninges, passage anaerobic organisms, 957 genital infections, treatment of, 1373 into, 1518 P-lactamase stability, 566 genital infections elimination, effect of plasmapheresis, in vitro activity, 566 doxycycline, comparative evaluation, 1171 in vitro and in vivo activities, 301 1373 pregnant women, 54 polymicrobial infection spiramycin, comparative evaluation, protein binding during pregnancy, 54 mice, 1531 1373 S. typhi 3'-quinolone carbamates OPC-17116 5 days, comparative evaluation, 1572 E. coli, mechanism of action, 559 in vitro and in vivo activities, 801 synergy 3'-quinolone esters sparfloxacin netilmicin, 207 E. coli, mechanism of action, 559 in vitro and in vivo activities, 801 streptococcal endocarditis, 207 3'-quinolone tertiary amines spiramycin tissue penetration during liver transplan- E. coli, mechanism of action, 559 comparative evaluation, 1373 tation, 1873 Ro 40-6890 genital infections, treatment of, 1373 xvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

tosufloxacin M. haemophilum M. avium, prophylaxis in mice, 1690 in vitro and in vivo activities, 801 in vitro activities, 2323 minocycline, 1690 Chloramphenicol M. pneumoniae RU-4055, 692 P. cepacia hamsters, 287 cross-resistance comparative evaluation, 123 N. gonorrhoeae frequency distribution curves, scatter- S. typhi antibacterial activities, 2244 grams, and regression analyses, 14 days, comparative evaluation, 1572 P. aeruginosa 2080 typhoid fever age and therapeutic outcome, 1856 gram-negative organisms 14 days, comparative evaluation, 1572 dose-ranging and fractionation, 1756 outer membrane permeability barrier, Chloramphenicol acetyltransferases in vitro model of infection, 1756 354 A. baumannii increased susceptibility in the pres- in vitro activities production by, 138 ence of vancomycin, 2506 frequency distribution curves, scatter- Chlorhexidine resistance to unrelated antibiotics, ef- grams, and regression analyses, S. mutans fects on, 1289 2080 in vitro susceptibility, 1158 P. cepacia Lyme disease Chloroquine comparative evaluation, 123 hamsters, 1329 P. falciparum pharmacokinetics M. avium clonal viability measurements to as- effects of cardiopulmonary bypass sur- cross-resistance, 2364 sess in vitro activity, 1102 gery on disposition, 2106 erratum, 2515 CI-960 multiple oral doses to healthy volun- human macrophages, 111 C. trachomatis teers, 2193 macrophages, inhibition of intracellu- salpingitis, monkey model, 8 seriously ill patients, 1073 lar growth, 1380 Cilastatin population pharmacokinetics prophylaxis in C57BL/6 mice, 1690 combinations optimal sampling strategies, 1065 M. avium complex, 692 imipenem, 51 postantibiotic effect M. haemophilum yeast colonization of the human gas- E. coli, in pooled cerebrospinal fluid in vitro activities, 2323 trointestinal tract, effect on, 51 and Mueller-Hinton broth, 1154 M. kansasii Cilofungin S. aureus susceptibility testing, 1997 C. albicans dose-ranging and fractionation, 1756 metabolite comparative evaluation, 729 in vitro model of infection, 1756 B. burgdorferi, susceptibility in vitro, disseminated infection in normal and resistance to unrelated antibiotics, ef- 1444 granulocytopenic mice, 729 fects on, 1289 P. aeruginosa Ciprofloxacin S. pneumoniae biofilms, interaction with, 1749 adverse effects mouse protection model, 234 S. pneumoniae resistance convulsions in mice, 1764 S. typhimurium resistance cultures from Providence, R.I., 1742 B. burgdorferi isolates from two patients, 662 T. pallidum in vitro susceptibility, 1444 serum bactericidal titers hamsters, 864 combinations multiple oral doses to healthy volun- Clavulanate ampicillin, 1904 teers, 2193 combinations E. faecium, 1904 synergy E. coli, 2059 novobiocin, 1904 ethambutol, 1285 sulbactam, 2059 comparative evaluation M. malmoense, 1285 tazobactam, 2059 DU-6859a, 2747 T-cell subsets and tumor necrosis factor E. coli ofloxacin, 2193 production P-lactamase, TEM type, resistant, disk elution mice infected with B. fragilis, effect 2059 M. avium complex susceptibility test- on, 1711 Clavulanic acid ing, 1556 typhoid fever combinations M. tuberculosis susceptibility testing, severe, in children, 1197 amoxicillin, 14 1556 vancomycin H. influenzae, P-lactamase producing E. coli increased susceptibility of P. aerugi- and nonproducing, ampicillin re- postantibiotic effect in pooled cerebro- nosa, 2506 sistant, 14 spinal fluid and Mueller-Hinton Citrobacterfreundii ticarcillin, 51 broth, 1154 ampD yeast colonization of the human gas- gonorrhea, uncomplicated sequences of wild-type and mutant trointestinal tract, effect on, 51 single-dose therapy, comparative eval- genes, comparison with those of Clindamycin uation, 1670 E. coli, 224 B. fragilis H. influenzae Clarithromycin in vivo efficacy, correlation with in adherence changes induced by subin- B. burgdorferi vitro susceptibility, 997 hibitory concentrations, 885 hamsters, 1329 mice, 997 in vitro activities in vitro activity, comparative evalua- bioavailability gram-negative organisms, 2017 tion, 1704 healthy volunteers and AIDS patients, gram-positive organisms, 2017 in vitro susceptibility, 1444 1137 K pneumoniae bite wound isolates E. coli adherence changes induced by subin- aerobic and anaerobic, 1150 in vivo efficacy, correlation with in hibitory concentrations, 885 Brucella spp. vitro susceptibility, 997 keratitis in vitro activity, comparative evalua- mice, 997 age and therapeutic outcome, 1856 tion, 911 peptidyl-RNA liposome incorporated C. bumetii dissociation from ribosomes, 2027 treatment of murine salmonellosis, in vitro susceptibilities, 2633 pharmacokinetics 2293 combinations bioavailability, 1137 M. catarrhalis granulocyte colony-stimulating factor, healthy volunteers and AIDS patients, adherence changes induced by subin- 692 1137 hibitory concentrations, 885 M. avium complex, 692 T. gondii VOL. 37, 1993 SUBJECT INDEX xvii

infectivity, 2571 process, minireview, 2517 Ro 11-8958, 1436 intracellular replication, 2571 Cryptosporidium parvum Daptomycin protein synthesis, 2571 sinefungin bactericidal activity Clofazamine curative and preventive activities, 889 albumin or serum, presence of, con- M. haemophilum immunosuppressed rat model, 889 trolled pH and calcium, 605 in vitro activities, 2323 Cycloguanil Decimal assay for additivity Clofazimine P. falciparum synergy and antagonism M. avium-M. intracellulare complex African isolates, 924 delineation of, 260 in vitro activities, 2584 Cyclothialidine Deglucoteicoplanin amides M. tuberculosis Eubactenum spp. E. coli in vitro activities, 2584 inhibition, 2656 uptake, mechanism of, 453 Clonal viability measurements Cytochrome P-450 P. aeruginosa P. falciparum dirithromycin uptake, mechanism of, 453 leupeptin, chloroquine, and 5-fluoro- type I binding spectrum, 265 Dental amalgam orotate, in vitro activity, 1102 macrolides mercury Clostridium difficile type I binding spectrum, 265 bacterial resistance, 825 cefixime Cytokines bacterial resistance, letter to the edi- effect on shedding in healthy volun- C. jejuni tor, 1730 teers, 1432 effect of oral recombinant interleukin 3'-Deoxy-2',3'-didehydrothymidine Clostridium spp. on mucosal immunity in mice, pharmacokinetics Bay Y3118 2688 disposition and metabolism in hepato- in vitro activity, 2509 interleukin-8 cytes and nonhuman primates, Co-trimoxazole nonspecific resistance to infection in 1816 P. cepacia neutropenic and normal mice, 276 2'-Deoxy-3'-thiacytidine comparative evaluation, 123 Cytomegalovirus human immunodeficiency virus type 1 P. pseudomallei resistance 1110U81 resistance biofilm cells, 2000 ganciclovir, potentiation of antiviral due to amino acid substitution at cata- Coumermycin Al effects, 602 lytic site of reverse transcriptase, B. burgdorferi potent inhibition of replication, 602 2231 growth inhibition and induction of re- ganciclovir Diarylsulfones laxation of supercoiled plasmids, decrease in frequency and severity of human immunodeficiency virus type 1 46 disease in liver transplant recipi- mechanism of action, 754 Coxiella bumetii ents treated with OKT3 monoclo- reverse transcriptase inhibitor, 754 ceftriaxone nal antibodies, 2490 Didanosine shell vial assay, 491 sensitivity at diagnosis and during human immunodeficiency virus resis- clarithromycin treatment, 1360 tance in vitro susceptibilities, 2633 ganciclovir resistance pol mutations, multiple resistance, Q fever point mutation in DNA polymerase 1480 minireview, 1733 gene, 19 salmonellae treatment of, 1733 (S)-1-(3-hydroxy-2-phosphonyl-methox- in vitro activities, 106 Coxsackievirus ypropyl)cytosine 2',3-Dideoxy-3-thiacytidine WIN 54954 interstitial pneumonitis after bone (-) enantiomer group B diabetogenic strain in mice, marrow transplantation, 218 human immunodeficiency virus, resis- 1593 phosphonylmethoxyalkyl derivatives, tance, characterization of, 875 CP-70,429 resistance to human immunodeficiency virus resis- in vitro antibacterial activity, 1547 point mutation in DNA polymerase tance P-lactamase stability, 1547 gene, 19 characterization of, 875 CP-99,219 phosphorothioate oligonucleotides conferred by the same mutation that gram-positive organisms ISIS 2922, in vitro activity of, 1945 confers resistance to ddl and in vitro activity, 366 ddC, 1390 in vitro activity, 349 D0870 generation of variants, 130 Cryptococcus neofornans A. fumigatus 2',3'-Dideoxy-5-fluoro-3'-thiacytidine amphotericin B in vivo and in vitro activities, 2412 (-) enantiomer in vitro susceptibility, 1383 B. dermatitidis human immunodeficiency virus, resis- recurrent meningitis, isolates from pa- murine blastomycosis, 1177 tance, characterization of, 875 tients with, 1383 blastomycosis human immunodeficiency virus resis- D0870 murine, 1177 tance in vitro activities, 2126 C. albicans characterization of, 875 in vivo and in vitro activities, 2412 in vitro activities, 2126 2',3'-Dideoxycytidine fluconazole in vivo and in vitro activities, 2412 human immunodeficiency virus resis- in vitro susceptibility, 1383 C. tance recurrent meningitis, isolates from pa- neoformans generation of variants, 130 tients with, 1383 in vitro activities, 2126 salmonellae itraconazole in vivo and in vitro activities, 2412 in vitro activities, 106 effects on cytochrome P-450-depen- comparative evaluation 2',3'-Dideoxyinosine dent sterol 14a-demethylation and fluconazole, 2412 salmonellae reduction of 3-ketosteroids, 2101 pathogenic yeasts in vitro activities, 106 NP-1 in vitro activities, 2126 2',3'-Dideoxynucleosides in vitro activity, 2628 Dapsone visna virus platelet microbicidal protein synergy inhibition of replication, 2540 fungicidal activity, 546 dihydrofolate reductase inhibitors, Dihydrofolate reductase susceptibility testing 1436 T. gondii current status of the standardization P. carinii, 1436 inhibitors, identification of, 1914 xviii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

trimethoprim resistance DR-3354 Endotoxic shock integron on a Tn2l-like element, 1297 comparative evaluation magainins Dihydrofolate reductase inhibitors accumulation by human polymorpho- eicosanoid release by rat peritoneal synergy nuclear leukocytes, 1882 macrophages, effect on, 393 dapsone, 1436 Drosophila melanogaster Enoxacin P. carinii, 1436 pyrimido[1,6-a]benzimidazoles infection prevention sulfamethoxazole, 1436 effects on topoisomerase II and Kc adults with acute nonlymphocytic leu- Dihydrofolate reductases cells, 2599 kemia, 474 S. aureus Ro 46-7864 pharmacokinetics characterization of gene for, 1400 effects on topoisomerase II and Kc oral antacids, effect on disposition, trimethoprim sensitive cells, 2599 775 S. aureus, characterization of gene Ro 47-3359 urinary tract infections, recurrent for, 1400 effects on topoisomerase II and Kc cefuroxime axetil, more rapid than, Diltiazem cells, 2599 1558 netilmicin Drug combination testing rapid symptom alleviation, 1558 nephrotoxicity in rabbits, induction fractional maximal effect method, 523 Enterobacter cloacae by, 1790 DU-6859a 3-N-acetyltransferase Diminazine aac(3)-VIa gene, biochemical analysis pharmacokinetics comparative evaluation of, 2074 Boran cattle, noninfected and infected ciprofloxacin, 2747 1-lactamase with T. congolense, 1050 fleroxacin, 2747 carbapenem hydrolyzing, biochemical Dinitroanilines levofloxacin, 2747 properties, 939 L. mexicana lomefloxacin, 2747 Enterococcus faecalis structure-function analysis, 1909 ofloxacin, 2747 3-lactamase trifluralin, 1909 Duck hepatitis B virus mobilization of gene, 1187 Dirithromycin suramin production, genes involved in regula- B. burgdorferi prevention of infection in vivo, 1539 tion, 1966 in vitro susceptibility, 1444 DV-7751a ,-lactamase producing, highly gentami- Brucella spp. fluoroquinolones cin resistant in vitro activity, comparative evalua- in vitro antibacterial activity, 2112 ampicillin-sulbactam, comparative tion, 911 evaluation, 1447 cytochrome P-450 complex formation E1077 vancomycin, comparative evaluation, rat and human livers, 265 in vitro and in vivo activities, 60 1447 polymorphonuclear leukocytes E-4868 endocarditis interactions may promote killing of in vitro and in vivo activities, 868 ampicillin-sulbactam, comparative infecting organisms, 2557 Efflux pump inhibitors evaluation, 1447 Disk elution vancomycin, comparative evaluation, ciprofloxacin susceptibility testing screening assay, 1624 1447 M. avium complex, 1556 Encephalitis virulence in a rabbit model conferred M. tuberculosis, 1556 foscarnet by plasmid-associated hemolysin DNA gyrases blood-brain barrier, penetration of, and aggregation substance pro- E. coli 1010 duction, 2474 quinolones, mechanism of action, 839 Endocarditis highly gentamicin resistant quinolones amphotericin B, 2030 molecular characterization of isolates E. coli, mechanism of action, 839 ampicillin-sulbactam lacking high-level streptomycin DNA gyrases S. aureus, P-lactamase hyperproduc- resistance, 134 C. jejuni ing, 507 penicillinase gene gyrA, cloning and nucleotide se- aztreonam, 308 mobilization of, 1187 quence, 457 aztreonam-amikacin, 308 polymerase chain reaction Eubacterium spp. C. parapsilosis, 2030 heterogeneity of chloramphenicol ace- cyclothialidine, characterization of, C. tropicalis, 2030 tyltransferase genes, 2593 2656 ceftazidime, 308 vancomycin resistance gene fluoroquinolones ceftazidime-amikacin, 308 homology with vanB, vanA, and single point mutation in E. coli A pro- ceftriaxone-netilmicin vanC, 1604 tein reduces binding, 126 Streptococcus spp., 1971 WIN 57273 Doxycycline synergy, 207 activity against high-level gentamicin- alpha-1-antitrypsin cephalosporins resistant strains, 2470 protection from human neutrophil col- Enterococcus faecium lagenase and gelatinase, 592 broad spectrum, 554 aac(6')-Ii B. burgdorferi E. faecalis, ,3-lactamase producing, specificity for, 1896 in vitro susceptibility, 1444 highly gentamicin resistant ampicillin resistance, 1904 C. trachomatis ampicillin-sulbactam, comparative ampicillin resistant, 2069 comparative evaluation, 1373 evaluation, 1447 endocarditis, 2069 genital infections, treatment of, 1373 vancomycin, comparative evaluation, gentamicin resistance, 1904 combinations 1447 gentamicin resistant, high level Brucella spp., 1831 fluconazole, 2030 isolates from different continents, rifampin, 1831 oxacillin comparison of, 681 E. coli S. aureus, 1-lactamase hyperproduc- novobiocin comparative evaluation, 846 ing, 507 in vitro activity against multiresistant epididymitis, 846 S. aureus, methicillin susceptible strains, 2736 epididymitis cephalosporins, broad spectrum, 554 penicillin resistance comparative evaluation, 846 Streptococcus spp. time-kill studies, 2427 E. coli, 846 ceftriaxone-netilmicin synergy, 207 polymerase chain reaction VOL. 37, 1993 SUBJECT INDEX xix

heterogeneity of chloramphenicol ace- frequency distribution curves, scatter- cefotaxime, comparative evaluation, tyltransferase genes, 2593 grams, and regression analyses, 846 streptogramin A acetyltransferase 2080 doxycycline, comparative evaluation, identification of satA, 2119 M. haemophilum 846 synergy in vitro activities, 2323 ofloxacin, comparative evaluation, 846 penicillin-gentamicin, 2427 P. aeruginosa fluoroquinolone resistant vancomycin resistance, 1904 serum sensitivity, effect of sub-MICs gyrA, mutations in, 696 vancomycin resistance gene on, 675 fluoroquinolone resistant, nalidixic acid homology with vanB, vanA, and peptidyl-RNA susceptible vanC, 1604 accumulation, 2027 gyrA point mutation, novel, 1247 vancomycin resistant, 2069 S. mutans gentamicin resistance to synergistic P-lactam in vitro susceptibility, 1158 kill kinetics and regrowth patterns af- combinations, 1238 S. pneumoniae resistance ter exposure, 914 Enterococcus spp. cultures from Providence, R.I., 1742 postantibiotic effect in cerebrospinal antimicrobial susceptibilities Escherichia coli fluid and Mueller-Hinton broth, isolates from hospitalized patients, amikacin resistance 1154 1190 bleomycin, increase of, 1982 isoniazid glycopeptide resistance ampD susceptibilities of oxyR regulon mu- genetics and mechanisms of, minire- sequences of wild-type and mutant tants, 2251 view, 1563 genes, comparison with those of lactoferrin-porin interaction glycopeptide resistant C. freundii, 224 antibacterial activity, effect on, 240 characterization of isolates from U.S. ampicillin-sulbactam mutants hospitals, 2311 comparative evaluation, 610 supersusceptibility to antibiotics, 2255 pulsed-field gel electrophoresis, 2311 azithromycin ofloxacin Epididymitis in vitro activity, 1203 comparative evaluation, 846 cefotaxime B. fragilis, polymicrobial infection pefloxacin comparative evaluation, 846 mice, 1531 one 800-mg versus two 400-mg doses, doxycycline B. thetaiotaomicron, polymicrobial in- 737 comparative evaluation, 846 fection plasmid complementation test E. coli mice, 1531 quinolone resistance, 2588 cefotaxime, comparative evaluation, 1-lactamase postantibiotic effect 846 ceftazidime resistance, 1989 correlation of tobramycin-induced in- doxycycline, comparative evaluation, ,-lactamase, TEM type, resistant hibition of protein synthesis, 2678 846 clavulanate, 2059 quinolone resistance ofloxacin, comparative evaluation, 846 sulbactam, 2059 plasmid complementation test, 2588 ofloxacin tazobactam, 2059 quinolones comparative evaluation, 846 ,-lactamases DNA gyrase, mechanism of action, Epipodophyllotoxins TEM-1, cephalosporinase activity of, 839 P. carinji 2438 in vivo efficacy, correlation with in activity in vitro and in a mouse model, cefoperazone-sulbactam vitro susceptibility, 997 1543 granulocytopenic mice, disseminated mice, 997 Epstein-Barr virus infections in, 1927 S. aureus tetK phosphorothioate oligodeoxynucleotides cefotaxime expression in, 191 inhibition of replication, 1420 comparative evaluation, 846 streptomycin resistance Equine herpesvirus 1 postantibiotic effect in cerebrospinal bleomycin, increase of, 1982 phosphonylmethoxyalkyl derivatives fluid and Mueller-Hinton broth, tobramycin resistance murine model for abortion, 2478 1154 3'-aminoglycoside phosphotransferase Errata cefoxitin type I, overproduction of, 78 M. avium comparative evaluation, 610 Ethambutol activities of quinolones, 2766 ceftazidime resistance Mycobacterium spp. clarithromycin, minocycline, and ri- P-lactamase, 1989 glucose metabolism, inhibition of, fabutin treatments of C57BL/6 cephalosporins 1536 mice, 2515 3'-quinolone esters, carbamates, and synergy quinolones tertiary amines, mechanism of amikacin, 1285 anti-M. avium activities, 2766 action, 559 ciprofloxacin, 1285 Erythromycin ciprofloxacin M. malmoense, 1285 B. burgdorferi postantibiotic effect in cerebrospinal rifampin, 1285 in vitro activity, comparative evalua- fluid and Mueller-Hinton broth, Eubacterium spp. tion, 1704 1154 DNA gyrases in vitro susceptibility, 1444 clindamycin cyclothialidine, characterization of, cross-resistance in vivo efficacy, correlation with in 2656 frequency distribution curves, scatter- vitro susceptibility, 997 grams, and regression analyses, mice, 997 2080 deglucoteicoplanin amide derivatives FDA approvals H. influenzae uptake, mechanism of, 453 anti-infective agents, biologics, and vac- distribution in patients with lower res- DNA gyrase cines approved in 1992, 926 piratory tract infections, effect on, quinolones, mechanism of action, 839 FK037 804 DNA gyrase A protein anaerobic organisms H. parainfluenzae fluoroquinolones, single point muta- in vitro activity, 957 distribution in patients with lower res- tion reduces binding, 126 B. burgdorfeni piratory tract infections, effect on, doxycycline in vitro susceptibility, 1444 804 comparative evaluation, 846 P-lactamase stability, 566 in vitro activities epididymitis in vitro activity, 566 xx SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

multicenter comparison, 1696 positron emission tomography, 18F 128 in vitro and in vivo activities labeled, 1270 sparfloxacin comparative evaluation, 301 uptake in human polymorphonuclear reduced susceptibilities of S. sonnei Flavimonas oryzihabitans leukocytes, 187 strains, 2486 aminoglycosides T. glabrata WIN 57273 in vitro activities against clinical iso- prophylaxis in neutropenic bone mar- E. faecalis, 2470 lates from patients with cancer, row transplant patients, 1847 Flurbiprofen 2504 Flucytosine keratitis carbapenems Candida spp. age and therapeutic outcome, 1856 in vitro activities against clinical iso- temperature, effect on activity, 685 P. aeruginosa lates from patients with cancer, cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-ox- age and therapeutic outcome, 1856 2504 athiolane-5-yl]cytosine Foscarnet extended-spectrum cephalosporins (-) and (+) enantiomers, 5'-triphos- human immunodeficiency virus in vitro activities against clinical iso- phates cerebrospinal fluid of patients with lates from patients with cancer, human immunodeficiency virus, 1720 AIDS, penetration of, 1777 2504 human immunodeficiency virus human renal proximal tubule cells monobactams (-) and (+) enantiomers, 5' triphos- nephrotoxicity, 2496 in vitro activities against clinical iso- phates, 1720 nephrotoxicity lates from patients with cancer, 5-Fluorocytosine human renal proximal tubule cells, 2504 P. mameffei 2496 ureidopenicillins response of human immunodeficiency pharmacokinetics in vitro activities against clinical iso- virus-infected patients, 2407 blood-brain barrier, penetration of, lates from patients with cancer, 5-Fluoroorotate 1010 2504 P. falciparum cerebrospinal fluid of patients with Fleroxacin clonal viability measurements to as- AIDS, penetration of, 1777 breast milk sess in vitro activity, 1102 Fosfomycin penetration into, 293 Fluoroquinolones B-lymphocyte function combinations ciprofloxacin immunomodulatory effect, 270 rifampin, 2132 reduced susceptibilities of S. sonnei T cells comparative evaluation strains, 2486 immunosuppressive effect, 2684 DU-6859a, 2747 combinations Fractional maximal effect method in vitro activities inhibitors of glycosylation and fatty antibiotic combinations gram-negative organisms, 2017 acid and peptide biosynthesis, 652 effect, characterization of, 523 gram-positive organisms, 2017 M. avium, 652 nonlinear pharmacodynamics pharmacokinetics CP-99,219 characterization of, 523 breast milk, penetration into, 293 gram-positive organisms, in vitro ac- effects in healthy volunteers by tivity, 366 Fullerenes positron emission tomography, in vitro activity, 349 human immunodeficiency virus 8F labeled, 2144 DNA gyrase activity against, 1707 lactating women, 293 E. coli A protein, single point muta- Fusidic acid rifampin, influence of, 2132 tion reduces binding, 126 combinations S. aureus, 2132 DV-7751a S. aureus, 2466 Fluconazole in vitro antibacterial activity, 2112 vancomycin, 2466 bioavailability E-4868 M. kansasii patients with AIDS, 2187 in vitro and in vivo activities, 868 susceptibility testing, 1997 C. albicans E. coli DNA gyrase A protein pharmacokinetics emergence of resistance of Norwegian single point mutation reduces binding, intravenous, cholestatic patients, 501 strains, 2443 126 Fusobacterium spp. patients infected with human immuno- E. coli resistance Bay Y3118 deficiency virus type 1, correla- gyrA, mutations in, 696 in vitro activity, 2509 tion to therapy and symptoms, E. coli resistance, nalidixic acid suscep- 2449 tible G418 C. glabrata resistance, 1962 gyrA, novel point mutation, 1247 T. brucei brucei resistance phenotype C. neoformans gram-positive cocci in vivo system to select for blood- in vitro susceptibility, 1383 bloodstream isolates, 896 stream-form 1167 recurrent meningitis, isolates from pa- in vitro activity, 896 transfectants, tients with, 1383 M. pneumoniae, 1826 Gamma interferon comparative evaluation ofloxacin receptors amphotericin B, 2030 reduced susceptibilities of S. sonnei relation to therapy of typhoid fever, endocarditis strains, 2486 2418 C. parapsilosis, 2030 OPC-17116 Ganciclovir C. tropicalis, 2030 accumulation by human polymorpho- cytomegalovirus intracellular activity nuclear leukocytes, 1882 1110U81, potentiation of antiviral ef- human polymorphonuclear leukocytes, penetration into bacterial cells fects, 602 187 minireview, 1393 prophylaxis decreases frequency and P. marneffei Q-35 severity in liver transplant recipi- response of human immunodeficiency in vitro and in vivo activities, 1826 ents treated with OKT3 monoclo- virus-infected patients, 2407 reduced phototoxicity in mice irradi- nal antibodies, 2490 pharmacokinetics ated with long-wavelength UV, sensitivity at diagnosis and during healthy human subjects, 1270 2217 treatment, 1360 influence of radiotherapy on penetra- S. aureus resistance cytomegalovirus resistance tion into human saliva, 2674 efflux mediated, 1086 point mutation in DNA polymerase patients with AIDS, 2187 NorA, multidrug efflux transporter, gene, 19 VOL. 37, 1993 SUBJECT INDEX

Gardnerella vaginalis Glycylcyclines ramoplanin agar dilution comparative evaluation in vitro activity, 896 susceptibilities to 25 antimicrobial in vitro and in vivo activities, 2270 RP59500 agents, 2733 minocycline and tetracycline, 2270 in vitro activity, 598 Gentamicin Gonorrhea vancomycin resistant E. coli ceftriaxone ramoplanin, 1364 kill kinetics and regrowth patterns af- single-dose therapy for women, com- RP59500, 598 ter exposure, 914 parative evaluation, 1670 Granulocyte colony-stimulating factor postantibiotic effect in pooled cerebro- ciprofloxacin combinations spinal fluid and Mueller-Hinton single-dose therapy for women, com- clarithromycin, 692 broth, 1154 parative evaluation, 1670 M. avium complex, 692 E. faecalis resistance, high level GR99060 M. avium complex, 692 molecular characterization of isolates antifungal activity, 1243 Granulocyte-macrophage colony-stimulat- lacking high-level streptomycin GR99062 ing factor resistance, 134 antifungal activity, 1243 pharmacokinetics E. faecium resistance, 1904 Gram-negative organisms zidovudine, administration with, 512 E. faecium resistance, high level anaerobic Griseofulvin isolates from different continents, Bay y3118, comparative susceptibili- comparative evaluation comparison of, 681 ties, 1649 itraconazole, 2064 glomerular basement membrane azithromycin tinea unguium, 2064 alteration of development after admin- outer membrane permeability barrier, 4-Guanidino-2,4-dideoxy-2,3-dehydro-N- istration during gestation, 1510 354 acetylneuraminic acid M. avium complex Bay y3118 influenza viruses AIDS patients with bacteremia, 1869 comparative susceptibilities, 1649 growth inhibition, 1473 nephrotoxicity biapenem sialidase, inhibition of, 1473 neonates, drug-treated pregnant in vitro activity, 2009 gyrA Wistar rats, 1510 CAP18 E. coli polyaspartic acid, protective effects, in vitro activity, 2534 fluoroquinolone resistance, 696 pharmacologic limits of, 347 clarithromycin mutations in, 696 P. aeruginosa outer membrane permeability barrier, E. coli, fluoroquinolone resistant, nali- A band and B band lipopolysaccha- 354 dixic acid susceptible rides, interaction with, 715 CP-70,429 point mutation, novel, 1247 pharmacokinetics in vitro activity, 1547 increased renal uptake in endotoxemic imipenem Haemophilus ducreyi rats receiving thromboxane A2 in vitro activity, 2009 chancroid, currently recommended and therapy, 2727 outer membrane permeability barrier newer agents for population pharmacokinetic models, azithromycin, clarithromycin, and in vitro susceptibilities, 1552 comparison of, 93 roxithromycin, 354 isolates from the United States and postantibiotic effect roxithromycin Thailand, 1552 E. coli, in pooled cerebrospinal fluid outer membrane permeability barrier, parenteral and oral antimicrobial agents and Mueller-Hinton broth, 1154 354 in vitro activities, 1986 S. mitis Gram-positive organisms Haemophilus influenzae chromosomally mediated high-level aerobic ampicillin resistance, 2740 MDL 62,879, 746 distribution in patients with lower res- TLC G-65, 1869 anaerobic piratory tract infections, effect on, Giardia lamblia Bay y3118, comparative susceptibili- 804 bis-benzimidazoles ties, 1649 ,-lactamase producing and nonproduc- correlation of antigiardial activity, Bay y3118 ing, ampicillin resistant DNA binding affinity, and giardial comparative susceptibilities, 1649 amoxicillin-clavulanic acid, suscepti- topoisomerase II inhibition, 2668 biapenem bility to, 14 structure-activity studies, 2668 in vitro activity, 2009 cefaclor, susceptibility to, 14 Giardia spp. bloodstream isolates cefixime, susceptibility to, 14 benzimidazoles fluoroquinolones, 896 cefotaxime, susceptibility to, 14 in vitro activity, 328 glycopeptides, 896 ceftibuten, susceptibility to, 14 tubulin inhibitors ramoplanin, 896 cefuroxime, susceptibility to, 14 in vitro activity, 328 CAP18 in vitro 2534 ciprofloxacin Glucan activity, adherence changes induced by subin- irradiated mice, therapy for after ad- CP-70,429 in vitro activity, 1547 hibitory concentrations, 885 verse effects from pefloxacin, 1877 ecblogy in sputum and saliva, 804 Glucose oxidase CP-99,219 in vitro activity, 366 erythromycin human immunodeficiency virus type 1 fluoroquinolones distribution in patients with lower res- virucidal effects, 26 in vitro activity, 896 piratory tract infections, effect on, Glucose peroxidase glycopeptides 804 human immunodeficiency virus type 1 in vitro activity, 896 macrolides virucidal effects, 26 imipenem subinhibitory concentrations, influence Glycopeptides in vitro activity, 2009 on human neutrophil chemilumi- Enterococcus resistance MDL 62,879 nescence, 1015 genetics and mechanisms of, minire- aerobic, 746 sparfloxacin view, 1563 PD 138312 adherence changes induced by subin- gram-positive cocci in vitro activities, 2563 hibitory concentrations, 885 bloodstream isolates, 896 PD 140248 trimethoprim in vitro activity, 896 in vitro activities, 2563 adherence changes induced by subin- xxii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

hibitory concentrations, 885 Herpesviruses drug susceptibility, determination of, Haemophilus parainfluenzae acyclic nucleoside phosphonates 1095 ampicillin (S) and (R) enantiomers, 332 protease inhibitors distribution in patients with lower res- (R)-9-(2-phosphonomethoxypropyl)-2,6- A77003, 115 piratory tract infections, effect on, diaminopurine, 332 reverse transcriptase inhibition 804 High-performance liquid chromatography nonnucleoside inhibitors, 1037 ecology in sputum and saliva, 804 carbenicillin epimers reverse transcriptase inhibitor erythromycin analysis in biological fluids, 2327 isolates resistant to related inhibitors, distribution in patients with lower res- Human immunodeficiency virus activity against, 947 piratory tract infections, effect on, antiretroviral agents reverse transcriptase inhibitor resistance 804 resistance to, minireview, 1207 mutant enzyme and viral variant as- Hafnia alvei (-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine sessment, 1576 ceftazidime resistant characterization of, 875 reverse transcriptase inhibitors ,B-lactamase producing, 1375 (-)-2',3'-dideoxy-3'-thiacytidine FTC, 5'-triphosphates of (-) and (+) Halofantrine characterization of, 875 enantiomers, 1720 P. falciparum, 1955 foscarnet infectious amplification from lympho- efficacy in semi-immune patients in cerebrospinal fluid of patients with cytes and modulation, 2206 Cameroon, 1955 AIDS, penetration of, 1777 S-2720, activity of, 1659 P. falciparum resistance, 2337 fullerene, derivatized C60 S-2720 Helicobacterpylori activity of, 1707 inhibition of reverse transcriptase and AG-2000 protease inhibitors viral replication, 1659 urease activity, inhibition of, 769 allophenylnorstatine containing, in thiazolo-iso-indolinones lansoprazole vitro activities, 810 resistance, 2612 urease activity, inhibition of, 769 XM323 U-90152 metronidazole and its hydroxymetabolite in vitro activity, 2606 replication, inhibition of, 1127 synergy, 1184 Human immunodeficiency virus type 1 zidovudine and didanosine resistant metronidazole's hydroxymetabolite-tet- 3TC resistance pol mutations, 1480 racycline-HCl conferred by same mutation that con- zidovudine sensitivity synergy, 1184 fers resistance to ddI and ddC, discontinuation of zidovudine treat- metronidazole's hydroxymetabolite- 1390 ment, effects on, 1525 amoxicillin A77003 Human immunodeficiency virus type 2 synergy, 1184 preclinical evaluation, 115 chimeric enzymes, inhibition of metronidazole-tetracycline-HCI protease inhibitor, 115 nonnucleoside inhibitors, 1037 synergy, 1184 anti-CD4-pokeweed antiviral protein im- Human renal proximal tubule cells metronidazole-amoxicillin munoconjugate nephrotoxicity synergy, 1184 in vitro activity, 835 in vitro studies, 2496 omeprazole 3'-azido-3'-deoxythymidine Hydatid disease urease activity, inhibition of, 769 replication in human fetal brain mac- albendazole Hepatitis B virus rophages, effect on, 1305 treatment of, 1679 antiviral agents C. albicans mebendazole assessment in vitro, high capacity, 441 fluconazole resistance, 2449 treatment of, 1679 duck carbovir (-)-9-[4-Hydroxy-2-(hydroxymethyl) suramin, prevention of infection in cellular metabolism, effects on, 1004 butyl]guanine vivo, 1539 metabolism, 1004 simian varicella virus Hepatitis C virus carbovir-3'-azido-2',3'-deoxythymidine African green monkeys, 1370 alpha interferon treatment synergy, 144 (S)-1-(3-Hydroxy-2-phosphonyl-methox- HCV RNA levels in patients with CGP 53437 ypropyl)cytosine chronic infections, 595 protease, inhibition of, 2087 cytomegalovirus RNA levels chimeric enzymes, inhibition of interstitial pneumonitis after bone patients with chronic infections receiv- nonnucleoside inhibitors, 1037 marrow transplantation, 218 ing interferon treatment, 595 2'-deoxy-3'-thiacytidine resistance Hydroxyitraconazole Herpes simplex virus due to amino acid substitution at cata- bioassay and chromatography, effect on, acyclovir and foscarnet resistant lytic site of reverse transcriptase, 2224 pencyclovir, 2241 2231 itraconazole, metabolism of, 2224 acyclovir resistant diarylsulfones 348-U87-acyclovir, 975 mechanism of action, 754 ICI 195,739 ribonucleotide reductase inhibitor-acy- reverse transcriptase inhibitor, 754 combinations clovir, 975 2',3'-dideoxy-3'-thiacytidine resistance Chagas' disease, murine, 1353 generation of variants, 130 T. 1353 acyclovir susceptibility 2',3'-dideoxycytidine resistance cruzi, strains from organ transplant recipi- generation of variants, 130 terbinafine, 1353 ents after acyclovir or ganciclovir drug susceptibility Imipenem prophylaxis, 357 peripheral blood mononuclear cell cul- B. wadsworthia acyclovir-5-fluorodeoxyuridine-2- ture assay, 1095 morphological response, 2638 acetylpyridine thiosemicarbazone fluconazole penicillin-binding protein patterns, three-dimensional analysis of, 540 C. albicans resistance, 2449 2638 pencyclovir FTC combinations in vitro activities, 2241 5'-triphosphates of (-) and (+) enanti- amikacin, 1931 Herpes simplex virus type 1 omers, 1720 cilastatin, 51 acyclovir glucose oxidase and peroxidase P. aeruginosa, 1931 comparative evaluation, 642 virucidal effects, 26 yeast colonization of the human gas- penciclovir peripheral blood mononuclear cell cul- trointestinal tract, effect on, 51 comparative evaluation, 642 ture assay P. aeruginosa VOL. 37, 1993 SUBJECT INDEX xxiii

phenotypic resistance induced by sa- effects on cytochrome P-450-depen- KNI-227 licylate, 2743 dent sterol 14a-demethylation and human immunodeficiency virus pharmacodynamics reduction of 3-ketosteroids, 2101 protease inhibitor, allophenylnorsta- P. aeruginosa, 1931 candidiasis, acute vaginal tine containing, 810 postantibiotic effect placebo-controlled trial, 89 KNI-272 repeated exposures, 1723 comparative evaluation human immunodeficiency virus R. equi resistance amphotericin B, 2307 protease inhibitor, allophenylnorsta- penicillin-binding proteins, potential griseofulvin, 2064 tine containing, 810 role in, 1406 interpatient variations in concentration, KRM-1648 Imipenem resistance 2224 M. avium, 722 P. aeruginosa P. marneffei mechanism of efficient elimination of response of human immunodeficiency L-696,229 protein D2, 2385 virus-infected patients, 2407 analogs Immune globulin pharmacokinetics human immunodeficiency virus iso- respiratory syncytial virus food interaction, 778 lates resistant to related inhibi- prophylaxis for high-risk infants, eval- steady state, 778 tors, 947 uation of, 1655 tinea unguium, 2064 human immunodeficiency virus Influenza virus Ivermectins isolates resistant to related inhibitors, rimantadine S. erythraea activity against, 947 susceptibilities of subtypes A/HlN1 glycosylation, microbial conversion Lactoferrin and A/H3N2, 2239 by, 1737 porin binding Influenza viruses E. coli antibacterial activity, relation- 4-guanidino-2,4-dideoxy-2,3-dehydro-N- Keratitis ship with, 240 acetylneuraminic acid ciprofloxacin S. typhimurium antibacterial activity, growth inhibition, 1473 age and therapeutic outcome, 1856 relationship with, 240 sialidase, inhibition of, 1473 flurbiprofen Lansoprazole Intercellular adhesion molecule 1 age and therapeutic outcome, 1856 H. pyloni E. coli, expression in P. aeruginosa urease activity, inhibition of, 769 functional studies, 1278 age and therapeutic outcome, 1856 Legionella micdadei soluble prednisolone azithromycin function studies of, 1278 age and therapeutic outcome, 1856 inhibition of intracellular strains, 2261 Interleukin-6 Ketoconazole intracellular amphotericin B, 1958 combinations azithromycin inhibition, 2261 C. albicans, 1958 Chagas' disease, murine, 1353 Legionella spp. receptors T. cruzi, 1353 RP 74501-RP 74502 relation to therapy of typhoid fever, terbinafine, 1353 in vitro activity, 908 2418 mevinolin Leishmania amazonensis Interleukin-8 T. cruzi, potentiation of antiprolifera- quinoline alkaloids nonspecific resistance to infection tive effects, 580 2 substituted, 859 neutropenic and normal mice, 276 P. marneffei Leishmania donovani Intestinal microflora response of human immunodeficiency amphotericin B anaerobic virus-infected patients, 2407 T-cell-deficient mice, 1504 resistance patterns, 1665 Klebsiella pneumoniae leishmaniasis Isepamicin P-lactamase trans-aconitic acid in combined che- pharmacokinetics P-lactams, broad spectrum, resistance motherapy, 2459 nephrotoxicity, influence on in rats, to, 984 licochalcone A 2042 j-lactams, extended spectrum, resis- inhibition of growth, 2550 ISIS 2922 tance to, 2020 pentamidine cytomegalovirus ceftazidime resistance, 1989 T-cell-deficient mice, 1504 in vitro activity, 1945 plasmid encoded, TEM derived, 2020 trans-aconitic acid Isoniazid plasmid mediated, AmpC type, trans- role in combined chemotherapy for E. coli ferable, 984 experimentally infected hamsters, susceptibilities of oxyR regulon mu- cefoperazone-sulbactam resistance 2459 tants, 2251 of two different resistance Leishmania major coexistence A S. typhimurium mechanisms, 1061 licochalcone susceptibilities of oxyR regulon mu- cefozopran inhibition of growth, 2550 tants, 2251 respiratory tract infection, 100 Leishmania mexicana Isoprinosine ceftazidime resistance dinitroanilines P. carinii P-lactamase, 1989 structure-function analysis, 1909 dihydropteroate synthetase inhibition, ciprofloxacin trifluralin, 1909 1227 adherence changes induced by subin- Leishmania panamensis Itraconazole hibitory concentrations, 885 sodium stibogluconate A. fumigatus resis- in vitro activities of fractions, 1842 efficacy in a rat model, 2762 interleukin-1-induced nonspecific tance Leishmania spp. alveolar macrophages, uptake by, 903 9-anilinoacridines aspergillosis, 2307 role of acute-phase proteins in studies with mice, 2527 in vitro activity, 991 bioassay and chromatography, discrep- structure-activity relationships, 991 ancies in sparfloxacin hydroxyitraconazole, metabolism to, adherence changes induced by subin- quinoline alkaloids 2224 hibitory concentrations, 885 2 substituted, 859 C. albicans trimethoprim Leishmania venezuelensis placebo-controlled trial, 89 adherence changes induced by subin- quinoline alkaloids C. neoformans hibitory concentrations, 885 2 substituted, 859 xy-jv SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Leishmaniasis relation to survival, 483 Mefloquine cutaneous neutropenic rat model of Pseudomo- malaria quinolone alkaloids, 2 substituted, 859 nas sepsis, 483 comparison of two regimens, 1977 quinoline alkaloids urinary tract infections P. falciparum 2 substituted, 859 3-day treatment, 574 comparative evaluation of two regi- visceral acute uncomplicated, 574 mens, 1977 amphotericin B, T-cell-deficient mice, comparative evaluation, 574 Meningitis 1504 Luciferase pneumococcal, penicillin and cephalo- pentamidine, T-cell-deficient mice, M. tuberculosis sporin resistant 1504 antimicrobial activity against, method treatment regimens, evaluation of, Leptospira interrogans for screening for, 1348 1630 Q-35 Lyme disease recurrent cryptococcal five serogroups, 901 clarithromycin susceptibility of C. neoformans iso- Letters to the editor hamsters, 1329 lates to amphotericin B and flu- aminoglycoside resistance genes conazole, 1383 nomenclature, 927 Macrolides Mercury Capnocytophaga spp. combinations bacterial resistance antimicrobial susceptibilities, 1206 inhibitors of glycosylation and fatty letter to the editor, 1730 cefotaxime acid and peptide biosynthesis, 652 mercury from dental fillings provokes S. pneumoniae breakpoint, 616 M. avium, 652 increased occurrence, 825 dental amalgam cytochrome P-450 complex formation Meropenem multiple antibiotic resistance, 1730 rat and human livers, 265 P. cepacia Nocardia spp. dirithromycin comparative evaluation, 123 susceptibility testing, 2514 interactions with polymorphonuclear pharmacokinetics S. pneumoniae leukocytes, 2557 patients with various degrees of renal cefotaxime breakpoint, 616 H. infuenzae function, 229 susceptibility data subinhibitory concentrations, influence Metabolic disposition multidimensional analysis, 929 on human neutrophil chemilumi- (-)-cis-5-fluoro-1-[2-(hydroxymethyl)- Leukemia nescence, 1015 1,3-oxathiolan-5-yl] cytosine enoxacin P. acidilactici resistance studies with rats, 2285 infection prevention in adults with genetic basis for, 789 Methicillin nonlymphocytic leukemia, 474 P. aeruginosa S. aureus resistance Leupeptin serum sensitivity, effect of sub-MICs abnormal peptidoglycan, 342 P. falciparum on, 675 j-lactam-I-lactamase inhibitor combi- clonal viability measurements to as- Magainins nations, 702 sess in vitro activity, 1102 eicosanoid release 1-lactams, 702 Levofloxacin rat peritoneal macrophages, effect on, penicillin-binding protein 2A, role in adverse effects 393 cell wall synthesis, 342 convulsions in mice, 1764 Magnesium-aluminum hydroxide S. aureus resistance and susceptibility aluminum hydroxide rufloxacin sequential acquisition of norfloxacin inhibition of absorption by, 2173 effects on absorption, 2212 and ofloxacin resistance in iso- comparative evaluation Malaria lates, 2278 accumulation by human polymorpho- amopyroquin Staphylococcus resistance nuclear leukocytes, 1882 intramuscular, 970 mec regulator genes, distribution of, DU-6859a, 2747 halofantrine 1219 synergy efficacy in semi-immune patients in Metronidazole oxacillin, 339 Cameroon, 1955 synergy S. aureus, quinolone resistant, 339 mefloquine amoxicillin, 1184 Licochalcone A P. falcipanum, 1977 H. pylon, 1184 L. donovani P. falciparum, 1955 hydroxymetabolite of metronidazole, inhibition of growth, 2550 amopyroquin, 970 1184 L. major mefloquine, 1977 tetracycline-HCl, 1184 inhibition of growth, 2550 Mastitis Mevinolin Lincomycin bovine T. cruzi peptidyl-RNA pirlimycin, activity and disk diffusion ketoconazole and terbinafine, potentia- accumulation, 2027 breakpoints, 1122 tion of antiproliferative effects, dissociation from ribosomes, 2027 pirlimycin 580 Lipophilic agents activity against bovine pathogens, Miconazole penetration into bacterial cells 1122 P. mameffei minireview, 1393 disk diffusion breakpoints, 1122 response of human immunodeficiency Liposomes virus-infected patients, 2407 MDL 62,879 Microdilution checkerboard method ciprofloxacin, liposome incorporated anaerobic 746 treatment of murine salmonellosis, bacteria, synergy measurement 2293 gram-positive organisms reproducibility, 613 LJC 10,627 aerobic, 746 Minireviews toxicity in vitro activity, 741 3-lactamases central nervous systems of rats, low Mebendazole induction of, molecular basis for, 153 levels of, 199 hydatid disease P-lactams Lomefloxacin treatment of, 1679 penicillin-binding protein resistance, comparative evaluation mec 2045 DU-6859a, 2747 Staphylococcus spp., methicillin resis- C. neoformans pharmacodynamics tant susceptibility testing, status of the concentration in plasma-time profile, distribution of regulator genes in, 1219 standardization process, 2517 VOL. 37, 1993 SUBJECT INDEX xxv

Candida spp. combination with inhibitors of glyco- ciprofloxacin susceptibility testing, status of the sylation and fatty acid and pep- in vitro activities, 2323 standardization process, 2517 tide biosynthesis, 652 clarithromycin Enterococcus spp. azithromycin resistance in vitro activities, 2323 glycopeptide resistance, genetics and clarithromycin, 2364 clofazamine mechanisms of, 1563 cross-resistance, 2364 in vitro activities, 2323 glycopeptides clarithromycin erythromycin Enterococcus resistance, genetics and erratum, 2515 in vitro activities, 2323 mechanisms of, 1563 human macrophages, 111 ofloxacin human immunodeficiency virus macrophages, inhibition of intracellu- in vitro activities, 2323 antiretroviral agents, resistance to, lar growth, 1380 rifabutin 1207 prophylaxis in C57BL/6 mice, 1690 in vitro activities, 2323 lipophilic agents with multiple protona- clarithromycin resistance rifampin tion sites azithromycin, 2364 in vitro activities, 2323 penetration into bacterial cells, 1393 cross-resistance, 2364 sparfloxacin new antibiotics clarithromycin-minocycline in vitro activities, 2323 discovery and development, problem prophylaxis in C57BL/6 mice, 1690 Mycobacterium kansasii of resistance, 377 fluoroquinolones susceptibility testing nosocomial pneumonia combination with inhibitors of glyco- azithromycin, 1997 critically ill patients, prevention of, sylation and fatty acid and pep- clarithromycin, 1997 931 tide biosynthesis, 652 fusidic acid, 1997 organ transplant recipients KRM-1648, 722 ofloxacin, 1997 antimicrobial strategies, 619 macrolides sparfloxacin, 1997 penicillin-binding proteins combination with inhibitors of glyco- Mycobacterium leprae 1-lactam resistance, 2045 sylation and fatty acid and pep- rifampin resistance Q fever tide biosynthesis, 652 molecular basis, 414 treatment of, 1733 minocycline Mycobacterium malmoense rifampin erratum, 2515 ethambutol nonstaphylococcal, nonmycobacterial quinolones ciprofloxacin, amikacin, rifampin, syn- disease, 1 in vitro activities, 1799 ergy with, 1285 Minocycline structure-activity relationship studies, susceptibility to antibacterial drugs and combinations 1807 drug combinations, 1285 clarithromycin, 1690 rifabutin Mycobacterium paratuberculosis M. avium, prophylaxis in mice, 1690 erratum, 2515 rifabutin rifabutin, 1690 prophylaxis in C57BL/6 mice, 1690 systemic infection in mice, 1645 M. avium rifabutin-minocycline Mycobacterium spp. erratum, 2515 prophylaxis in C57BL/6 mice, 1690 AM-1155 Monobactams Mycobacterium avium complex in vitro activity, comparative evalua- F. oryzihabitans azithromycin tion, 1259 in vitro activities against clinical iso- rats treated with cyclosporine, 398 lates from patients with cancer, benzoxazinorifamycin ethambutol 2504 radiometric method, determination by, glucose metabolism, inhibition of, Moraxella catarrhalis 67 1536 ciprofloxacin clarithromycin, 692 roxithromycin adherence changes induced by subin- gentamicin in vitro activity, 1560 hibitory concentrations, 885 AIDS patients with bacteremia, 1869 pH, effect on radiometric MICs, 1560 sparfloxacin TLC G-65, 1869 Mycobacterium tuberculosis adherence changes induced by subin- granulocyte colony-stimulating factor, antimicrobial activity hibitory concentrations, 885 692 method for screening for, 1348 trimethoprim granulocyte colony-stimulating factor- CGI 17341 adherence changes induced by subin- clarithromycin, 692 in vitro and in vivo activities, 183 hibitory concentrations, 885 rifabutin clofazimine Mupirocin rats treated with cyclosporine, 398 in vitro activities, 2584 S. aureus resistance, high level rifapentine luciferase expressing isoleucyl-tRNA synthetases, evidence rats treated with cyclosporine, 398 antimicrobial activity against, method for two distinct, 32 RU-40555, 692 for screening for, 1348 Mupirocin resistance RU-40555-clarithromycin, 692 multidrug resistant S. aureus Mycobacterium avium-M. intracellulare studies with mice, 2344 detection and characterization, 2003 complex polymerase chain reaction Mureidomycins clofazimine detection, 2054 bacterial translocase reaction in pepti- in vitro activities, 2584 doglycan synthesis, inhibition of, resorcinomycin resorcinomycin 980 in vitro activities, 2584 in vitro activities, 2584 Murine leukemia virus Mycobacterium fortuitum rifampin resistant protease inhibitors amikacin detection, 2054 antiretroviral activity, 71 postantibiotic effect, 1001 single-strand conformation polymor- Mutagenicity ofloxacin phism analysis quinolones postantibiotic effect, 1001 detection, 2054 Ames Salmonella TA102 assay, 213 Mycobactenum haemophilum sparfloxacin, 407 Mycobactenum avium amikacin Mycoplasma bovis activities of quinolones in vitro activities, 2323 antimicrobial susceptibilities, 317 erratum, 2766 azithromycin Mycoplasma dispar aminoglycosides in vitro activities, 2323 antimicrobial susceptibilities, 317 xxvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Mycoplasma fermentans Nocardia brasiliensis bioequivalence after multiple doses to susceptibility testing rifampin healthy volunteers, 1468 in vitro strains from AIDS patients, inactivation of, 1313 multiple oral doses to healthy volun- 2500 Nocardia farcinica teers, 2193 in vitro strains from non-AIDS pa- 13-lactamases postantibiotic effect tients with acute respiratory dis- characterization, 1850 M. fortuitum, 1001 ease, 2500 Nocardia spp. serum bactericidal titers tissue culture, 2500 antimicrobial susceptibilities multiple oral doses to healthy volun- Mycoplasma hominis in vitro, 882 teers, 2193 OPC 17116 susceptibility testing Omeprazole susceptibility in vitro, 1726 letter to the editor, 2514 H. pylon Mycoplasma pneumoniae Norfloxacin urease activity, inhibition of, 769 ciprofloxacin urinary tract infections OPC 17116 hamsters, 287 3-day treatment, 574 M. hominis ofloxacin acute uncomplicated, 574 susceptibility in vitro, 1726 hamsters, 287 comparative evaluation, 574 M. pneumoniae OPC 17116 Northern (RNA) blot analysis susceptibility in vitro, 1726 susceptibility in vitro, 1726 C. albicans U. urealyticum Q-35 picolinic acid, protective effect on susceptibility in vitro, 1726 in vitro and in vivo activities, 1826 mice, 2422 OPC-17116 temafloxacin Novobiocin C. pneumoniae hamsters, 287 combinations in vitro and in vivo activities, 801 Myeloperoxidase ciprofloxacin, 1904 C. psittaci C. albicans E. faecium, 1904 in vitro and in vivo activities; 801 human recombinant, candidicidal ac- rifampin, 1334 C. trachomatis tivity, 142 S. aureus, methicillin resistant, eradi- in vitro and in vivo activities, 801 human recombinant cation of, 1334 comparative evaluation C. albicans, candidicidal activity, 142 E. faecium accumulation by human polymorpho- in vitro activity against multiresistant nuclear leukocytes, 1882 Neissena gonorrhoeae strains, 2736 N. gonorrhoeae ciprofloxacin NP-1 antibacterial activities, 2244 antibacterial activities, 2244 C. neofortnans Ophthalmitis ofloxacin fungicidal properties, 2628 sparfloxacin antibacterial activities, 2244 in vitro activity, 2628 rabbit model, efficacy in, 633 in vitro susceptibilities, 2007 Oral flora OPC-17116 Ofloxacin mercury resistant antibacterial activities, 2244 B. burgdorferi mercury from dental fillings provokes Neisseria meningitidis in vitro susceptibility, 1444 increased occurrence, 825 ofloxacin combinations Oral microflora doses to eradicate tonsillopha- Brucella spp., 1831 single rifampin, 1214, 1831 anaerobic ryngeal carriage in Norway, 2024 Staphylococcus-infected orthopedic resistance patterns, 1665 penicillin susceptible, moderately implants, 1214 Organ transplant patients isolation in Argentina, 1728 comparative evaluation antimicrobial strategies Nephrotoxicity accumulation by human polymorpho- minireview, 619 gentamicin nuclear leukocytes, 1882 Ornidazole neonates, drug-treated pregnant ciprofloxacin, 2193 concentrations in plasma during liver Wistar rats, 1510 DU-6859a, 2747 transplantation, 1873 Netilmicin E. coli tissue penetration during liver transplan- combinations comparative evaluation, 846 tation, 1873 ceftriaxone, 1971 epididymitis, 846 Orthopedic implants endocarditis, 1971 epididymitis Staphylococcus infections diltiazem comparative evaluation, 846 rifampin-ofloxacin, 1214 nephrotoxicity in rabbits, effects on, E. coli, 846 Otitis media 1790 in vitro activities S. pneumoniae, penicillin resistant synergy gram-negative organisms, 2017 amoxicillin, increased dosages of, 1599 ceftriaxone, 207 gram-positive organisms, 2017 Oxacillin streptococcal endocarditis, 207 M. fortuitum endocarditis Nevirapine postantibiotic effect, 1001 S. aureus, 1-lactamase hyperproduc- pharmacokinetics M. haemophilum ing, 507 single-rising-dose study in humans, in vitro activities, 2323 S. aureus 178 M. kansasii P-lactamase hyperproducing, 507 Nitrofurazone susceptibility testing, 1997 synergy urinary tract infections M. pneumoniae levofloxacin, 339 catheter associated, 2033 hamsters, 287 S. aureus, quinolone resistant, 339 Nitroimidazoles N. gonorrhoeae Oxidase inhibitors CGI 17341 antibacterial activities, 2244 P. berghei M. tuberculosis, 183 in vitro susceptibilities, 2007 drug susceptibility, enhancement of, M. tuberculosis N. meningitidis 1318 CGI 17341, 183 single doses to eradicate tonsillopha- P. falciparum NM394 ryngeal carriage in Norway, 2024 drug susceptibility, enhancement of, antibacterial activity, 793 pharmacokinetics 1318 VOL. 37, 1993 SUBJECT INDEX xxvii

Panipenem Penicillin-binding proteins azithromycin P. aeruginosa, 322 B. wadsworthia pediatric patients, multiple oral doses diffusion through outer membrane, inhibition by imipenem, 2638 of suspension, 314 role of OprD protein, 322 ,-lactam resistance carbenicillin epimers phenotypic resistance induced by sa- minireview, 2045 stereoselective renal tubular secretion, licylate, 2743 expression of a novel membrane pro- 2327 Papillomavirus tein and increased expression of cefazolin E2 mRNA penicillin-binding protein 2 com- protein binding in rats, 1781 phosphorothioate oligonucleotides, plex, 2432 cefepime potential treatment for genital minireviews cystic fibrosis patients, 1414 warts, 171 P-lactam resistance, 2045 cefixime phosphorothioate oligonucleotides R. equi biliary excretion in patients with E2 mRNA, potential treatment for imipenem resistance, potential role in, T-tube drainage, 1488 genital warts, 171 1406 cefonicid Pasteurella multocida S. aureus protein binding in adult and neonatal Tet H blaI and blaRl, regulation by, 1144 sera, 1343 active efflux of tetracycline, 2699 cell wall synthesis, role in, 342 cefotaxime PBP 2a S. pneumoniae cerebrospinal fluid of patients with S. aureus 2B and 2X, genetic diversity of, 1938 uninflamed meninges, passage blaI and blaRI, regulation by, 1144 Penicillium marneffei into, 1518 PD 127391 human immunodeficiency virus cefpodoxime proxetil P. cepacia response of patients to antifungal ther- studies with patients receiving contin- comparative evaluation, 123 apy, 2407 uous ambulatory peritoneal dialy- PD 131628 Pentamidine sis, 2650 P. cepacia L. donovani cefprozil comparative evaluation, 123 T-cell-deficient mice, 1504 tonsillar and adenoidal tissues, pene- PD 138312 leishmaniasis, visceral tration into, 1180 gram-positive organisms T-cell-deficient mice, 1504 ceftazidime in vitro activities, 2563 Peptide antibiotics patients with septic multiple-organ PD 140248 AS-48 failure during intermittent hemo- gram-positive organisms neutralizing antibodies, immunocyto- filtration, 464 in vitro activities, 2563 logical studies, 148 serum bactericidal activities, 1835 Pediococcus acidilactici MDL 62,879 side effects, 1835 macrolide resistance in vitro activity, 741 ceftriaxone genetic basis for, 789 Peptidoglycan synthesis inhibitors cerebrospinal fluid of patients with Pediococcus spp. mureidomycins uninflamed meninges, passage antimicrobial susceptibilities, 789 bacterial translocase reaction, inhibi- into, 1518 Pefloxacin tion of, 980 elimination, effect of plasmapheresis, bactericidal activities Peptostreptococcus spp. 1171 one 800-mg versus two 400-mg doses, Bay Y3118 liver transplantation, 1873 737 in vitro activity, 2509 pregnant women, 54 irradiated mice, adverse effects on and Peripheral blood mononuclear cell culture protein binding during pregnancy, 54 glucan therapy for, 1877 assay cefuroxime pharmacokinetics human immunodeficiency virus protein binding in adult and neonatal one 800-mg versus two 400-mg doses, drug susceptibility, determination of, sera, 1343 737 1095 ciprofloxacin Penciclovir Peritonitis effects of cardiopulmonary bypass sur- herpes simplex virus type 1 bacterial, spontaneous gery on disposition, 2106 comparative evaluation, 642 ceftriaxone versus cefonicid, 1587 healthy volunteers, multiple oral Pencyclovir cefonicid doses, 2193 herpes simplex virus comparative evaluation, 1587 seriously ill patients, 1073 acyclovir and foscarnet resistant, 2241 ceftriaxone (-)-cis-5-fluoro-1-[2-(hydroxymethyl)- in vitro activities, 2241 comparative evaluation, 1587 1,3-oxathiolan-5-yl] cytosine herpes simplex virus resistance Pharmacokinetics studies with rats, 2285 pencyclovir, 2241 3'-deoxy-2',3'-didehydrothymidine clindamycin Penems disposition and metabolism in hepato- bioavailability, 1137 CP-70,429 cytes and nonhuman primates, healthy volunteers and AIDS patients, ,-lactamase stability and in vitro ac- 1816 1137 tivity, 1547 allopurinol riboside diminazine Penicillin probenecid, effects of, 1193 Boran cattle, noninfected and infected E. faecium resistance alpha interferon with T. congolense, 1050 time-kill studies, 2427 transplacental passage, two assay enoxacin haptenation techniques, 1232 oral antacids, effect on disposition, serum proteins, facilitation of, 1463 amikacin 775 N. meningitidis, moderately susceptible attachment to collagen for local deliv- fleroxacin isolation in Argentina, 1728 ery in wounds, 1890 breast milk, penetration into, 293 S. mutans patients with septic multiple-organ effects in healthy volunteers by in vitro susceptibility, 1158 failure during intermittent hemo- positron emission tomography, synergy filtration, 464 8F labeled, 2144 gentamicin, 2427 amoxicillin lactating women, 293 Penicillin V local gastric and serum concentrations rifampin, influence of, 2132 tonsillopharyngitis, streptococcal after different oral applications, fluconazole comparative evaluation, 1620 1506 healthy human subjects, 1270 xxviii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

influence of radiotherapy on penetra- fleroxacin-rifampin, 2132 Pirlimycin tion into human saliva, 2674 SCE-2787 bovine mastitis, isolates from patients with AIDS, 2187 serum bactericidal activities, 1835 activity of, 1122 positron emission tomography, 18F side effects, 1835 disk diffusion breakpoints, 1122 labeled, 1270 sparfloxacin Plasmids uptake in human polymorphonuclear ocular penetration in rabbits with oph- R751 leukocytes, 187 thalmitis, 633 multidrug resistance to antiseptics and foscarnet stavudine disinfectants, 761 blood-brain barrier, penetration of, cynomolgus monkeys, 1160 resistance 1010 teicoplanin S. aureus, 2003 fusidic acid evaluation of a fluorescence polariza- Plasmodium berghei intravenous, cholestatic patients, 501 tion immunoassay, 1924 oxidase inhibitors gentamicin prophylaxis in monolateral and bilat- drug susceptibility, enhancement of, increased renal uptake in endotoxemic eral total knee replacement proce- 1318 rats receiving thromboxane A2 dures, 2693 Plasmodium falciparum therapy, 2727 ticarcillin-clavulanic acid 5-fluoroorotate population pharmacokinetic models, healthy volunteers, 1860 clonal viability measurements to as- comparison of, 93 trimethoprim-sulfamethoxazole sess in vitro activity, 1102 patients with AIDS and severe AIDS- 12/60 mg/kg/day, multiple dose, 448 amopyroquin related complex, 512 healthy volunteers, 448 malaria treatment, 970 isepamicin vancomycin chloroquine nephrotoxicity, influence on in rats, obesity, effect on, 436 clonal viability measurements to as- 2042 pulmonary lining fluid, penetration sess in vitro activity, 1102 itraconazole into, 281 chloroquine resistant alveolar macrophages, uptake by, 903 serum protein-binding characteristics, 9-anilinoacridines, 403 food interaction, 778 1132 clonal viability measurements steady state, 778 zidovudine leupeptin, chloroquine, and 5-fluoro- lomefloxacin effects of standard breakfast in pa- orotate, in vitro activity, 1102 concentration in plasma-time profile, tients with AIDS, 2153 cross-resistance patterns, 2337 relation to survival, 483 prodrugs, enhanced levels in brain tis- cycloguanil neutropenic rat model of Pseudomo- sue, 818 African isolates, 924 nas sepsis, 483 rifampin, interaction with, 1426 halofantrine resistance, 2337 meropenem zidovudine-granulocyte-macrophage col- leupeptin patients with various degrees of renal ony-stimulating factor clonal viability measurements to as- function, 229 patients with AIDS and severe AIDS- sess in vitro activity, 1102 nevirapine related complex, 512 malaria single-rising-dose study in humans, Pharyngitis amopyroquin, 970 178 halofantrine, 1955 nonparametric expectation maximization cefuroxime axetil suspension mefloquine, 1977 oncology patients receiving amino- comparative evaluation, 159 mefloquine glycoside therapy, 1025 Streptococcus spp., group A malaria treatment, 1977 ofloxacin cefuroxime axetil suspension, compar- oxidase inhibitors bioequivalence after multiple doses to ative evaluation, 159 drug susceptibility, enhancement of, healthy volunteers, 1468 (R)-9-(2-Phosphonomethoxypropyl)-2,6- 1318 healthy volunteers, multiple oral diaminopurine Platelet microbicidal protein doses, 2193 herpesviruses, 332 C. neoforinans ornidazole retroviruses, 332 fungicidal activity, 546 liver transplantation, 1873 Phosphonylmethoxyalkyl derivatives Candida spp. pefloxacin cytomegalovirus resistance fungicidal activity, 546 one 800-mg versus two 400-mg doses, point mutation in DNA polymerase Pneumocystis carinji 737 gene, 19 8-aminoquinolones piperacillin Phosphorothioate oligodeoxynucleotides in vivo and in vitro studies, 2166 healthy volunteers, 1860 Epstein-Barr virus amsacrine piperacillin-tazobactam inhibition of replication, 1420 activity in vitro and in a mouse model, healthy volunteers, 1860 Picolinic acid 1543 population C. albicans bis-benzimidazoles ciprofloxacin, optimal sampling strate- protective effect on mice, 2422 pneumonia, treatment of, 1713 gies, 1065 Picornavirus biguanide folate antagonist nonparametric approach, 1025 binders PS-15, immunosuppressed rat model, ribavirin capsid 1417 children with human immunodefi- detection with soluble intercellular bilobalide ciency virus infection, 532 adhesion molecule 1, 1693 in vitro and in vivo activities, 1492 rifampin Piperacillin camptothecin fleroxacin, influence on, 2132 combinations activity in vitro and in a mouse model, zidovudine, interaction with, 1426 comparative evaluation, 1580 1543 rufloxacin skin and skin structure infections, dihydrofolate reductase inhibitors and biliary excretion in humans, 2545 1580 dapsone patients with impaired renal function, tazobactam, 1580, 2578 synergy, 1436 637 pharmacokinetics dihydrofolate reductase inhibitors and S-1108 healthy volunteers, 1860 sulfamethoxazole safety of and carnitine status of pa- Piperacillin-tazobactam synergy, 1436 tients, 1043 pharmacokinetics epipodophyllotoxins S. aureus healthy volunteers, 1860 activity in vitro and in a mouse model, VOL. 37, 1993 SUBJECT INDEX xxix

1543 Postantibiotic effect infections in, 1927 isoprinosine benzylpenicillin cefozopran dihydropteroate synthetase inhibition, Bioscreen C, 2200 urinary tract infection, 100 1227 Streptococcus and Pneumococcus ceftazadime, 308 pneumonia spp., 2200 ceftazidime-amikacin, 308 bis-benzimidazoles, cationically substi- E. coli ciprofloxacin tuted, activity of, 1713 correlation of tobramycin-induced in- age and therapeutic outcome, 1856 PS-15 hibition of protein synthesis, 2678 dose-ranging and fractionation, 1756 folate antagonism, 1417 imipenem in vitro model of infection, 1756 immunosuppressed rat model, 1417 repeated exposure to, 1723 increased susceptibility in the pres- quinolones temafloxacin ence of vancomycin, 2506 activity in vitro and in a mouse model, repeated exposure to, 1723 resistance to unrelated antibiotics, ef- 1543 tobramycin fects on, 1289 Ro 11-8958-dapsone hyperoxia, prolongation by, role of clarithromycin synergy, 1436 reactive oxygen species, 120 biofilms, interaction with, 1749 Ro 11-8958-sulfamethoxazole P. aeruginosa, 120 deglucoteicoplanin amide derivatives synergy, 1436 repeated exposure to, 1723 uptake, mechanism of, 453 topoisomerase inhibitors Prednisolone erythromycin activity in vitro and in a mouse model, keratitis sub-MICs, effect on serum sensitivity, 1543 age and therapeutic outcome, 1856 675 Pneumonia P. aeruginosa flurbiprofen cytomegalovirus age and therapeutic outcome, 1856 age and therapeutic outcome, 1856 ganciclovir sensitivity at diagnosis and Prevotella spp. gentamicin during treatment, 1360 Bay Y3118 A band and B band lipopolysaccha- nosocomial in vitro activity, 2509 rides, interaction with, 715 critically ill patients, prevention of, Pristinamycin resistance imipenem 931 S. aureus phenotypic resistance induced by sa- minireview, 931 isolates responsible for outbreak in licylate, 2743 Pneumonitis Parisian hospital, 2159 imipenem resistance cytomegalovirus Probenecid mechanism of efficient elimination of (S)-1-(3-hydroxy-2-phosphonyl-meth- allopurinol riboside protein D2, 2385 oxypropyl)cytosine, 218 pharmacokinetics, effects on, 1193 imipenem-amikacin Poloxamers Protease inhibitors in vitro pharmacodynamic effects, T. gondii, 2265 human immunodeficiency virus 1931 toxoplasmosis, 2265 in vitro activity of XM323, 2606 interleukin-1-induced nonspecific resis- Poly(I):poly(Cl2U) murine leukemia virus tance biologic effects antiretroviral activity, 71 role of acute-phase proteins in studies healthy volunteers, 429 simian immunodeficiency virus with mice, 2527 Polyaspartic acid antiretroviral activity, 71 keratitis gentamicin PS-15 age and therapeutic outcome, 1856 nephrotoxicity, protective effects, P. carinii macrolides pharmacologic limits of, 347 folate antagonism, 1417 sub-MICs, effect on serum sensitivity, nephrotoxicity immunosuppressed rat model, 1417 675 gentamicin, protective effects, phar- Pseudomonas aeruginosa panipenem, 322 macologic limits of, 347 6'-N-acetyltransferase diffusion through outer membrane, Polymerase chain reaction aac(6')-Ib, characterization of, 1456 role of OprD protein, 322 E. faecalis antiflagella monoclonal antibodies phenotypic resistance induced by sa- heterogeneity of chloramphenicol ace- therapeutic effects in a murine model, licylate, 2743 tyltransferase genes, 2593 164 postantibiotic effect E. faecium ant(4')-IIa tobramycin, prolongation by hyper- heterogeneity of chloramphenicol ace- nucleotide sequence analysis and oxia, role of reactive oxygen spe- tyltransferase genes, 2593 DNA hybridization studies, 708 cies, 120 M. tuberculosis aztreonam, 308 prednisolone rifampin resistant, 2054 aztreonam-amikacin, 308 age and therapeutic outcome, 1856 S. pneumoniae ,3-lactamase tobramycin heterogeneity of chloramphenicol ace- extended spectrum, characterization postantibiotic effect, prolongation by tyltransferase genes, 2593 of, 962 hyperoxia, role of reactive oxygen Polymorphonuclear leukocytes OXA-11, extended-spectrum variant of species, 120 dirithromycin OXA-10, 1637 vancomycin interactions may promote killing of biapenem increased susceptibility to ciprofloxa- infecting organisms, 2557 phenotypic resistance induced by sa- cin, 2506 suramin licylate, 2743 Pseudomonas cepacia suppression of bactericidal activity, biofilms ,-lactamase 495 clarithromycin, interaction with, 1749 strain 249 chromosomal penicillinase, Porphyromonas spp. inhibition of formation on prosthetic member of AmpC family, 667 Bay Y3118 devices by proteolytic enzymes, ceftazidime in vitro activity, 2509 2618 comparative evaluation, 123 Positron emission tomography BO-2727 chloramphenicol fleroxacin in vitro activity, 2756 comparative evaluation, 123 pharmacokinetics, 18F labeled, 2144 carbapenem resistance ciprofloxacin pharmacokinetics cephalosporinase, role in, 1387 comparative evaluation, 123 fleroxacin, "8F labeled, 2144 cefoperazone-sulbactam co-trimoxazole fluconazole, "8F labeled, 1270 granulocytopenic mice, disseminated comparative evaluation, 123 SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

meropenem DNA gyrase mutations, characteriza- Respiratory pathogens comparative evaluation, 123 tion of, 457 ciprofloxacin PD 127391 cefazolin-induced seizures adherence changes induced by subin- comparative evaluation, 123 DBA/2 mice, potentiation of, 1497 hibitory concentrations, 885 PD 131628 CI-960 sparfloxacin comparative evaluation, 123 C. trachomatis salpingitis, 8 adherence changes induced by subin- Pseudomonas pseudomallei combinations hibitory concentrations, 885 ceftazidime resistance Brucella spp., 1831 trimethoprim biofilm cells, 2000 comparative evaluation, 1831 adherence changes induced by subin- co-trimoxazole CP-115,953 hibitory concentrations, 885 biofilm cells, 2000 activities against mammalian systems, Respiratory syncytial virus Pulsed-field gel electrophoresis comparative evaluation, 2179 immune globulin enterococci DNA gyrases prophylaxis for high-risk infants, eval- characterization of glycopeptide-resis- E. coli, mechanism of action, 839 uation of, 1655 tant isolates from U.S. hospitals, E. coli Respiratory tract infections 2311 DNA gyrase, mechanism of action, cefozopran, 100 Pyrimethamine 839 K. pneumoniae combinations cefozopran, 100 azithromycin, 1993 in vivo efficacy, correlation with in Retroviruses T. gondii, 1993 vitro susceptibility, 997 acyclic nucleoside phosphonates creatinine secretion, renal mice, 997 (S) and (R) enantiomers, 332 inhibition of, 1056 E. coli resistance (R)-9-(2-phosphonomethoxypropyl)-2,6- Pyrimido[1,6-a]benzimidazoles plasmid complementation test, 2588 diaminopurine, 332 D. melanogaster M. avium Reverse transcriptase inhibitors effects on topoisomerase II and Kc in vitro activities, 1799 diarylsulfones cells, 2599 structure-activity relationship studies, human immunodeficiency virus, 754 1807 FTC Q-35 M. pneumoniae human immunodeficiency virus, 1720 L. interrogans hamsters, 287 human immunodeficiency virus five serogroups, 901 NM394 diarylsulfones, mechanism of action, M. pneumoniae antibacterial activity, 793 754 in vitro and in vivo activities, 1826 OPC 17116 FTC, 5'-triphosphates of (-) and (+) mice irradiated with long-wavelength M. hominis, M. pneumoniae, and U. enantiomers, 1720 UV urealyticum, 1726 L-696,229, activity against isolates re- reduced phototoxicity, 2217 P. carindi sistant to related inhibitors, 947 Q fever activity in vitro and in a mouse model, nonnucleoside inhibitors, 1037 C. bumetii 1543 S-2720, 1659 minireview, 1733 PD 138312 human immunodeficiency virus resis- treatment of in vitro activities, 2563 tance minireview, 1733 PD 140248 mutant enzyme and viral variant as- Quinapyramine in vitro activities, 2563 sessment, 1576 T. congolense, resistant clone proconvulsant human immunodeficiency virus type 1 derivation and characterization, 1163 effects infectious amplification from lympho- Quinoline alkaloids DBA/2 mice, 1497 cytes and modulation, 2206 2 substituted T-3761 L-696,229 L. amazonensis, 859 in vitro and in vivo activities, 384 human immunodeficiency virus iso- L. venezuelensis, 859 topoisomerase II lates resistant to related inhibi- leishmaniasis, cutaneous, 859 stereospecificity for the C-11 methyl tors, 947 L. amazonensis, 859 group, 646 S-2720 L. venezuelensis, 859 topoisomerase II and cultured cells, ac- human immunodeficiency virus, 1659 leishmaniasis, 859 tivities against, 2179 thiazolo-iso-indolinones Quinolones human immunodeficiency virus type 1 1-8 bridged R751 resistance, 2612 topoisomerase II, stereospecificity for integron U-90152 the C-11 methyl group, 646 multidrug resistance to antiseptics and human immunodeficiency virus, 1127 AM-1155 disinfectants, 761 Rhinovirus antimycobacterial activities, compara- Ramoplanin WIN 54954 tive evaluation, 1259 gram-positive organisms prophylaxis, efficacy of, 297 Rhodococcus equi Ames Salmonella TA102 assay bloodstream isolates, 896 in vitro activity, 896 penicillin-binding proteins bacterial mutagenicity, 213 imipenem resistance, potential role in, antibiotic carryover vancomycin resistant, 1364 1406 antibiotic-removal beads, elimination "Red man syndrome" Ribavirin with, 1377 vancomycin pharmacokinetics anti-M. avium activities skin tests to healthy volunteers, 2139 children with human immunodefi- erratum, 2766 Renal function ciency virus infection, 532 B. fragilis creatinine secretion safety and tolerance in vivo efficacy, correlation with in pyrimethamine, inhibition of, 1056 children with human immunodefi- vitro susceptibility, 997 Resorcinomycin ciency virus infection, 532 mice, 997 M. avium-M. intracellulare complex Rickettsia spp. Bay y 3118 in vitro activities, 2584 spotted fever group broth macrodilution assays, 2348 M. tuberculosis in vitro susceptibilities to clarithromy- C. jejuni resistance in vitro activities, 2584 cin, 2633 VOL. 37, 1993 SUBJECT INDEX xxxi

Rifabutin Ro 41-3399 supersusceptibility to antibiotics, 2255 combinations metabolite Salmonellae M. avium, prophylaxis in mice, 1690 antimicrobial susceptibility, 893 acyclovir, 106 minocycline, 1690 disk diffusion susceptibility, 893 antimicrobial resistance M. avium Roxithromycin Spanish hospital, 1200 erratum, 2515 Brucella spp. azithromycin prophylaxis in C57BL/6 mice, 1690 in vitro activity, comparative evalua- in vitro activity, 1203 M. avium complex tion, 911 2',3'-dideoxycytidine, 106 rats treated with cyclosporine, 398 gram-negative organisms 2',3'-dideoxyinosine, 106 M. haemophilum outer membrane permeability barrier, zidovudine, 106 in vitro activities, 2323 354 Salmonellosis M. paratuberculosis Mycobacterium spp. murine systemic infection in mice, 1645 in vitro activity, 1560 ciprofloxacin, 2293 Rifampin pH, effect on radiometric MICs, 1560 Salpingitis combinations RP 74501-RP 74502 CI-960 Brucella spp., 1831 Legionella spp. monkey model, 8 doxycycline, 1831 in vitro activity, 908 SCE-2787 fleroxacin, 2132 RP59500 pharmacokinetics novobiocin, 1334 gram-positive organisms healthy volunteers, 1835 ofloxacin, 1214, 1831 vancomycin resistant, 598 serum bactericidal activities, 1835 S. aureus, methicillin resistant, eradi- RU-40555 side effects, 1835 cation of, 1334 combinations Screening assays Staphylococcus-infected orthopedic clarithromycin, 692 anti-P. carinii agents implants, 1214 M. avium complex, 692 development and characterization, M. haemophilum M. avium complex, 692 1674 in vitro activities, 2323 Rufloxacin Shell vial assay M. leprae resistance comparative evaluation C. bumetii susceptibility molecular basis, 414 amoxicillin, 2298 shell vial assay, 491 minireview chronic bronchitis, 2298 Shigella sonnei nonstaphylococcal, nonmycobacterial magnesium-aluminum hydroxide dysentery disease, 1 effects on absorption, 2212 fluoroquinolones, 2486 N. brasiliensis pharmacokinetics fluoroquinolones inactivation of drug by glycosylation, biliary excretion in humans, 2545 reduced susceptibilities of strains from 1313 patients with impaired renal function, patients with dysentery, 2486 nonstaphylococcal, nonmycobacterial 637 Shigella spp. disease T-cell subsets and tumor necrosis factor azithromycin minireview, 1 production in vitro activity, 1203 pharmacokinetics mice infected with B. fragilis, effect Simian immunodeficiency virus fleroxacin, influence on, 2132 on, 1711 antibodies, neutralizing S. aureus, 2132 macrophages, comparative evaluation, zidovudine, interaction with, 1426 S-1108 360 S. epidermidis pharmacokinetics, 1043 3'-azidothymidine diffusion through a biofilm, 2522 safety of and carnitine status of patients, macrophages, comparative evaluation, staphylococcal bacteremia 1043 360 use with neonates, 2401 S-2720 protease inhibitors synergy human immunodeficiency virus antiretroviral activity, 71 ethambutol, 1285 inhibition of reverse transcriptase and Simian varicella virus M. malmoense, 1285 viral replication, 1659 (-)-9-[4-hydroxy-2-(hydroxymethyl)bu- zidovudine Saccharomyces cerevisiae tyl]guanine pharmacokinetic interaction with, 1426 bleomycin African green monkeys, 1370 Rifapentine cell wall anchorage of mannoproteins, Sinefungin Brucella spp. disruption of, 1264 Cryptosporidium parvum in vitro activity, comparative evalua- Ro 09-1470 curative and preventive activities, 889 tion, 911 inhibition of P-450 lanosterol C-14 immunosuppressed rat model, 889 M. avium complex demethylase, 2662 Skin infections rats treated with cyclosporine, 398 Saccharopolyspora erythraea piperacillin-tazobactam Rimantadine avermectins and ivermectins, glycosyl- comparative evaluation, 1580 influenza virus ation, microbial conversion by, 1737 ticarcillin-clavulanate susceptibilities of subtypes A/HlN1 Salmonella typhi comparative evaluation, 1580 and A/H3N2, 2239 ceftriaxone Sodium stibogluconate Ro 11-8958 L. panamensis synergy 5 days, comparative evaluation, 1572 in vitro activities of fractions, 1842 dapsone, 1436 chloramphenicol Soluble intercellular adhesion molecule 1 P. caninii, 1436 14 days, comparative evaluation, 1572 picornavirus capsid binders sulfamethoxazole, 1436 Salmonella typhimurium. detection of, 1693 Ro 40-6890 ciprofloxacin resistance Sparfloxacin antimicrobial susceptibility, 893 isolates from two patients, 662 bite wound isolates disk diffusion susceptibility, 893 isoniazid aerobic and anaerobic, 1150 S. aureus susceptibilities of oxyR regulon mu- C. pneumoniae antibiotic activity and host defense tants, 2251 in vitro and in vivo activities, 801 mechanisms, 2622 lactoferrin-porin interaction C. psittaci pharmacodynamic activity in human antibacterial activity, effect on, 240 in vitro and in vivo activities, 801 skin blister fluid, 2622 mutants C. trachomatis xxxii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

in vitro and in vivo activities, 801 dihydrofolate reductase, trimethoprim penicillin-binding protein 2 com- H. influenzae sensitive plex, 2432 adherence changes induced by subin- characterization of gene for, 1400 tetK hibitory concentrations, 885 enhanced intracellular antibacterial ac- E. coli, expression in, 191 K pneumoniae tivity, 2318 TetK, TetA(B), and TetA(C) adherence changes induced by subin- fibronectin-coated surfaces, isolates on substrate specificities, comparison of, hibitory concentrations, 885 antimicrobial susceptibility, 625 191 M. catarrhalis fleroxacin-rifampin vancomycin adherence changes induced by subin- pharmacokinetics, 2132 adherence, effect of subinhibitory con- hibitory concentrations, 885 fluoroquinolone resistance centrations on, 921 M. haemophilum efflux mediated, 1086 Staphylococcus epidermidis in vitro activities, 2323 NorA, multidrug efflux transporter, adherence M. kansasii 128 teicoplanin, effect of subinhibitory susceptibility testing, 1997 levofloxacin-oxacillin concentrations on, 921 M. tuberculosis, 407 synergy, 339 vancomycin, effect of subinhibitory ophthalmitis methicillin resistant concentrations on, 921 rabbits with, efficacy in, 633 13-lactam-1-lactamase inhibitor combi- biofilms pharmacokinetics nations, 702 diffusion of rifampin, 2522 ocular penetration in rabbits with oph- P-lactams, 702 diffusion of vancomycin, 2522 thalmitis, 633 blaI and blaRI regulate P-lactamase inhibition of formation on prosthetic Spiramycin and PBP 2a production, 1144 devices by proteolytic enzymes, C. trachomatis ciprofloxacin, resistance to unrelated 2618 comparative evaluation, 1373 antibiotics, effects on, 1289 teicoplanin genital infections, treatment of, 1373 endocarditis, 2466 adherence, effect of subinhibitory con- Staphylococcus aureus fusidic acid, alone or in combination centrations on, 921 abscesses with vancomycin, 2466 vancomycin cefazolin, ,-lactamase-mediated inacti- penicillin-binding protein 2A, role in adherence, effect of subinhibitory con- vation and efficacy, 203 cell wall synthesis, 342 centrations on, 921 cefmetazole, 3-lactamase-mediated rifampin-novobiocin, 1334 Staphylococcus spp. inactivation and efficacy, 203 methicillin resistant and susceptible adherence adherence sequential acquisition of norfloxacin teicoplanin, effect of subinhibitory teicoplanin, effect of subinhibitory and ofloxacin resistance, 2278 concentrations on, 921 concentrations on, 921 methicillin susceptible vancomycin, effect of subinhibitory vancomycin, effect of subinhibitory cephalosporins, broad spectrum, 554 concentrations on, 921 concentrations on, 921 methicillin susceptible, borderline mec regulator genes ampicillin-sulbactam ,B-lactam-13-lactamase inhibitor combi- distribution in methicillin-resistant P-lactamase-hyperproducing strain, nations, 702 strains, 1219 507 P-lactams, 702 methicillin resistant antimicrobial susceptibility mupirocin resistance mec regulator genes, distribution of, fibronectin-coated surfaces, isolates detection and characterization, 2003 1219 on, 625 mupirocin resistance, high level orthopedic implant infections azithromycin isoleucyl-tRNA synthetases, evidence rifampin-ofloxacin, 1214 uptake by human monocytes, 2318 for two distinct, 32 rifampin-ofloxacin B. fragilis, polymicrobial infection NorA infected orthopedic implants, 1214 mice, 1531 Bmr, comparison of substrate specific- teicoplanin B. thetaiotaomicron, polymicrobial in- ities, 128 adherence, effect of subinhibitory con- fection multidrug efflux transporter, 128 centrations on, 921 mice, 1531 oxacillin vancomycin bacteremia ,-lactamase-hyperproducing strain, adherence, effect of subinhibitory con- use of intravenous rifampin with neo- 507 centrations on, 921 nates, 2401 pefloxacin Stavudine ,-lactamase one 800-mg versus two 400-mg doses, pharmacokinetics production, genes involved in regula- 737 cynomolgus monkeys, 1160 tion, 1966 povidone iodine Streptococcus mitis P-lactamases irrigation, 2754 gentamicin blaI and blaRl, regulation of, 1144 pristinamycin resistance chromosomally mediated high-level blaI and blaRI isolates responsible for outbreak in resistance, 2740 P-lactamase and PBP 2a regulation, Parisian hospital, 2159 Streptococcus mutans 1144 quinolone resistant amoxicillin cefazolin levofloxacin-oxacillin synergy, 339 in vitro susceptibility, 1158 P-lactamase-mediated inactivation and rifampin cefuroxime efficacy, 203 use with neonates, 2401 cefmetazole Ro 40-6890 in vitro susceptibility, 1158 P-lactamase-mediated inactivation and antibiotic activity and host defense chlorhexidine efficacy, 203 mechanisms, 2622 in vitro susceptibility, 1158 cefozopran, 100 pharmacodynamic activity in human erythromycin cephalosporins skin blister fluid, 2622 in vitro susceptibility, 1158 broad spectrum, 554 teicoplanin penicillin ciprofloxacin adherence, effect of subinhibitory con- in vitro susceptibility, 1158 dose-ranging and fractionation, 1756 centrations on, 921 tetracycline in vitro model of infection, 1756 teicoplanin resistance in vitro susceptibility, 1158 resistance to unrelated antibiotics, ef- expression of a novel membrane pro- trimethoprim-sulfamethoxazole fects on, 1289 tein and increased expression of in vitro susceptibility, 1158 VOL. 37, 1993 SUBJECT INDEX xxxiii

Streptococcus pneumoniae Streptomycin group streptococci from neutro- cefotaxime breakpoint combinations penic patients receiving ciproflox- letter to the editor, 616 B. melitensis, 2333 acin, 2493 ciprofloxacin ciprofloxacin, doxycycline, and ri- dye uptake assay mouse protection model, 234 fampin, 2333 in vitro activity of clarithromycin clarithromycin resistance E. coli resistance against spotted fever group rick- cultures from Providence, R.I., 1742 bleomycin, increase of, 1982 ettsiae, 2633 erythromycin resistance Sulbactam erythromycin cultures from Providence, R.I., 1742 combinations blood culture isolates of viridans meningitis ampicillin, 251, 507, 610, 1447 group streptococci from neutro- penicillin and cephalosporin resistant, cefoperazone, 1927 penic patients receiving ciproflox- evaluation of treatment regimens, clavulanate, 2059 acin, 2493 1630 comparative evaluation, 610 G. vaginalis penicillin and cephalosporin resistant E. coli, 1927, 2059 agar dilution, 2733 meningitis, evaluation of treatment E. coli intra-abdominal abscess model, M. fermentans regimens, 1630 610 in vitro strains from AIDS patients, penicillin resistant E. faecalis, P-lactamase producing, 2500 otitis media, treatment with amoxicil- highly gentamicin resistant, 1447 in vitro strains from non-AIDS pa- lin, 1599 endocarditis, 507, 1447 tients with acute respiratory dis- penicillin-binding proteins 2B and 2X, P. aeruginosa, 1927 ease, 2500 genetic diversity of, 1938 S. aureus, P-lactamase hyperproduc- tissue culture, 2500 polymerase chain reaction ing, 507 M. kansasii heterogeneity of chloramphenicol ace- susceptibility testing with a predictor azithromycin, 1997 tyltransferase genes, 2593 panel, 251 clarithromycin, 1997 Streptococcus pyogenes tazobactam, 2059 fusidic acid, 1997 poloxamer 188 E. coli ofloxacin, 1997 effects of scrubbing, 2754 ,B-lactamase, TEM type, resistant, sparfloxacin, 1997 Streptococcus spp. 2059 Nocardia spp. ceftriaxone-netilmicin oxidant-scavenging activities letter to the editor, 2514 endocarditis, 207 neutrophil functions, effect on, 950 piperacillin-tazobactam synergy, 207 Sulfamethoxazole predictor panel for evaluating meth- endocarditis synergy ods, 2578 ceftriaxone-netilmicin, 1971 dihydrofolate reductase inhibitors, plaque assay ceftriaxone-netilmicin synergy, 207 1436 in vitro activity of clarithromycin group A P. carinii, 1436 against spotted fever group rick- antibiotic susceptibilities, hospital iso- Ro 11-8958, 1436 ettsiae, 2633 lates, 1717 Suramin roxithromycin cefuroxime axetil suspension, compar- duck hepatitis B virus Mycobacterium spp., effect of pH on ative evaluation, 159 prevention of infection in vivo, 1539 MICs, 1560 group A, beta-hemolytic polymorphonuclear leukocyte bacteri- yeasts bacterial interference, role in infection cidal activity 39 management, 1452 suppression of, 495 broth macrodilution, P-lactamase production, role in infec- Susceptibility testing multicenter evaluation, 39 tion management, 1452 agar dilution Synergy tonsillopharyngitis G. vaginalis, 2733 3'-azido-2',3'-deoxythymidine cefprozil versus penicillin V, 1620 amoxicillin carbovir, 144 viridans group blood culture isolates of viridans human immunodeficiency virus type 1, activities of potential therapeutic and group streptococci from neutro- 144 prophylactic antibiotics against penic patients receiving ciproflox- carbovir blood culture isolates, 2493 acin, 2493 3'-azido-2',3'-deoxythymidine, 144 neutropenic patients receiving cipro- ampicillin-sulbactam human immunodeficiency virus type 1, floxacin, 2493 predictor panel, 251 144 Streptogramin A acetyltransferases azlocillin decimal assay for additivity, 260 E. faecium blood culture isolates of viridans E. faecium identification of satA, 2119 group streptococci from neutro- penicillin-gentamicin, 2427 Streptogramins penic patients receiving ciproflox- ethambutol-amikacin acin, 2493 M. malmoense, 1285 RP 74501-RP 74502 broth microdilution Legionella spp., 908 ethambutol-ciprofloxacin multicenter evaluation, 39 M. malmoense, 1285 RP59500 yeasts, 39 gram-positive organisms, vancomycin ethambutol-rifampin C. neoformans 1285 resistant, 598 current status of the standardization M. malmoense, Streptomyces clavuligerus process, minireview, 2517 levofloxacin-oxacillin cephalosporin 7oa-hydroxylase Candida spp. S. aureus, quinolone resistant, 339 cloning and expression in S. lividans, current status of the standardization M. malmoense 84 process, minireview, 2517 ethambutol-amikacin, 1285 Streptomyces spp. clarithromycin ethambutol-ciprofloxacin, 1285 chromosomal DNA blood culture isolates of viridans ethambutol-rifampin, 1285 role in multiple antibiotic resistance, group streptococci from neutro- microdilution checkerboard method 2379 penic patients receiving ciproflox- measurement of, reproducibility of multiple antibiotic resistance acin, 2493 results, 613 chromosomal DNA in antibiotic prep- co-amoxiclav penicillin-gentamicin arations, 2379 blood culture isolates of viridans E. faecium, 2427 xxxiv SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

T-3761 Tetracycline Tonsillopharyngitis in vitro and in vivo activities, 384 C. jejuni resistance cefprozil Tazobactam effect of mutational alteration of Asn- comparative evaluation, 1620 1-lactamases 128, 2645 penicillin V kinetic interactions, 851 resistance determinants comparative evaluation, 1620 combinations TetA(D), nucleotide and deduced pro- streptococcal clavulanate, 2059 tein sequences, 1253 cefprozil versus penicillin V, 1620 E. coli, 2059 S. mutans Topoisomerase inhibitors piperacillin, 2578 in vitro susceptibility, 1158 P. carinii sulbactam, 2059 Tet(O) activity in vitro and in a mouse model, E. coli effect of mutational alteration of Asn- 1543 P-lactamase, TEM type, resistant, 128, 2645 Topoisomerases 2059 TetA(D) quinolones Teicoplanin nucleotide and deduced protein se- 1-8 bridged, stereospecificity for the adherence quences, 1253 C-11 methyl group, 646 Staphylococcus spp., effect of subin- relationship to other antimicrobial activities against mammalian systems, hibitory concentrations on, 921 transport proteins, 1253 comparative evaluation, 2179 bactericidal activity Tetracycline-HCl Torulopsis glabrata albumin or serum, presence of, con- synergy fluconazole trolled pH and calcium, 605 H. pylori, 1184 prophylaxis in neutropenic bone mar- pharmacokinetics metronidazole, 1184 row transplant patients, 1847 evaluation of a fluorescence polariza- metronidazole, hydroxymetabolite of, Tosufloxacin tion immunoassay, 1924 1184 C. pneumoniae prophylaxis in monolateral and bilat- Tetracyclines in vitro and in vivo activities, 801 eral total knee replacement proce- glycylcyclines C. psittaci dures, 2693 comparative evaluation, 2270 in vitro and in vivo activities, 801 S. aureus resistance penetration into bacterial cells C. trachomatis expression of a novel membrane pro- minireview, 1393 in vitro and in vivo activities, 801 tein and increased expression of screening assay, 1624 Toxicity penicillin-binding protein 2 com- Thiazolo-iso-indolinones A77003 plex, 2432 human immunodeficiency virus type 1 preclinical evaluation, 115 Staphylococcus spp. resistance, 2612 amphotericin B adherence, effect of subinhibitory con- Thiosemicarbazones mono-methyl ester derivative, 419 centrations on, 921 Abelson murine leukemia virus neurotoxicity, comparative evaluation, Temafloxacin v-abl protein, suppression of, 2483 419 B. fragilis Ticarcillin 3'-azido-3'-deoxythymidine evaluation of activity by an in vitro combinations time of administration, effect on, 1771 pharmacodynamic system, 2454 clavulanate, 1580 gentamicin bite wound isolates clavulanic acid, 51 polyaspartic acid, protective effects, aerobic and anaerobic, 1150 comparative evaluation, 1580 pharmacologic limits of, 347 M. pneumoniae skin and skin structure infections, human renal proximal tubule cells hamsters, 287 1580 use in studying foscarnet-induced postantibiotic effect yeast colonization of the human gas- nephrotoxicity in vitro, 2496 repeated exposures, 1723 trointestinal tract, effect on, 51 LJC 10,627 Terbinafine Ticarcillin-clavulanic acid central nervous systems of rats, low Candida spp. C. albicans levels of, 199 temperature, effect on activity, 685 colonization of the human gastrointes- nephrotoxicity combinations tinal tract, effect on, 51 isepamicin, 2042 Chagas' disease, murine, 1353 pharmacokinetics neurotoxicity ICI 195,739, 1353 healthy volunteers, 1860 amphotericin B, 419 ketoconazole, 1353 yeast colonization of the human gastro- amphotericin B mono-methyl ester T. cruzi, 1353 intestinal tract, effect on, 51 derivative, 419 mevinolin Time-kill curves Toxoplasma gondii T. cruzi, potentiation of antiprolifera- mathematical model for comparison of, anticoccidial agents tive effects, 580 1685 susceptibility and resistance, 2358 Terconazole Time-kill studies atovaquone-clarithromycin Candida spp. turbidimetric assay in vitro and in vivo activities, 2371 temperature, effect on activity, 685 viable bacterial densities, quantitation atovaquone-minocycline tet(Q) 371 in vitro and in vivo activities, 2371 B. fragilis of, atovaquone-pyrimethamine nucleotide and deduced amino acid Tinea unguium in vitro and in vivo activities, 2371 sequences, 2037 griseofulvin atovaquone-sulfadiazine TetA(D) ultramicrosize, 2064 in vitro and in vivo activities, 2371 nucleotide and deduced protein se- itraconazole, 2064 azithromycin quences, 1253 Tobramycin combinations, in vitro activities of, relationship to other antimicrobial trans- E. coli resistance 1993 port proteins, 1253 3'-aminoglycoside phosphotransferase protein synthesis, inhibition of, 1701 TetK type I, overproduction of, 78 clindamycin S. aureus postantibiotic effect infectivity, 2571 E. coli, expression in, 191 hyperoxia, prolongation by, role of intracellular replication, 2571 substrate specificities, comparison reactive oxygen species, 120 protein synthesis, 2571 with those of TetA(B) and P. aeruginosa, 120 dihydrofolate reductase TetA(C), 191 repeated exposures, 1723 inhibitors, identification of, 1914 VOL. 37, 1993 SUBJECT INDEX xxxv

poloxamers Trypanosoma (Schizotrypanum) cruzi hibitory concentrations on, 921 toxoplasmosis, 2265 mevinolin B. burgdorfeni pyrimethamine ketoconazole and terbinafine, potentia- in vitro activity, 1115 combinations, in vitro activities of, tion of antiproliferative effects, 580 E. faecalis 1993 Tuberculosis 1-lactamase producing, highly gentam- toxoplasmosis multidrug resistant icin resistant, 1447 poloxamers, 2265 studies with mice, 2344 endocarditis, 1447 Toxoplasmosis Tumor necrosis factor E. faecalis resistance gene poloxamers, 2265 murine models homology with vanB, vanA, and T. gondii, 2265 amphotericin B, 2228 vanC, 1604 Treponema pallidum receptors E. faecium resistance, 1904 clarithromycin relation to therapy of typhoid fever, endocarditis, 2069 hamsters, 864 2418 E. faecium resistance gene Triazino[5,6-b]indoles Tumor necrosis factor alpha homology with vanB, vanA, and GR99060 amphotericin B, 1958 vanC, 1604 antifungal properties, 1243 C. albicans, 1958 gram-positive organism resistance GR99062 Turbidimetric assays ramoplanin, 1364 antifungal properties, 1243 viable bacterial densities, quantitation of gram-positive organisms, resistance Triazoles E. coli, 371 RP59500, 598 D0870 Typhoid fever pharmacokinetics blastomycosis, murine, 1177 ceftriaxone obesity, effect on, 436 pathogenic yeasts, 2126 5 days, comparative evaluation, 1572 pulmonary lining fluid, penetration Tnchophyton mentagrophytes chloramphenicol into, 281 butenafine 14 days, comparative evaluation, 1572 serum protein-binding characteristics, guinea pigs, 363 ciprofloxacin 1132 Trimethoprim severe, in children, 1197 pulmonary lining fluid dihydrofolate reductase cassette interleukin-6, gamma interferon, and tu- penetration into, 281 integron on a Tn2l-like element, 1297 mor necrosis factor receptors "red man syndrome" H. influenzae relation to outcome of antimicrobial skin tests to healthy volunteers, 2139 adherence changes induced by subin- therapy, 2418 S. epidermidis hibitory concentrations, 885 severe diffusion through a biofilm, 2522 K pneumoniae ciprofloxacin, 1197 Staphylococcus spp. adherence changes induced by subin- adherence, effect of subinhibitory con- hibitory concentrations, 885 U-90152 centrations on, 921 M. catarrhalis human immunodeficiency virus type 1 Visna virus replication, inhibition of, 1127 acyclic nucleoside phosphonate analogs adherence changes induced by subin- Ureaplasma diversum inhibition of replication, 2540 hibitory concentrations, 885 antimicrobial susceptibilities, 317 2',3'-dideoxynucleosides resistance Ureaplasma urealyticum inhibition of replication, 2540 dihydrofolate reductase cassette in- OPC 17116 serted on an integron on a Tn2l- susceptibility in vitro, 1726 WIN 54954 like element, 1297 Ureidopenicillins coxsackievirus Trimethoprim-sulfamethoxazole F. oryzihabitans group B diabetogenic strain in mice, pharmacokinetics in vitro activities against clinical iso- 1593 12/60 mg/kg/day, multiple dose, 448 lates from patients with cancer, rhinovirus healthy volunteers, 448 2504 prophylaxis, efficacy of, 297 S. mutans Urinary tract infections WIN 57273 in vitro susceptibility, 1158 acute uncomplicated E. faecalis Tritrichomonas foetus lomefloxacin, 3 days, comparative activity against high-level gentamicin- zinc evaluation, 574 resistant strains, 2470 electron microscopic study, 2722 norfloxacin, 3 days, comparative eval- Trypanosoma brucei brucei uation, 574 Yeasts N-n-alkyl-3,4-dihydroxybenzamide cefozopran, 100 D0870 in vitro and in vivo activities, 1082 enoxacin in vitro activities, 2126 G418 resistance phenotype cefuroxime axetil, more rapid than, susceptibility testing in vivo system to select for blood- 1558 broth macrodilution, 39 stream-form transfectants, 1167 rapid symptom alleviation, 1558 multicenter evaluation, 39 Trypanosoma congolense lomefloxacin 3 days, comparative evaluation, 574 Zalcitabine Boran cattle nitrofurazone diminazine pharmacokinetics, effect of catheter associated, 2033 salmonellae infection on, 1050 norfloxacin in vitro activities, 106 quinapyramine resistant 3 days, comparative evaluation, 574 Zidovudine derivation and characterization, 1163 P. aeruginosa embryos, implantation of Trypanosoma cruzi cefozopran, 100 prevention of, 1610 N,N'-bis(benzyl)-substituted polyamine recurrent human immunodeficiency virus resistance analogs enoxacin, rapid symptom alleviation, pol mutations, multiple resistance, inhibition of host cell invasion and 1558 1480 intracellular replication, 2235 rapid symptom alleviation, 1558 human immunodeficiency virus type 1 ICI 195,739-terbinafine sensitivity murine model, 1353 Vancomycin discontinuation of zidovudine treat- ketoconazole-terbinafine adherence ment, effects on, 1525 murine model, 1353 Staphylococcus spp., effect of subin- pharmacokinetics xxxvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

effects of standard breakfast in pa- sue, 818 pharmacokinetic interaction with, 1426 tients with AIDS, 2153 rifampin, interaction with, 1426 salmonellae granulocyte-macrophage colony-stimu- prodrugs in vitro activities, 106 lating factor, administration with, pharmacokinetics, enhanced levels in Zinc 512 brain tissue, 818 T. foetus prodrugs, enhanced levels in brain tis- rifampin electron microscopic study, 2722

Statement of Ownership, Management and Circulation (Required by 39 U.S.C. 3685) IA. Title of Publication 1S. PUBLICATION NO. 2. Date of Filing Antimicrobial Aqents and Chemotherapy 0 0 6 161 41 81 0 4 10-12-93 3. Frequency of Issue No. of Issues Published 38. Annual Subscription Price Annually Monthly 12 $49 mbr, $250 nonmbr

4. Complete Mailing Address of Known Office ol Publication (Strre City, Cse,. ad ZIP+4 Code) (No priaters) American Society for Mlicrobiology 1325 Massachusetts Ave., N.W., Washinqton, D.C. 20005-4171 5. Complete Mailing Address of the Headquarters of General Business Offices of the Publisher (Not priaer)

(Same as above)

6. Full Names and Complete Mailing Address of Publisher, Editor, end Wanaging Editor (In Now MUST NOT be lank) Publisher (Name and Complete Mailing Address)

(Same as above) Editor (Name and Complete Mailing Address) Robert C. Moellering, Jr. (Address same as above) Managing Editor (Name and Complete Mailing Adress) Linda M. Illig (Address same as above) 7. Owner (ifsohned bv a corporation. its name and address et be stated aed also imledately thereunder the nams oand addresses of stosckholders owning or holding I per ent sJr mnore of total amount of stck. If nor owned by a cotpoaton. the nams nd addresses of the ildindual owners must be gisen. If otrned bh a partners/ip or other unincorporatedfirn. its nomw and address, as swll at that of eac* diWdl erst be given. Ifthe publication is published by a nonprofit organizatissn. its name and address must be stated.) (Item must be coepleted.) FuN Name Complete MelIng Address %merican Society for Microbiology 1325 Massachusetts Ave., N.W. Washington. D.C. 20005-4171

8. Known Bondholders, Mortgagees, and Other Security Holders Owning or HoldIng 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (if there are none, so state) FuN Nam Complete MeIUng Address None

--I

9. For Completion by Nonprofit Organizations Authorized To MaN at Specil Rates (DIM Secdon 424.12 only) The purpose, function, and nonprofit status of this organization and the exempt atatus for Federal income tax purposes (Chesi osse) Ill 121 W Has Not Changed During Has Changed During (if changed, publisher must submit explanation of LAlPreceding 12 Months I Preceding 12 Months chagewith this statement.) 10. Extent and Nature of Circulation Averae No. Copies Each Issue During Actual No. Copies of Single Issue (See instructions on reverse side) Proceding 12 Months Published Nearest to Filing Date A. Total No. Copies (Net Press Run) 8,775 8,800 B. Paid and/or Requested Circulation 1. Sales through dealers and carriers, street vendors and counter sWas 2. Mail Subscription (Paid and/or requested) 7,171 7, 751 C. Total Paid and/or Requested Circulation 1Sum of 10I11 and /082/ 7,171 7,751 D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies 1 10 1 10 E. Total Distribution (Sum of CandD7,D867,28 F. Copies Not Distributed 1. Office ise, left over, unaccounted, spoiled after printing 1 ,494 939 2 Return from News Agents

G. TOTAL (Sum sf E, Fl and 2-should equal ne press unR shoun in A) 8,775 8,800 Manager, or Owner I certify that the statements made by Signature and Titie of Editor, Publisher, Businhss me above are correct and complete A . K Director, Journals

(See instructions on reverse)~~~~~~~~~~~~~~~~~ PSPSFormForm3526,3526.JanuarvJanuary1991 M-f instmWtroa on reverse)